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Abstract 
In order to understand the huge complexity of brain function, and to determine 
the mechanisms underlying various psychiatric (e.g. schizophrenia) and neuronal 
disorders (Alzheimer‟s disease), it is imperative that the basic machinery 
involved in neuronal transmission is fully elucidated. This involves exocytosis of 
synaptic vesicles (SVs) and subsequent release of neurotransmitter. SVs can 
exocytose by two different modes: full fusion (FF) and kiss-and-run (K&R). 
There is much debate as to whether SV fusion in the nerve terminal can occur via 
K&R mode of exocytosis and this has been studied herein, using cerebrocortical 
synaptosomes from adult rats. Switching between the two modes depends upon 
the secondary messenger calcium and protein phosphorylation reactions. Dr. 
Ashton has previously demonstrated that an increase in intracellular calcium 
levels regulates the switch between these modes of exocytosis, and thus the role 
of voltage-gated calcium channels (VGCCs) was studied. Blockade of L-type (but 
not N-and P-type) VGCCs switch K&R exocytosis to FF mode in control 
terminals, indicating that such channels contribute to the calcium increase that 
induces K&R mode. These results (for the first time) demonstrate that distinct 
VGCC subtypes contribute to the specific mode of exocytosis. Very surprisingly, 
it has been discovered that in diabetic terminals (prepared from streptozotocin 
treated rats: a model for type 1 diabetes), higher amount of K&R exocytosis 
occurs relative to non-diabetic terminals due to a higher stimulus evoked change 
in intracellular calcium. Whether this was due to an over-activation of certain 
VGCCs was studied. Fascinatingly, L-type channels did not regulate the mode of 
exocytosis but diabetic terminals displayed a higher dependence on N-type 
channels. Blockade of calcium/calmodulin dependent kinase II (CaMKII) was 
found to inhibit completely the release of reserve pool (RP) of vesicles, with no 
effect on readily releasable pool (RRP) of vesicles in control terminals. However, 
by studying the release of just the RRP of SV it was discovered that, inhibition of 
CaMKII leads to a switch from K&R to FF, suggesting this enzyme when 
activated can phosphorylate substrate proteins that induces K&R mode of 
exocytosis. Inhibition of myosin II induces a switch from K&R to FF in both 
control and diabetic terminals; although results suggest that myosin II may only 
regulate the fusion mode of the RRP. In control terminals, blockade of calcineurin 
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induces more K&R. By blocking both myosin II and calcineurin in control 
synaptosomes, more K&R was apparent. This indicates that RP of vesicles switch 
to K&R mode of exocytosis independently of the role of myosin II, and that 
calcineurin exclusively works on RP of vesicles. The inhibition of dynamins 
switched the mode of exocytosis of the RP of SVs from K&R to FF in diabetic 
terminals, whilst failing to regulate the mode of exocytosis of the RRP for both 
control and diabetic terminals when a strong stimulus was applied. It has been 
established that inhibition of protein phosphatase 2A and activation of protein 
kinase C induces RRPs that undergo K&R in control terminals to FF mode of 
exocytosis. Similar experiments were performed on diabetic terminals. Each drug 
treatment alone switched the RRP vesicles in diabetic terminals to undergo FF, 
but the dual treatment switched all vesicles that previously underwent K&R (i.e. 
the RRPs and some RPs) to a FF mode of exocytosis. The results obtained should 
help future research to understand precisely the molecular mechanisms that occur 
in the switching of the mode of different pools of SVs.  
The diabetic terminals respond differently to various drugs that perturb protein 
phosphorylation, [Ca
2+
]i and specific phospho-proteins. We hypothesised that 
these characterized biochemical changes may affect synaptic plasticity and could 
result in some behavioural changes. With the long-term goal of establishing a link 
between the biochemical and behavioural findings, which may represent subtle 
changes in synaptic plasticity, difference in the behaviours of STZ-induced 
diabetic rats in comparison to the age-matched control rats were measured. A 
newly developed behaviour registration system, Laboratory Animal Behaviour 
Observation, Registration and Analysis System (LABORAS) was utilized. The 
diabetic animals showed significantly decreased locomotive and rearing 
behaviour whilst the grooming, drinking and eating behaviour was substantially 
increased over this period. Intriguingly, whilst the incidence of locomotive 
behaviour was decreased in diabetic animals, the average speed and distance 
covered over a period of 24hrs was significantly more in such rats than the 
control rats. These initial observations established behavioural differences that 
could be related to the biochemical changes seen, and future experiments will 
attempt to find a correlation between these. 
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Note to Readers 
This study aims to explore two main areas in extensive detail, namely 
biochemical and behavioural changes. Due to the nature and scope of this study, 
it has been necessary to include many important and pioneering results and 
analyses, which has led to this thesis being very detailed. Although every effort 
has been made to keep the information as concise as possible, the extensive 
nature of the research undertaken and its novel findings have meant this thesis is 
comparatively extensive, to preserve the flavor of the research and present its 
findings in a manner in which it is best understood. 
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I. Introduction 
The human body is very complex and various systems work in synchrony for the 
normal functioning and well-being of an individual. The distinct systems that 
work together are the musculoskeletal system, the cardiovascular system 
(circulatory system), the digestive system, the endocrine system, the 
integumentary system, the urinary system, the immune system, the respiratory 
system, the reproductive system and the nervous system (Widmaier et al., 2006). 
The nervous system co-ordinates all the other mentioned systems. It consists of 
the central nervous system (CNS) and the peripheral nervous system. The CNS 
consists of the brain and spinal cord, and the peripheral nervous system consists 
of the nerves and ganglia that are outside the brain and spinal cord. The 
peripheral nervous system is further sub-divided into the autonomic and the 
somatic nervous system (Widmaier et al., 2006). The CNS, mainly brain, is 
discussed further in this thesis. The nervous system is exceptional in the 
numerous complexes of thought processes and control of the activities that it 
performs.  
I.1 Brain Cells/ Neurons 
Neurons are the core components of the nervous system (Widmaier et al., 2006). 
It is believed that the human brain has 10
11
 neurons. A typical brain neuron will 
have connections with at least 1,000 other neurons (Widmaier et al., 2006; Lodish 
et al., 2008). Various kinds of neurons can be found in the nervous system. Their 
effect can be excitatory, inhibitory or modulatory; and their functions can be 
motor, sensory or secretory (Siegel et al., 1999). A large range of 
neurotransmitters (NT) and hormones can influence the properties of neurons. 
This enormous repertoire of functions, associated with various developmental 
influences on different neurons, is largely reflected in the variation of dendritic 
and axonal outgrowth (Lodish et al., 2008).  
A neuron is a polymorphic cell with the cell body, the perikaryon or soma, with 
broad dendrites emerging from one pole and a fine axon emerging from the 
opposite pole (Siegel et al., 1999). The signal that flows between two neurons 
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originates from the dendrite or soma, and propagates to the axon (Lodish et al., 
2008). An axon of one neuron passes the information to the dendrites of the 
neighbouring neurons (Siegel et al., 1999). A synapse is a specialised structure 
that permits a neuron to pass a signal to another cell (Giagtzoglou et al., 2009). 
Sir Charles Scott Sherrington and colleagues conceived word "synapse" from the 
Greek work "synaptein" ["syn-" ("together") and "haptein" ("to clasp")]. 
Individual neurons can form thousands of discrete synaptic connections with their 
postsynaptic partners (Graf et al., 2009). The neurons communicate with each 
other, and the electrical movement within synapses is caused by a propagation 
of nerve impulses. This phenomenon is called synaptic transmission or 
neurotransmission (Peters et al., 1996), and its propagation is unidirectional (only 
in the forward direction). 
I.2 Synapses and the process of exocytosis 
There are two types of synapses: electrical and chemical. Electrical synapses 
work via gap junctions, thereby allowing the flow of ions freely from one cell to 
another. Most of the signal transmission that occurs in the nervous system is via 
chemical substances called NTs (small water-soluble molecules) (Widmaier et al., 
2006). This includes acetylcholine, norepinephrine, histamine, gamma-
aminobutyric acid (GABA), glycine, serotonin and glutamate. These NTs are 
synthesized intracellularly in the cytosol and packaged via specific 
transmembrane protein transporters into synaptic vesicles (SVs) (Park and Kim, 
2009; Omiatek et al., 2010), which mediate fast synaptic transmission (Xia et al., 
2009). For instance, glutamate is transported into the SVs via proteins that make 
up vesicular glutamate transporters (VGLUTs).  
Synapses are composed of presynaptic and postsynaptic compartments 
(Shupliakov, 2009). Each synapse comprises of tightly apposed pre- and 
postsynaptic membranes, a postsynaptic cluster of NT receptors, and a 
presynaptic complex of proteins that promotes NT release (Graf et al., 2009). The 
excitatory or inhibitory terminal has two important structures for their normal 
functioning: SVs/dense core vesicles (DCVs) and mitochondria (Xia et al., 2009). 
Upon stimulation, the SVs containing NTs release their contents into the synaptic 
cleft, which either leads to excitation or inhibition of the postsynaptic neuron 
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(Refer Fig A). Adenosine-5‟-triphosphate (ATP) from the mitochondria provides 
energy for the process of neurotransmission (Lodish et al., 2008).  
The pre- and postsynaptic events are highly coordinated and are subject to use-
dependent changes, which form the basis for plasticity and learning in the CNS. 
Although, direct electrical connections also occur, these account for transmission 
of information between nerves only in specialized cases. The release of NTs is of 
central importance for the normal functioning of the brain. The presynaptic 
neurons/nerve terminal has highly evolved machinery that is specialized for the 
release of chemical NTs, and SVs are the organelles that are intimately involved 
in this process (Siegel et al., 1999). The SVs are small membrane-bounded 
organelles and serve as the primary intracellular unit for the highly efficient 
storage and discharge of the NTs during signalling processes (Omiatek et al., 
2010). They fuse with the plasma membrane (PM) to release NTs, a key aspect of 
signalling between neurons (Zhang et al., 2007). These NTs are released from the 
intracellular compartment of the presynaptic terminals into the extracellular 
domains by the process of exocytosis, which is a calcium (Ca
2+
) dependent 
mechanism (Jackson, 2007; Hosoi et al., 2009). In this process, upon the arrival 
of the action potential (AP), the voltage-gated Ca
2+
 channels (VGCCs) get 
activated resulting in the influx of Ca
2+ 
ions to the inside of the cells (Sudhof, 
1995; Fdez and Hilfiker, 2006; Serulle et al., 2007; Sudhof and Malenka, 2008). 
This causes localized rise in the cytosolic Ca
2+
 levels which triggers the SVs to 
migrate to the active zone (AZ) and fuse at the PM, thereby releasing their 
content into the synapses (Hosoi et al., 2009). These messengers interact with 
various receptors on target cells to communicate, after which they are recaptured 
or metabolized (Omiatek et al., 2010). A complex meshwork of actin filaments, 
tethers, and scaffolding proteins mediates vesicle recruitment at the AZ, where 
SVs are captured and tethered to presynaptic dense projections, and some are 
placed in close proximity to Ca
2+
 channels (Giagtzoglou et al., 2009; Kim and 
von Gersdorff, 2009). The released NTs can then activate receptors on the 
postsynaptic target cells, thereby allowing the signalling between these cells 
(Fdez and Hilfiker, 2006; Widmaier et al., 2006) (Refer Figure A for the 
overview of the process of exocytosis). Transmission electron microscopy 
determined the size (typically 50–800nm diameter) and morphology of SVs 
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involved in exocytosis (Omiatek et al., 2010). The fusion of SVs with these 
electron-dense regions of the presynaptic PM is spatially and temporally 
regulated (Wasser and Kavalali, 2009). A detailed understanding of how a CNS 
functions requires analysis of its chemical signalling, which is largely mediated 
by regulated vesicle exocytosis (Xia et al., 2009). 
 
Figure A. Schematic View of an Excitatory Synapse Formed by an Axonal Varicosity 
(Left) onto a Dendritic Spine (Right):  Key elements of the apparatus mediating synaptic 
transmission are indicated, as is the trafficking of postsynaptic AMPA-type glutamate 
receptors (Sudhof and Malenka, 2008). 
In synaptic terminals, phosphorylation of pre- and postsynaptic proteins is 
required for basal neurotransmission and synaptic plasticity at both excitatory and 
inhibitory connections (Munton et al., 2007). Activity-dependent protein 
phosphorylation is one of the most ubiquitous and vital biochemical processes, 
which contribute to the regulation and fine-tuning of numerous cellular functions 
in many cell types (Leenders and Sheng, 2005). At the molecular level, the 
addition or removal of a phosphate residue can considerably affect the function 
and/or localization of proteins including enzymes, ion-channels, scaffolding 
proteins, or signalling molecules.  
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The events that occur during the synaptic transmissions are detailed in Figure B             
 
Figure B. Synaptic Transmission: 1.Depolarization opens VGCCs in the presynaptic 
nerve terminal. The influx of Ca
2+
 and the resulting high Ca
2+
 concentrations at AZ on 
the PM trigger 2. The exocytosis of small SVs that store NT involved in fast 
neurotransmission. Released NT interacts with 3. receptors in the postsynaptic 
membrane, which couple directly with ion channels and with receptors that act through 
second messengers, such as 4. G-protein coupled receptors. 5. NT receptors, also in the 
presynaptic nerve terminal membrane, either inhibit or enhance exocytosis upon 
subsequent depolarization. Released NT is inactivated by reuptake into the nerve 
terminal by 6. A transport protein coupled to the Na
+
 gradient, for example, dopamine, 
norepinephrine, glutamate and GABA; by 7. Degradation (acetylcholine, peptides); or 
by 8.  uptake and metabolism by glial cells (glutamate). The SV membrane is recycled 
by 9. clathrin-mediated endocysosis. Neuropeptides and proteins are stored in 10. larger, 
dense core granules within the nerve terminal that are released from 11. sites distinct 
from AZ after repetitive stimulation (Siegel et al., 1999). Note that this is a conventional 
text book diagram and does not take into account the Kiss-and-run type exocytosis which 
is the subject of this thesis. 
There are mainly two types of synaptic transmitter release: spontaneous and 
evoked synchronous (Chang and Mennerick, 2010).  Presynaptic APs and 
resulting Ca
2+
 influx cause rapid (within a millisecond) synchronous vesicle 
fusion (Chung et al., 2010). A third type of release, asynchronous release is 
believed to complement the phasic release, but this is not yet fully understood.  
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I.2.1 Initiation and Propagation of Action Potential  
The exocytosis of SVs occurs on the arrival of the AP. The neurons maintain an 
electrical polarized state, by maintaining the voltage difference across the PM 
(Lodish et al., 2008).  Ion-pumps and ion-channels play a major role in 
maintaining this homoeostasis.  On an arrival of a stimulus, the ion pumps work 
in a way to generate depolarization across the membrane upto the threshold, 
thereby generating AP. In simplistic terms, the proteins of the ion-channel exist in 
either of two conformations, the open-channel state or closed-channel state. 
During resting conditions, the channels are closed. Whether an ion-channel is 
open or closed is controlled by distinct mechanisms, dependent upon the type of 
ion-channels. The opening and closing of ion-channels either depends on the 
voltage across the membrane (voltage-gated ion-channels) or on some controlling 
chemical (chemically-gated ion-channels). Axons have voltage-gated ion- 
channels, whereas synapses contain both voltage-gated and chemically-gated ion-
channels. Dendrites typically have more chemically-gated than voltage-gated ion-
channels (Siegel et al., 1999).  
The voltage-gated channels that play an important role in the transmission of APs 
are sodium (Na
+
) and potassium (K
+
) channels. Na
+ 
channels are more sensitive 
to voltage change than K
+ 
channels, and open more rapidly. Thus, in a 
depolarization, the Na
+ 
ions will rush into the axon faster than the K
+ 
ions will 
rush out. This sudden depolarization (called an AP) will briefly result in a 
+30 mV potential difference (Lodish et al., 2008). This process of positive 
feedback continues until all the Na
+ 
channels are activated. Within milliseconds 
(ms), the rising membrane potential results in the closure of the Na
+ 
channels and 
opening of the K
+ 
channel thereby, restoring the negative potential across the 
membrane, and terminating the AP (Widmaier et al., 2006). 
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I.3 Role of Calcium ions in the process of exocytosis 
Once the AP reaches the presynaptic terminal, it causes a third kind of voltage-
gated ion-channel to open (Wykes et al., 2007): Ca
2+
channels (Giagtzoglou et al., 
2009). VGCCs are a diverse family of molecularly and pharmacologically distinct 
ion-channels underlying various forms of synaptic plasticity (Fourcaudot et al., 
2009). In several mammalian synapses such as hippocampus, cerebellar, calyx of 
Held, it has been shown that NT release requires Ca
2+
 entry into the presynaptic 
terminals via numerous VGCCs (Bucurenciu et al., 2010). The VGCCs are 
clustered at the AZ (Giagtzoglou et al., 2009). It is well established that Ca
2+
 
influx through VGCCs, following arrival of APs to the nerve terminal, results in a 
rapid and localized Ca
2+
 signal that interacts with Ca
2+ 
sensors on the exocytotic 
apparatus and initiates various membrane trafficking events (Zhu et al., 2010) that 
trigger SV fusion with the PM, thus releasing NT (Sudhof, 1995). In the CNS, 
Ca
2+ 
influx plays an essential role for the exocytosis of NT release (Wright and 
Angus, 1996; Fourcaudot et al., 2009; Atlas, 2010), process outgrowth and 
synaptic plasticity (Nachman-Clewner et al., 1999). Voltage-activated and 
receptor-operated Ca
2+ 
channels are located on the PM and on the internal 
membrane of cytosolic organelles of neurons in most brain areas. Ca
2+ 
also plays 
a crucial role in regulating various cellular processes such as; synaptic 
transmission, muscle contraction, gene transcription, synaptic plasticity (Verma et 
al., 2009), and even neurotoxicity and neuronal death (Bertolino and Llinas, 
1992; Bucurenciu et al., 2010). VGCCs are essential elements of fast stimulus-
secretion coupling in presynaptic terminals of the neurons (Zhu et al., 2010). 
Under resting conditions, the Ca
2+
concentration of the extracellular fluid is in the 
millimolar (mM) range, whereas the intracellular free Ca
2+
concentration is 100 
nanomolar (nM). Vesicular fusion may occur at 10–25µM Ca2+, but during 
normal synaptic activity intracellular Ca
2+
 concentration ([Ca
2+
]i) may exceed 
200µM locally (Omiatek et al., 2010). Two major consecutive Ca
2+
 binding 
events characterize the dynamics of the release process: first, Ca
2+
 binds at the 
selectivity filter, the polyglutamate EEEE motif of the VGCC and subsequently 
following a brief and intense Ca
2+
 inflow; Ca
2+
 binds to synaptotagmin, a 
vesicular protein (Atlas, 2010). The effect of the NT on the postsynaptic 
membrane (on the subsequent neuron) will depend on the nature of the NT, the 
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nature of the postsynaptic receptors, and whether the postsynaptic ion-channels 
are voltage-gated (Wright and Angus, 1996) or chemically-gated.  
Ca
2+
 also acts as a secondary messenger to co-ordinate the release of enzymes, 
opening/closing of the ion-channels, the expression of genes that are responsible 
for cellular responses such as long-term potentiation (LTP) (Bertolino and Llinas, 
1992). Additionally, the coupling between presynaptic Ca
2+
 channels and Ca
2+ 
sensors of exocytosis is of fundamental importance for the timing and efficiency 
of synaptic transmission (Bucurenciu et al., 2010). 
VGCCs play a crucial role in the normal functioning and in various pathological 
processes that occurs in neuronal, neurosecretory and muscle cells (Dolphin, 
2006). An interesting property of the VGCCs in the transmembrane Ca
2+ 
entry is 
the fact that multiple Ca
2+ 
channels coexist within the same cell (Serulle et al., 
2007). The study done by Bucurenciu et al., (2010) concluded that, opening of a 
large number of Ca
2+
 channels is necessary for exocytosis at mammalian 
synapses (Bucurenciu et al., 2010). These channels can be distinguished by their 
particular pharmacological and biophysical properties (Bertolino and Llinas, 
1992). Various classifications of Ca
2+ 
channels are a simplification and do not 
reflect the structural heterogeneity of these heterooligomeric integral membrane 
proteins. Progress in molecular biology has revealed that VGCCs are formed as a 
complex of several different subunits: α1, α2δ, β1-4, and γ (Catterall and Few, 
2008). The α1 subunit forms the ion-conducting pore while the associated 
subunits have several functions including modulation of gating (Dolphin, 2006). 
The multiple VGCCs are subdivided into two classes by the pattern of channel 
activation; 1) low voltage-activated (LVA) or low threshold and 2) high-voltage 
activated (HVA) or high threshold channels. Researchers have showed that LVAs 
conductance is situated in the soma whilst HVA Ca
2+ 
conductances are localized 
in the dendrites and terminals  of the neurons. LVA channels are also called "T" 
(for transient), and HVA channels are further divided into three subclasses: "L" 
(for long-lasting), "N" (for neither T nor L or neuronal) and "P" (for Purkinje cell) 
(Bertolino and Llinas, 1992; Wright and Angus, 1996). Many of these channels 
appear to have a complex structure comprising the ionophore and multiple ligand 
binding sites that regulate the activity of the channel. Among various VGCCs, N-
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type and P/Q-type Ca
2+ 
channels play a major role in regulating the presynaptic 
NT release (Zhu et al., 2010).  
The HVA Ca
2+ 
channels are composed of five polypeptide subunits with different 
molecular masses. They are α1 subunit (~175 kd), which form the ion-channel 
and may contain the 1,4 dihydropyridine (DHP) and the phenylalkylamine 
binding site. The α2 subunit (~143 kd) is associated with α1 and does not contain 
any high-affinity binding site; and the three low molecular weight subunits, β 
(~54 kd), γ (~30 kd) and δ (~27 kd) in an approximately stoichiometric ratio 
(Dolphin, 2006). The α1 and β subunits contain phosphorylation sites for cyclic 
AMP-dependent protein kinase (Bertolino and Llinas, 1992). 
The α1 subunit is believed to be the principle structure of the Ca
2+ 
channels, which 
has four homologous domains that are predicted to criss-cross the cell membrane 
and form channel pore. Each of these domains is composed of six transmembrane 
segments (Bertolino and Llinas, 1992). The α1 subunit forms the Ca
2+
 selective 
pore, which contains voltage-sensing machinery and the drug/toxin-binding sites. 
Ten distinct α1 subunits have been identified in humans (Nachman-Clewner et al., 
1999). 
Hydropathy analysis indicated that, the α1 subunits have 24 putative 
transmembrane segments that are arranged into four homologous repeated 
domains, with intracellular linkers and N- and C-termini. The four members of 
the CaV1 family are all L-type channels. CaV1.1 is skeletal muscle isoform, and 
CaV1.2 is prevalent in cardiac muscle, CaV1.3 and 1.4 are activated at lower 
voltage thresholds, and have restricted distribution. CaV2.1 is the molecular 
counterpart of P/Q-type Ca
2+ 
channels CaV2.2 or α1B is the molecular counterpart 
of the neuronal N-type Ca
2+ 
channels (Fourcaudot et al., 2009). CaV2.3 or α1E 
was initially thought to be a LVA channel, but it is now thought to contribute to 
the molecular counterpart of the R-type Ca
2+
 current (Dolphin, 2006).  
Various combinations of the L-type Ca
2+
 channel subunits gives rise to a variety 
of Ca
2+
channels that differ in their Ca
2+
 permeation properties and characteristics 
of their DHPs binding sites. The α1-β combination results in greater number of 
DHPs binding sites (Nachman-Clewner et al., 1999).  
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The β-subunit is believed to contribute in the activation and inactivation 
properties of the channel. Gating of the channel is accelerated when the β-subunit 
is present and helps in stabilizing the α1 subunit (Bertolino and Llinas, 1992).  
The α2 is the extracellular glycosylated subunit that interacts with the α1 subunit. 
The δ subunit has a single transmembrane region with a short intracellular 
portion, which serves to anchor the protein in the PM (Dolphin, 2006). 
The γ subunit glycoprotein (33 kDa) is composed of four transmembrane 
spanning helices. The γ1 subunit does not play a role regulating the channel 
complex. However, γ2, γ3, γ4 and γ8 are also associated with AMPA glutamate 
receptors (Dolphin, 2006). 
I.3.1 T-type calcium channels 
These types of VGCCs are activated with a weak depolarization and carry a 
transient current at negative membrane potentials that inactivates rapidly during a 
prolonged pulse. The experiments carried out on the rat dorsal root ganglion cells 
demonstrated that, the T currents are activated at approximately -50mV, reaches 
its maximum value between -40 to -10mV, and is inactivated by holding the 
potential more positive than -60mV. However, interestingly these experiments 
found that the inactivation is eliminated if the potential decreases form -60mV to 
-100mV (Bertolino and Llinas, 1992). The precise structure of the T-type channel 
has not been elucidated, due to the lack of selective ligands. 
As the T-type VGCCs are activated at a negative potential close to the membrane 
resting potential, it is responsible for neuronal oscillatory activity, that is, 
spontaneous membrane potential fluctuations that are not mediated by synaptic 
activity. These oscillatory activities may play an important role in various brain 
functions, such as regulation of wakefulness, motor coordination, and neuronal 
circuit specification during ontogenesis via oscillatory electrical activity 
(Bertolino and Llinas, 1992). The studies carried out on the thalamic neurons, 
confirmed that tonic-firing activity is most commonly recorded in wake animals 
and phasic firing corresponds to slow-wave sleep. It is believed that, phasic firing 
is dependent on Ca
2+
entry through T-type Ca
2+ 
channels. The experiments on 
inferior olivary nucleus neurons in brain stem slices showed that, intrinsic phasic 
 
 
11 
oscillatory activity occurs due to the activation of a low-threshold Ca
2+
 
conductance, which produces an after depolarization responsible for the initiation 
and maintenance of the oscillatory activity (Bertolino and Llinas, 1992). 
I.3.2 L-Type (long lasting) Calcium channels 
As mentioned earlier, L-type VGCCs are classed under HVA channels, as they 
require large depolarization to be activated, and they inactivate slowly (Nachman-
Clewner et al., 1999). They are present in muscle, heart, smooth muscle and 
neurons (Dolphin, 2006). The L-type channels are sensitive to DHPs. The L-type 
Ca
2+ 
channels play a role in the generation of AP, signal transduction events at the 
cell membrane (Bertolino and Llinas, 1992), neuronal differentiation, neurite 
outgrowth and NT release (Nachman-Clewner et al., 1999). 
One of the striking features of the L-type VGCCs is that the channels open during 
the membrane depolarization only when phosphorylated (Bertolino and Llinas, 
1992). L-type channels generally regulate Ca
2+
 influx into the soma and dendrites 
(Yang et al., 2009), whereas other VGCCs control presynaptic activities (Verma 
et al., 2009), although some of this data is based on the lack of effect of inhibition 
of L-type channels on NT release from nerve terminals. This question has been 
addressed in this thesis. Existence of L-type Ca
2+
 channels have been confirmed 
in many regions of the CNS, such as the hippocampus, cerebral cortex, 
cerebellum, spinal cord, and retina. The microfluorometric imaging studies on 
brain slices demonstrated that, L-type channels are located on the cell bodies and 
proximal dendrites of neurons, and are clustered at high density at the base of the 
major dendrites i.e. they represent a major postsynaptic channel. The wide 
distribution of the L-type Ca
2+
 channel, both at the level of the CNS and of a 
single neuron, reflects the multiple cellular functions of this channel (Bertolino 
and Llinas, 1992). However, L-type channels are also presynaptic and can be 
localized at the nerve terminal e.g. experiments on ribbon synapses concluded 
that, L-type Ca
2+
 channel activity on nerve terminals stimulates 
neurotransmission and contributes to presynaptic structural plasticity (Nachman-
Clewner et al., 1999). 
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Albrecht Fleckenstein coined the term Ca
2+
 antagonist for any drug that blocked 
excitation-contraction coupling in the same way as removal of external Ca
2+
ions. 
He later discovered nifedipine (Nif) as a Ca
2+
 antagonist, the first molecule of 
many in the therapeutically important class of DHPs. The various classes of Ca
2+
 
antagonists were found to block Ca
2+
 currents with differential selectivity in 
cardiac and smooth muscle in a state-dependent manner, and this forms the basis 
of their therapeutic role as antihypertensive and antianginal drugs (Dolphin, 2006; 
Yang et al., 2009). Nif binds to a specific recognition site associated with the α1 
subunit (Dolphin, 2006). Bay K 8644 selectively increases the current generated 
by L-type channels. Single-channel analysis has demonstrated that DHP Ca
2+
 
antagonists affect the activity of the channel by favouring particular modes of 
gating rather than by blocking the pore of the channel. It has been exhibited that, 
these pharmacological agents can either up- or down-regulate the DHP binding 
sites (Bertolino and Llinas, 1992). 
Dolphin, (2006) indicated that in neurons some HVA Ca
2+
 current was not L-
type, as it was not blocked by DHPs (Dolphin, 2006). This current was inferred to 
be particularly prevalent at presynaptic terminals, as synaptic transmission was 
generally found to be DHP insensitive (but see experiments performed in this 
thesis). The additional non-L-type current component was then subdivided 
according to its biophysical properties, and subsequently explored with the aid of 
several invaluable toxins (Bertolino and Llinas, 1992).  
I.3.3 N-Type (for Non-L and Neuronal) channels 
 N-type Ca
2+
 channels are predominantly expressed on presynaptic terminals 
(Verma et al., 2009). In dorsal root ganglion neurons, the N-type channel was 
distinguished by range of inactivation between -120 and -30mV. The N-type Ca
2+
 
channel was insensitive to DHPs and seemed to have slow inactivating 
component and a sustained long-lasting component, and the same N-type channel 
seems to be responsible for both of these two components (Bertolino and Llinas, 
1992).  
N-type channels are blocked by toxic peptides isolated from the fish-eating 
marine cone shell mollusc snail, Conus geographus, termed ω-conotoxin GVIA 
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(Bertolino and Llinas, 1992; Wright and Angus, 1996; Dolphin, 2006; Verma et 
al., 2009). Thus, GVIA can inhibit NT release from the nerve terminals by a pre-
junctional action (Wright and Angus, 1996). GVIA blocks highly selectively N-
type channels, and does not affect any other neuronal VGCCs, or post-junctional 
L-type Ca
2+
 channels (Wright and Angus, 1996). This N-type channel blocker is 
potent, rapid, and rapidly reversible (McDonough et al., 1996). GVIA irreversibly 
blocks stimulus-evoked release of acetylcholine at the frog neuromuscular 
junction by inhibiting the presynaptic Ca
2+
 channels. Furthermore, studies 
performed on isolated frog dorsal root ganglion neurons showed that synthetic 
GVIA selectively caused depression of Ca
2+
current without an effect on the Na
+
 
current or affecting the L-type channels (Bertolino and Llinas, 1992). Allodynia 
and hyperalgesia due to neuropathic pain has also been observed to be causally 
related to the N-type VGCCs (Verma et al., 2009).  
I.3.4 P/Q-type Calcium channels 
 A very slowly inactivating Ca
2+
 channel was identified in many mammalian 
central neurons such as cerebellum granule (Wright and Angus, 1996) and 
Purkinje cells (Dolphin, 2006). Such cells were highly resistant to responses to 
both DHP and GVIA following nerve depolarization (Dolphin, 2006). The P/Q-
type channel is thought to be a widely distributed Ca
2+
 channel in the mammalian 
CNS (Bertolino and Llinas, 1992). They are present in Purkinje cells (particularly 
in the dendrites and presynaptic terminals), the inferior olivary nucleus, several 
nuclei in the brain stem, olfactory bulb, enthorinal cortex, the hippocampus and 
the neocortex. They are also detected in retina, the hypophysis, and developing 
granule cells in the cerebellum. Additionally, the P/Q-type channel appears to be 
the channel responsible for the high-threshold Ca
2+
 current (Dolphin, 2006). 
The P/Q-type Ca
2+
 channel contains a pore-forming α1A subunit and several 
regulatory subunits, including intracellular β subunits (CaVβ1–4) that bind to the 
intracellular loop between transmembrane domains I and II of α1A (see Figure C 
for an illustration of the channel complex). The effect of the regulatory subunits is 
essential for increasing the expression levels and modulating the voltage-
dependent activation and inactivation of P/Q channels (Serra et al., 2010). It is 
believed that, deletion of both alleles of the P⁄Q-type VGCCs Cav2.1 (α1A) 
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subunit gene in mouse leads to severe ataxia and early death (Lonchamp et al., 
2009). 
Initially, these channels were called P-type (for Purkinje), and were found to be 
sensitive to a component of the venom from the American funnel-web spider, 
Agelenopsis aperta. Eventually it was established that a peptide, ω-Agatoxin IVA 
(Aga TK) isolated from the venom of the funnel web spider was a selective 
antagonist (at concentration <100 nM) and blocked P-type channels (Wright and 
Angus, 1996; Serulle et al., 2007).  
Another Aga TK-sensitive current (blocked at high concentration of ≥100 nM), 
that was also blocked by the toxin ω-conotoxin MVIIC (MVIIC) from the venom 
gland of the snail Conus magus, (McDonough et al., 1996; Wright and Angus, 
1996), showed more rapid inactivation and had a lower affinity for the Aga TK 
and was identified in cerebellar granule cells. Aga TK actions was slow in onset, 
but it was very slowly reversible (McDonough et al., 1996). This current was 
originally thought to represent a different channel, and it was termed the Q-type 
channel (Dolphin, 2006). These two distinct current components are now usually 
combined and labelled as the P/Q channel, and the differences probably arise due 
to different splicing of the same molecular entity or association with different β-
subunits (Dolphin, 2006). N-, P- and Q-type Ca
2+
 channels are inhibited by 
MVIIC, with differences in relative potency and kinetics (Wright and Angus, 
1996). It is established that, MVIIC binds to N-type Ca
2+
 channels with an 
affinity of 10-100 fold lower than GVIA (Randall and Tsien, 1995). It also blocks 
P-type Ca
2+
 channels at concentrations 100-1000 fold higher than Aga TK with 
very slow on/off kinetics. It is believed that, MVIIC and Aga TK are equipotent 
at inhibiting Q-type channels (Wright and Angus, 1996).  
There is also a Residual or R-type Ca
2+ 
channel component that is resistant to 
DHPs and the N- and P/Q-type  Ca
2+ 
channel toxins (Randall and Tsien, 1995). 
R-type VGCCs are blocked by Ni
2+
 (Fourcaudot et al., 2009). 
Previous studies have suggested that N-type and P/Q-type but not L-type Ca
2+ 
channels are involved in presynaptic transmission. Furthermore, N-type VGCCs 
regulate NT release at both peripheral and central synapses, whereas the P/Q-type 
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VGCCs play a primary role only at the central synapses (Zhu et al., 2010). Both 
P⁄Q- and N-type VGCCs play a role in glutamate release, while the P⁄Q-type is 
essential in GABA exocytosis in the cerebellum (Lonchamp et al., 2009). These 
VGCCs are critical to stimulus-secretion coupling in the nervous system; 
feedback regulation of such channels by Ca
2+
 is therefore predicted to profoundly 
influence neurotransmission (Wykes et al., 2007; Watanabe et al., 2010). They 
play a prominent role in NT release at most synapses; and coexist at most release 
sites but are not uniformly distributed (Lonchamp et al., 2009).  
Inactivation of the VGCCs is also important to determine its function as it helps 
to define the temporal properties of Ca
2+
 signals. There are two factors that 
control the VGCCs inactivation; voltage and Ca
2+
. Both of these are regulated by 
multiple domains within the pore forming α and auxiliary β subunit. It is believed 
that calmodulin (CaM), a calcium sensor, plays an important role in mediating 
Ca
2+
 dependent inactivation (Wykes et al., 2007). 
VGCCs are also thought to play an additional role in SV exocytosis through 
direct interactions with syntaxin, SNAP-25, and synaptotagmin (Syt) (see later on 
for my information on these particular proteins) at the synprint site in a large 
intracellular loop between transmembrane domains II and III (L II-III) of the 
VGCC α1 subunit  (Refer Figure C) (Watanabe et al., 2010). VGCC synprint sites 
anchor a fraction of AP-2 complex, which is likely linked to the PM via 
interactions with phosphatidylinositol 4,5-bisphosphate [PI(4,5)P2]. This 
synprint-AP-2 interaction occurs for both N- and P/Q-type VGCCs (Watanabe et 
al., 2010).  
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Figure C. Pedigree segregating the A454T mutation and protein location of the amino 
acid change:  Location of the alanine-tothreonine mutation at position 454 (A454T) in 
the I-II intracellular loop of the P/Q channel α1A subunit (Serra et al., 2010). 
I.4 Synaptic vesicles and their various pools 
In a typical synapses, the presynaptic terminal contain copious amounts of SVs 
(approximately 40 nm in size); an AZ at the presynaptic PM, at which the 
numerous SVs are clustered (Fdez and Hilfiker, 2006); and in front of the 
presynaptic AZ, the postsynaptic cell also forms a thickening in the PM, which is 
referred to as postsynaptic density (PSD) (Sudhof, 1995). Such vesicle clusters, 
together with local vesicle recycling events, allow nerve terminals to regularly 
convert APs into secretory signals over a large firing range. There are about 200-
500 SVs per nerve terminal. However, there are no more than 30 SVs bound to 
the AZ at a synapse, and most SVs are free in the cytosol of the nerve terminal 
(Peters et al., 1991). 
In a classic presynaptic nerve terminal, various pools of SVs are observed. These 
vesicles can be subdivided into distinct pools based on their morphology and 
physiology. Morphologically these pools are distinguished according to their 
proximity to the PM. The pools that are situated closely to the PM (at AZ) are 
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called the docked vesicle pools (5-10%) and those that are away are called the 
reserve pool (Fdez and Hilfiker, 2006). The docked vesicles are generally thought 
to be ready for release since they can be fused by rapid uncaging of intrasynaptic 
Ca
2+
, a 10ms Ca
2+
current pulse, a brief high-frequency train of APs or by 
hypertonic stimulation (Wasser and Kavalali, 2009).  
Physiologically the pools are divided by the vesicles‟ ability to be released. These 
were readily releasable pools (RRP), reserve pool (RP) and silent pool (Refer 
Figure D) (Santos et al., 2009; Cheung et al., 2010). This release-ready pool of 
vesicles is referred to as the immediately releasable pool or the RRP, are primed 
for release and thought to be docked to the AZ (Fernandez-Busnadiego et al., 
2010). RRP are the pool from which the vesicles are recruited by low-frequency 
stimulation (Igarashi and Watanabe, 2007). In addition to the morphological 
docking, a “priming” step is required to make vesicles fully release competent 
(Wasser and Kavalali, 2009). Direct association between the morphological and 
physiological pools are not defined however, the RRP feeds from both docked as 
well as non-docked vesicles and the recycling pool/also called the RP (in this 
thesis this term is prefered as the RRP is also included as part of a recycling 
pool), defined as vesicles that are capable of entering the exocytic/endocytic cycle 
under normal conditions corresponds to around 20% of the total vesicle pool. The 
RP is believed to be spatially distant from the release sites and replenishes the 
vesicles in the RRP that have exocytosed. The number of vesicles contained in 
the RRP is a critical parameter that regulates the probability of release, which is 
defined as the probability that a presynaptic AP can result in an exocytotic event 
(Wasser and Kavalali, 2009). Another pool of vesicles are thought to exist, who 
do not play a role in the synaptic transmission and are called „silent‟ or „reluctant‟ 
or „resting‟ pool of vesicles. Their role is still to be elucidated (Fdez and Hilfiker, 
2006; Wasser and Kavalali, 2009). This functional allocation of SVs into pools 
aims to account for the properties of evoked NT release during activity (Wasser 
and Kavalali, 2009). 
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Figure D The classic three-pool model of synaptic vesicle: The silent/resting pool makes 
up 80–90% of the total pool, and the recycling pool consisting of the RRP and the RP is 
significantly smaller ( 15–20%). The RRP consists of a few vesicles ( 1%) that seem to 
be docked and primed for release (Rizzoli and Betz, 2005). 
I.4.1 Synaptic Vesicle cycle  
The relationship between APs and release is regulated by intracellular signal 
transduction cascades, and can be drastically altered by the repeated use of a 
synapse (Fdez and Hilfiker, 2006). NT release involves specialized pathway of 
intracellular trafficking. SVs go through a cycle of processes before the NT is 
released (Details in Figure E) (Fernandez-Busnadiego et al., 2010). To serve the 
special needs of synaptic secretion, the SV cycle differs from many other 
intracellular trafficking pathways (Lodish et al., 2008). The major differences are 
in the high degree of regulation of intracellular trafficking in the nerve terminal, 
the exclusive targeting of SVs exocytosis to AZ, the high speed with which 
Ca
2+
 can trigger release, the tight coordinate regulation of all steps of the cycle 
and the restriction of SV exocytosis in any given nerve terminal to one SV at a 
time. In spite of these differences, however, the SV cycle has all of the basic 
characteristics of other intracellular trafficking pathways and shares the same 
fundamental mechanisms (Siegel et al., 1999). Details of this cycle explained in 
supplementary introduction. 
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Figure E. The classical synaptic vesicle cycle (Full Fusion): The pathway of SVs in the 
nerve terminal is divided into 9 stages. 1: Empty SVs take up NTs by active transport 
into their lumen using an electrochemical gradient that is established by a proton pump 
activity. 2: Filled SVs are translocated to the AZ. 3: SVs attach to the AZ of the 
presynaptic plasma membrane but, to no other component of the presynaptic PM, in a 
targeted reaction (docking). 4: SVs are primed for fusion in order to be able to respond 
rapidly to a Ca
2+
 signal later. Priming probably is a complicated, multicomponent 
reaction that can be subdivided further into multiple steps. 5: Ca
2+
 influx through 
voltage-gated channels triggers NT release in less than 1ms. Ca
2+
 stimulates completion 
of a partial fusion reaction initiated during priming. 6: Empty SVs are coated by clathrin 
and associated proteins in preparation for endocytosis. Ca
2+
 may be involved in this 
process. 7: Empty SVs shed their clathrin coat, acidify via proton pump activity and 
retranslocate into the backfield of the nerve terminal. 8: SVs fuse with early endosomes 
as an intermediate sorting compartment to eliminate aged or mis-sorted proteins. 9: SVs 
are freshly generated by budding from endosomes. Although some SVs may recycle via 
endosomes (steps 8 and 9), it is likely that the endosomal intermediate is not obligatory 
for recycling and that SVs can go directly from step 7 to step 1 (Siegel et al., 1999). 
(Futher note that this cycle does not include the non-clathrin dependent Kiss-and-run 
recycling of SVs that is discussed in detail in this thesis.) 
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1.5 Modes of Exocytosis  
The aqueous compartment inside a vesicle makes its first connection with the 
extracellular fluid through an intermediate structure termed the exocytotic fusion 
pore (Jackson and Chapman, 2006). Lipidic fusion pores are fusion intermediates 
with highly curved membrane, and deforming membranes into such an hourglass 
shape requires a substantial amount of energy. Distinctly, fusion pore composed 
of protein can connect two membranes without bending them (Zhang and 
Jackson, 2010). Ca
2+
 is one of the major factors that affects the opening and 
dilation of the fusion pore. In DCVs fusion pore openings and re-closures were 
regulated by Ca
2+
 levels selectively meditated by L-type Ca
2+
channel entry (Xia 
et al., 2009). Ca
2+
-triggered exocytosis membrane bending opposes fusion pore 
dilation rather than fusion pore formation. Ca
2+ 
-triggered exocytosis begins with 
a proteinaceous fusion pore with less stressed membrane, and becomes lipidic as 
it dilates, bending membrane into a highly curved shape. A Ca
2+
-induced shift of 
exocytic modes to kiss-and-run has been reported for endocrine cells. L-type Ca
2+
 
channels exclusively mediate the Ca
2+
 influx that triggers DCV exocytosis in the 
soma of hippocampal neurons. Previous work indicated that L-type Ca
2+
 channels 
are localized to somatodendritic regions, where they mediate depolarization-
induced entry of Ca
2+
, which regulates gene transcription. The distribution of L-
type Ca
2+
 channels might also underlie the differences in release probability and 
fusion pore kinetics observed above for DCVs in the cell body and neuritis (Xia 
et al., 2009). Therefore, the appearance of the SVs at rapid synapses is such that 
least energy is used and NTs are released with a greater speed.   
I.5.1 Full Fusion  
In the full fusion (FF) mechanism, the fusion pore expands such that the SV 
membrane collapses on the PM and fuses completely with it via an “Ω” figure to 
permit the absolute release of the NTs (Zhang et al., 2007; Lynch et al., 2008; 
Aoki et al., 2010). Thereafter, the excess of membrane is retrieved by 
endocytosis.  In the classical model of SV recycling after neurotransmission, the 
membrane retrieval occurs at a distant location from AZ, and fusion of the 
internalized membrane with an endosome-like compartment (Alés et al., 1999). A 
major pathway for SV recycling is endocytosis by clathrin-coated vesicles 
(CVVs) (Henkel et al., 2001; Rizzoli and Jahn, 2007). It is mediated by complex 
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protein machinery that controls membrane lipid composition, cargo recognition, 
clathrin coat assembly, membrane invagination, membrane fission, and coat 
disassembly (Brose and Neher, 2009). It has been proposed that fast and slow 
endocytosis represent clathrin-independent (Shupliakov, 2009) and clathrin-
dependent membrane retrieval, respectively (Figure F) (Lou et al., 2008b). Both 
are initiated by CaM and require GTP hydrolysis and dynamin (Wu et al., 2009). 
Figure F. Neurotransmitter Release at Active Zones under Low- and High-Stimulation 
Frequencies: (A) SVs (orange) in nerve terminals are tethered to a filamentous 
cytoskeleton. A small subsets of SVs are in close physical contact with the PM (depicted 
as three docked vesicles). Postsynaptic dense projections (purple) on the PM tether 
docked vesicles and Ca
2+
 channels (green). At low-stimulation frequencies, a single 
docked vesicle near a Ca
2+
 channel may undergo exocytosis and release NT into the 
synaptic cleft. The local Ca
2+
-microdomain that triggers vesicle fusion dissipates quickly 
and global levels of [Ca
2+
]i remain low. Fast endocytosis allows for the rapid clearance of 
the fused vesicular membrane from the AZ, so that empty docking sites may be quickly 
reused. The AZ remains organized and suffers minimal disruption. Vesicles retain their 
identity and recycle back to the RP.(B) At high firing frequencies several Ca
2+
 channels 
open at the AZ and multiple vesicles may fuse with the PM. Global [Ca
2+
]i levels are 
now high, and more time and energy is needed to reduce [Ca
2+
]i levels. The large 
increase in AZ area may temporarily disrupt the organization of the AZ and vesicle pool 
depletion may contribute to synaptic depression. In addition, as proposed by, slow 
endocytosis may be triggered by local Ca
2+
-microdomains to promote recovery from 
short-term synaptic depression (Kim and von Gersdorff, 2009). 
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I.5.2 Kiss-and-run 
An alternative model, the „kiss-and-run‟ (K&R), proposes that the fusion pore 
(either a lipophilic pore or proteinaceous pore) either abruptly closes or the fusion 
pore dilates but subsequently recloses and the SVs may transiently fuse with the 
PM (Henkel et al., 2001; Richards, 2009), without losing its shape and possibly 
other aspects of their identity (Elhamdani et al., 2006; Zhang et al., 2007); 
thereby releasing their contents through a partially open fusion pore without 
merging with PM (Rizzoli and Jahn, 2007; Aoki et al., 2010) (Figure G). As the 
fusion pore of the SVs is resealed before complete dilation, this transient mode of 
vesicle exocytosis leads to the partial release of NTs depending on the size and 
diffusibility of the cargo (Lynch et al., 2008; Aoki et al., 2010). As glutamate is a 
small molecule, it can all be released during the transient opening of the fusion 
pore whilst other NTs such as NA need to de-complex from the vesicle core 
containing chromogranins and so not all may be released, if the fusion pore only 
has a finite lifetime. However, the molecular mechanism(s) that regulate and 
maintain the transient fusion pore are still unclear (Aoki et al., 2010). This type of 
mechanism is highly Ca
2+ 
dependent and is thought to occur during fast 
endocytosis and is believed to be completely independent of clathrin-dependent 
endocytosis (Graham et al., 2002; Elhamdani et al., 2006; Lou et al., 2008b). 
Although K&R is accepted as a mode of transmitter release both in central 
neurons and neuroendocrine cells, the prevalence of this mechanism compared 
with FF is still in doubt (Elhamdani et al., 2006). The existence of both dynamin-
dependent i.e clathrin-dependent and dynamin-independent pathways for fast 
K&R contributes to the determination of quantal size released by the nerve 
terminals (Graham et al., 2002). The K&R mechanism is thought to be occurring 
at the AZ, whilst clathrin-mediated endocytosis and bulk endocytosis occur at the 
periactive zone surrounding the sites of release. Note it has been suggested by 
some that dynamin plays a role in the K&R mode and this thesis provides 
evidence for this. 
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Figure G. Part of the „Vesicle Cycle‟ of Exo and Endocytosis: For simplicity, the case of 
K&R exo-endocytosis is depicted on the right side. However, the argument about rate 
limitation of the site-clearing step 5a would also hold for classical endocytosis, if it is 
assumed that the interaction between an AZcomponent and some component of the 
vesicle or release machinery has to be reversed before another vesicle can dock (Neher 
and Sakaba, 2008). 
Ca
2+
 may modulate the mode of exocytosis–endocytosis by regulating the rate at 
which fusion pores re-close following fusion (Lynch et al., 2008). At low Ca
2+
 
concentrations, vesicles incorporate completely into the PM, whilst with increase 
in Ca
2+
 accumulation from 10 to 200µM, increases the probability and rate of re-
closure of the fusion pore, leading preferentially to K&R events (Alés et al., 
1999). Additionally, the phosphorylation of certain proteins regulates the mode of 
exocytosis by affecting the conductance and stability of the pore (Henkel et al., 
2001). Blocking rapid endocytosis that normally terminates transient fusion 
events also promotes FF events. Thus, [Ca
2+
]i controls the transition between 
transient and FF, each of which is coupled to different modes of endocytosis 
(Elhamdani et al., 2006). 
Recent experiments using styryl-FM fluorescent dyes (explained in detail later) 
have provided evidence that SVs can be internalized much faster than was 
previously thought, in the order of few seconds, and that SVs are recycled 
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without passing through an endosomal compartment (Alés et al., 1999). Evidence 
is provided that fusion pore mediated release (K&R) gives rise to different 
concentration profiles of glutamate in the synaptic cleft (Rizzoli and Jahn, 2007). 
The result of this is very weak activation of alpha-amino-3- hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptors, which gives rise to a predominant 
receptor desensitization, while (under conditions where the magnesium blockade 
is lifted) the NMDA receptors are activated at levels equivalent to those elicited 
by FF (Richards, 2009). 
I.6 Process of Endocytosis  
After exocytosis, the granular membrane has to be recycled in order to avoid 
infinite growth of the PM (Henkel et al., 2001). Central nerve terminals have a 
limited supply of SVs, which must be quickly and reliably recycled to maintain 
NT release, this is particularly important during high stimulation period (Cheung 
et al., 2010). In order to sustain high-frequency NT release, SVs must be 
recaptured rapidly with high fidelity, for regenerating release-competent vesicles, 
such that the newly exocytosed lipid constituents are quickly removed to prevent 
expansion of the presynaptic membrane (Zhu el al., 2009).   
There are three known mechanisms of SVs endocytosis: (1) clathrin-dependent 
endocytosis after full collapse of the fusing vesicle (which a principle mechanism 
of exocytosis) (Elhamdani et al., 2006), (2) bulk endocytosis via large membrane 
invaginations, and (3) K&R fusion and retrieval, during which only a transient 
fusion pore is formed (Brose and Neher, 2009) (Figure H). Experiments have 
demonstrated that K&R is the major mechanism of vesicle exocytosis under 
moderate stimulation conditions; sustained stimulation favours the incidence of 
FF events at the expense of transient events. Stimulation frequency controls the 
open time and the conductance of the fusion pore; high [Ca
2+
]i favours FF, not 
K&R. Rapid endocytosis is associated with K&R events. When RE is abrogated, 
FF takes place and vesicles are recovered by SE, a process that was previously 
shown to be similar to CCVs endocytosis (Elhamdani et al., 2006). In the results, 
it is  shown that these statements are not exactly correct as they do not take into 
account the different pools of SVs and these statements are re-worded in the 
discussion. 
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Endocytosis allows the internalization of these vesicles to undergo another round 
of secretion. A characteristic property of presynaptic terminals is their high 
endocytic capacity. This property enables synapses to function reliably even 
during high frequency axonal firing (Lou et al., 2008b). It is believed that 
exocytosis and endocytosis are coupled (Richards, 2009). It is, however, 
uncertain whether exocytosis and endocytosis are tightly coupled, such that 
secretory vesicles fuse only transiently with the PM before being internalized (the 
K&R mechanism), or whether endocytosis occurs by an independent process 
following complete incorporation of the SV into the PM (FF) (Alés et al., 1999; 
Zhu et al., 2009).  
Bulk endocytosis is the process in which nerve terminals retrieve large amounts 
of SV membrane during episodes of strong stimulation intensity. Bulk 
endocytosis invaginates large areas of presynaptic membrane from which SVs 
can be generated over time. These large endosomes can remain attached to the 
PM for a considerable amount of time, and these allow SVs to bud from them 
(Figure H). Alternatively, the large endosomes enters into the terminal where 
budding of SV subsequently occurs. The process is rapidly activated and is 
thought to be Ca
2+
 dependent in a similar manner to SVs exocytosis (Clayton et 
al., 2007). Additionally, different forms of bulk membrane retrieval can be 
recruited in central synapses during intense stimulation (Ales et al., 1999). It has 
been suggested that clathrin-mediated endocytosis (CME) is dominant during 
mild neuronal activity, and activity dependent bulk endocytosis (ADBE) is 
dominant during intense neuronal activity. ADBE is a fast, high capacity SV 
retrieval mode that invaginates large regions of PM, creating bulk endosomes 
from which SVs can bud (Cheung et al., 2010).  
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Figure H. Multiple SV retrieval pathways in central nerve terminals: Three different 
mechanisms are proposed to retrieve SV membrane after exocytosis in nerve terminals. 
K&Ris a mechanism where the SV never fully fuses with the PM and is retrieved intact. 
Classical clathrin-dependent endocytosis involves the invagination of a single clathrin-
coated bud from the PM before its fission and uncoating. Bulk endocytosis is the process 
where large areas of nerve terminal membrane are invaginated to produce endosomes 
from which SVs can bud (Clayton et al., 2007). 
I.7 Proteins that participate in the process of exocytosis and 
endocytosis 
I.7.1 Synapsin  
Existence of synapsins is confirmed in all vertebrates and organisms with a 
nervous system. Synapsins are a multigene family of neuron-specific 
phosphoproteins and these represent the most abundant SV proteins (Fdez and 
Hilfiker, 2006). They are encoded by three distinct genes; synapsin I, II and III, 
and alternative splicing generates further variants containing distinct C-termini. 
Most neuronal synapses express synapsins I and II whereas; the levels of synapsin 
III are less abundant. Highly systemic arrangements of cytoskeletal fibers in the 
axon terminals help localize SVs in the AZ (Figure I step 9).  
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Figure I: Presynaptic terminal depicting the main stages of the SV cycle, characterized 
by complete fusion and clathrin-mediated endocytosis: Ten stages can be defined: (1) SV 
docking to the PM, (2) vesicle priming for fusion, (3) Ca
2+
-triggered vesicle fusion, (4) 
clathrin-mediated budding and SV formation, (5) fission of a new vesicle, (6) clathrin 
uncoating, (7) NT loading, (8) vesicle trafficking, (9) tethering in RP and (10) 
mobilization and targeting to the PM release site. Cytoskeletal and tethering proteins 
interact with vesicle lipids to traffic and sequester SVs (Rohrbough and Broadie, 2005). 
The SVs are linked to each other by synapsins that bind the fibrous proteins actin 
and spectrin, and these proteins are associated with the cytosolic surface of all SV 
membrane. Additionally, synapsin filaments radiate from the PM and attach to 
vesicle-associated synapsin. These interactions may allow the SVs to face in the 
right direction, i.e. towards the PM. Synapsins are preferentially located near the 
RPs at the ultrastructural level i.e near the vicinity of the AZ (Figure J). Thus, 
synapsin play a crucial role in recruiting the SVs to the AZ. Such a role is 
supported by the observation that, disruption of synapsin function leads to a 
depletion of the RP of vesicles and an increase in synaptic depression (Fdez and 
Hilfiker, 2006).  Mice lacking synapsin, although viable, are prone to seizures 
during a train of stimulations.  
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Figure J: Synapsins located near the reserve pools at the ultrastructural level i.e near the 
vicinity of the AZ: At the presynaptic terminal, some SVs (those belonging to the RRP 
(dark green) are found docked at the AZ, where they undergo exocytosis to release NTs. 
Numerous vesicles that presumably belong to the RP(light green) are located centrally, 
where they are interlinked to each other by short actin filaments (shown in red) and by 
synapsin (not shown). The subgroups are linked to longer filaments that extend from the 
PM, some of them from the AZ(Leenders and Sheng, 2005). 
It appears that phosphorylation of synapsins is responsible for an important 
functional regulatory switch involved in vesicle mobilization. Synapsins are 
dependent on phosphorylation by a variety of protein kinases. All synapsins are 
substrates for phosphorylation by cAMP dependent protein kinase A (PKA) and 
Ca
2+
/calmodulin-dependent protein kinase II (CaMKII) (Shupliakov, 2009). Thus, 
a rise in cytosolic Ca
2+
 triggers their phosphorylation. Additionally, synapsins are 
differential targets for phosphorylation by CaMKII, with synapsin I (but not 
synapsin II being regulated). Subtle changes in the biochemical properties of 
synapsins are observed due to phosphorylation. Phosphorylation of synapsins by 
PKA/CaMKII drastically decreases their affinity for SVs (Fdez and Hilfiker, 
2006). This appears to cause the release of SVs from the cytoskeleton, thereby 
increasing the number of vesicles available for fusion. It is generally believed that 
synapsins and actin are largely responsible for the clustering of the distal pool of 
vesicles not associated with the scaffolding proteins of the AZ. In addition, 
synapsin migrates to the periactive zone upon stimulation and plays a role in 
promoting actin filament formation at the periactive zone of the synapse, most 
probably aiding in the proper organization in order to promote efficient vesicle 
recycling (Shupliakov, 2009). 
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By altering actin dynamics, activity that elicits synaptic plasticity could remodel 
pre- and postsynaptic actin scaffold, the organization of SV pools or the 
organization of the postsynaptic receptors that are supported by the scaffold. In 
addition, altered actin dynamics could modulate steps of the SV cycle and 
postsynaptic receptor activity or traffic, which are directly regulated by actin 
turnover. Overall, these changes would affect the efficacy of synaptic 
transmission and, thus, synaptic plasticity (Cingolani and Goda, 2008). 
I.7.2 Clathrin  
The composition of lipids and lipid modifications play a critical role in various 
cellular internalization mechanisms, including SV endocytosis (Shupliakov, 
2009). In a typical neuron, there is plethora of SVs, many with a protein coat on 
the cytosolic surface and their membrane, which are formed by reversible 
polymerization of an explicit set of protein subunits under precise regulated 
conditions. This coat subunit protein polymerizes around the cytosolic face of a 
budding vesicle during the vesicle formation. This is crucial, as these coats help 
the vesicle to pinch off from the parent organelle. Clathrin coat is responsible for 
transporting the SVs from the PM and the trans-Golgi network to late endosomes. 
In this process, some coat-protein subunits or associated adapter proteins (AdPs) 
select which membrane and soluble proteins will enter the transport vesicles 
as cargo proteins. These cargo proteins contain short signal sequences, which 
direct them to the precise type of transport vesicle (Siegel et al., 1999). Thirdly, 
the final pinching off requires the GTP-binding protein, dynamin that regulates 
the rate of the vesicle formation (Min et al., 2007).   
The clathrin coat and its AdPs enable internalization of specific cargo proteins or 
SVs. Once internalized, coat rapidly disassembles, thereby allowing the clathrin 
to recycle while the vesicle is transported to a variety of locations. After the 
formation of the bud, only a narrow membrane neck remains, which connects the 
SVs to the PM. The separation of this is carried out by large GTPase dynamin. It 
overcomes the energy for bilayer fusion barrier and membrane separation 
(Lundmark and Carlsson, 2009). Two other proteins have been identified as 
essential for the formation of CCVs: amphyphysin, which binds to dynamin and 
assembly particles (Hosoi et al., 2009), and synaptojanin, which binds to 
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amphyphysin and dynamin. Amphiphysin interacts with dynamin and links 
clathrin-coats to dynamin (Lu et al., 2009). Amphyphysin is believed to recruit 
dynamin to the neck of budding vesicles but the actual function of these two 
proteins to pinch off the SVs with dynamin is still to be elucidated. Additionally, 
Ca
2+
 and amphiphysin may modulate the release of vesicle contents by 
controlling the duration of the open “Ω” shape rather than by selecting between 
K&R and FF modes of fusion (Llobet et al., 2008). Another protein that plays an 
important role in sorting is nexin 9 (SNX9). It strongly binds to dynamin, 
stabilizes the assembled dynamin oligomer and is partially responsible for the 
recruitment of GTPase to sites of endocytosis. SNX9 stimulates GTPase activity 
of dynamin, facilitates the scission reaction, and destabilizes the membrane 
bilayer (Lundmark and Carlsson, 2009).  
CCV-based endocytosis (including receptor-mediated endocytosis) depends on 
intracellular K
+
 (Artalejo et al., 2002).
 
The CCVs are known to be stable at the 
pH and ionic composition of the cell cytosol. The SVs lose their clathrin coat and 
the assembly particles after their formation. Cytosolic Hsc70, a chaperone protein 
is believed to catalyze depolymerization of the clathrin coat into triskelions. 
These triskelions can then be recycled and reused in the formation of additional 
pits and vesicles. The formation and the depolymerization of the CCVs are highly 
regulated, as both these processes occur concurrently (Lodish et al., 2008).  
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Figure K. Model for the formation of a clathrin-coated pit and the selective 
incorporation of integral membrane proteins into clathrin-coated vesicles: The cytosolic 
domains of certain membrane proteins bind specifically to assembly particles that, in 
turn, bind to clathrin as it polymerizes spontaneously over a region of membrane. 
Proteins that do not bind to assembly particles are excluded from these vesicles. 
Dynamin then polymerizes over the neck of the pit; regulated by dynamin-catalyzed 
hydrolysis of GTP, the neck pinches off, forming a clathrin-coated vesicle (Lodish et al., 
2008).  
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I.7.3 Dynamin  
Dynamins (approximately 900-amino-acid cytosolic protein) are a family of 
proteins that are involved in vesicular fission reactions at various membranes 
(Artalejo et al., 2002) and in Drosophila melanogaster, these proteins are 
encoded by shibire (Kramer and Kavalali, 2008). Dynamin has been implicated in 
both rapid endocytosis and receptor-mediated endocytosis (Artalejo et al., 2002). 
It plays a crucial role in the complete formation of clathrin-coated pit, but its role 
in bulk endocytosis is controversial (Lou et al., 2008b).  
There are two types of dynamin: dynamin 2, which is ubiquitously expressed, and 
dynamin 1 that is brain-specific (Artalejo et al., 2002). Expression of dynamin 1 
is essential to allow slow, clatharin-mediated endocytosis to function efficiently 
over wide range of activity (Lou et al., 2008b; Hosoi et al., 2009). It enables the 
presynapse to accommodate high levels of slow endocytosis in response to a 
strong endocytotic load (Lou et al., 2008b). Dynamin1-deficient cortical neurons 
display a large attenuation in evoked responses with no change in the frequency 
of spontaneous events (Fdez et al., 2008). Dynamin2 may mostly control 
receptor-mediated endocytosis in all somatic cells, as it is ubiquitously distributed 
and this form of endocytosis is universal. Whereas, dynamin1 has a much more 
restricted expression and is especially concentrated at nerve terminals, where it 
might participate in rapid endocytotic events governing rapid SV recycling 
(Artalejo et al., 2002). 
Dynamin 1 assembles and polymerizes around the neck of an invaginated pit 
(Bashkirov et al., 2008), like a spring (Robinson, 2007). As dynamin 1 expands 
and twists, it pinches off the membrane from the rest of the PM and this can 
reform the SVs (Robinson, 2007). It binds and hydrolyses GTP to regulate 
contraction of the polymeric dynamin until the vesicle pinches off (Kramer and 
Kavalali, 2008). Hydrolysis of dynamin GTP by the GTPase activity is essential 
for the pinching of the fused CCVs (Fdez et al., 2008). It is thought that, a 
concerted nucleotide dependent conformational change such as a GTP binding 
dependent constriction, hydrolysis-dependent longitudinal expansion of a pre-
assembled dynamin scaffold generates the force required to separate membranes 
(Bashkirov et al., 2008; Pucadyil and Schmid, 2008). The cellular expression of 
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mutant dynamins that cannot bind GTP blocks the formation of CCVs, resulting 
in accumulation of long-necked pits covered with polymerized dynamin. 
Dynamin is designed to selectively target highly curved membrane necks and 
probe their mechanical stability by repetitive squeezing (Bashkirov et al., 2008). 
Dynamin 1 normally becomes activated during the arrival of AP, when it 
becomes dephosphorylated and is inhibited immediately after stimulation by re-
phosphorylation (Robinson, 2007). Dynamin I has two major interactions: one 
which is phosphorylation-independent (i.e. will occur regardless of stimulation 
intensity) and is essential for clathrin-dependent endocytosis (amphiphysin), and 
the other which is phosphorylation-dependent (i.e. will occur only during strong 
stimulation) and is therefore implicated in bulk endocytosis (syndapin). The 
phosphorylation-dependent recruitment of syndapin by the activity-dependent 
dephosphorylation of dynamin I may be the key molecular event in bulk 
endocytosis, a process which is important to nerve terminal function (Clayton et 
al., 2007). It should be noted that dynamin is required for rapid replenishment of 
the RRP of SVs (Lu et al., 2009) and has been implicated in regulating K&R 
exocytosis and this is the subject of some of this thesis.  
Dynasore is a small membrane-permeable compound that functions as a non-
competitive and specific inhibitor of dynamin 1 and dynamin 2 GTPase activity 
in vitro and blocks endocytic functions previously shown to require dynamin 
(Refer Figure L) (Thompson and McNiven, 2006; Kramer and Kavalali, 2008; Xu 
et al., 2008; Hosoi et al., 2009; Chung et al., 2010).  Dynasore provides a means 
to rapidly block the formation of CCVs. It blocks SV endocytosis completely, 
without an immediate effect on exocytosis; thereby suggesting an essential role of 
dynamin in all forms of compensatory SV endocytosis, including K&R events 
(Newton et al., 2006). Clathrin-coated pits were blocked at two stages of vesicle 
formation, an early phase representing shallow pits and a later phase that seemed 
to represent late-stage vesicles that were unable to undergo the final scission 
(Thompson and McNiven, 2006). Dynasore may also act at a downstream step 
involving dynamin activity and subsequently provide constitutive inactivation of 
dynamin across the endocytic cycle (Lu et al., 2009). It inhibits PI(4,5)P2- 
stimulated dynamin 1 activity in a dose-dependent manner (Chung et al., 2010). 
In the study by Newton et al, (2006) it was concluded that dynasore did not have 
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any effect on exocytosis, suggesting that acute and rapid block of dynamin 
function does not have an immediate effect on SV exocytosis. This observation 
also rules out any effect of dynasore on AP propagation, Ca
2+
 channel function, 
or exocytic machinery (Newton et al., 2006). 
 
Figure L. Dyansore-reversible inhibitor of dynamin: Clathrin-coated pits (black) trapped 
at the PM as a result of inhibition of dynamin (red) by dynasore (colored dinosaurs) are 
shown (arrows highlight an example). Also shown are endosomes (yellow), mitochondria 
(green), the Golgi (orange) and the nucleus (brown) (Thompson and McNiven, 2006).I.8 
Soluble N-Ethyl-maleimide-sensitive factor (NSF) attachment 
protein receptors (SNAREs) 
Exocytosis involves the fusion of secretory vesicles with the PM and is governed 
by complex protein machinery that includes SNARE proteins as central 
components (McEwen and Kaplan, 2008; Rizo, 2010). Priming is the process that 
occurs after docking and before SVs fusion (Fdez et al., 2008). SV fusion is 
mediated by the formation of SNARE (SNAP receptor, where SNAP is defined as 
soluble NSF attachment protein) complexes (Vrljic et al., 2010) from the SNARE 
proteins synaptobrevin/VAMP, syntaxin-1 and SNAP-25 (Verona et al., 2000; 
Fdez and Hilfiker, 2006; McEwen and Kaplan, 2008; Darios et al., 2009; Hosoi et 
al., 2009). There is specific v-SNARE for specific types of vesicles, which direct 
them to their respective membrane fusion partner (Jackson and Chapman, 2006). 
Similarly, every cell‟s target membrane has t-SNARE as an integeral membrane 
proteins and SNAP25, a ubiquitous fusion protein. The t-SNARE on the target 
membrane and SNAP25 work together and specifically bind a particular type of 
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v-SNARE on the cargo vesicle to form the core complex (Vrljic et al., 2010; Xue 
et al., 2010). t-SNARE complex would recruit synaptotagmins and change the 
conformation of synaptotagmin with Ca
2+
-binding loops of both C2 domains 
positioned in the vicinity of the same membrane (Refer Figure M) (Vrljic et al., 
2010). All eukaryotic cells express several related v-SNARE and t-SNARE 
proteins, thus permitting each type of transport vesicle to be targeted correctly 
(Igarashi and Watanabe, 2007). 
Figure M. Diagram summarizing the main features of the model of how synaptotagmins 
and SNAREs cooperate in Ca
2+
-dependent membrane fusion: Syntaxin is shown in 
yellow (without its N-terminal region), synaptobrevin in red and SNAP-25 in green. The 
synaptotagmin C2A domain is shown in purple and the C2B domain in blue, with bound 
Ca
2+
 ions shown as orange circles. The relative orientation between the two C2 domains 
is meant to reflect the orientation observed in a synaptotagmin crystal structure, with 
their Ca
2+
-binding loops located on the same side so that they can bind to the same 
membrane. The synaptotagmin–SNARE complex interaction is based on the smFRET 
model built for the synaptotagmin-1–SNARE complex5 and involves the bottom side of 
the C2B domain. The two membranes may be hemifused before Ca
2+
 influx, but this 
feature is not essential. As an alternative, the model shown here assumes that there is no 
hemifusion before Ca
2+
 influx. The left panel represents the two membranes before 
fusion, with some bending in the middle that is induced by the mechanical action of the 
assembled SNARE complex. This effect, together with perturbations caused by binding 
of synaptotagmin to one or both of the membranes, would lead to membrane fusion 
(Rizo, 2010).  
In neurons, the process of fusion is tightly regulated by Ca
2+
 concentration, but 
SNARE complex assembly does not have any Ca
2+
 sensitivity. Other proteins 
interacting with the core of the SNARE complex, such as VGCCs and 
synaptotagmin (a putative Ca
2+
sensor), are considered crucial for the Ca
2+ 
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dependence of release and also molecular mediators of synaptic plasticity 
(Verona et al., 2000; Xue et al., 2009; Rizo, 2010; Vrljic et al., 2010).  
The Ca
2+
-sensing proteins, the synaptotagmins, are a large family of SV proteins 
that, among other functions, act as Ca
2+
regulators of exocytosis. They have a 
hierarchy of Ca
2+
affinities (Johnson et al., 2010).  Synaptotagmin, is believed to 
be a key Ca
2+ 
sensor protein that triggers the SVs exocytosis (Hosoi et al., 2009; 
Opazo et al., 2010) and is a vesicular protein (Lynch et al., 2008). Ca
2+
sensing 
triggers for vesicle fusion are synaptotagmins I and II, which are found 
throughout the CNS and visual system (Johnson et al., 2010). 
Synaptotagmins are comprised of a short intralumenal or extracellular sequence, a 
single transmembrane helix (N-terminal transmembrane domain) that anchors to 
the protein to the SV, a linker and two Ca
2+
-binding domains termed C2A and 
C2B (Jackson, 2007; McMahon et al., 2010; Opazo et al., 2010; Vrljic et al., 
2010). The C2A domain may bind the vesicle/granule membrane, while the C2B 
domain may bind the PM (McMahon et al., 2010). These two C2 domains can 
bind to phospholipids and Ca
2+
 (Igarashi and Watanabe, 2007; Lee et al., 2010). 
Severe loss of Ca
2+
 dependent synchronous release is observed during the genetic 
deletion of synaptotagmin. In response to Ca
2+
 binding, synaptotagmin may 
promote the completion of SNARE-complex, and this brings the SVs and the PM 
into close proximity and that may promote the two lipid bilayers (Refer Figure 
N). This is achieved by inducing a high positive curvature in target membranes 
following C2 domain membrane insertion (Lee et al., 2010). The association of 
VGCC proteins with synaptotagmin and t-SNARE proteins has been suggested to 
be important for the formation of SNARE complexes at AZ (Zhu et al., 2010).   
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Figure N. Synapticvesicle and plasmamembrane proteins important for vesicle docking 
and fusion: Interaction of the t-SNAREs syntaxin and SNAP25 with the v-SNARE 
VAMP is aided by Rab3A. Neurexin, Ca
2+
 channels, and other PM proteins localized to 
the synaptic region may also interact with SV proteins. The vesicle protein 
synaptotagmin is the major Ca
2+
 sensor that triggers vesicle fusion (Siegel et al., 1999).  
I.8.1 Role of SNAREs and SNAPs  
Various biochemical studies have established that v-SNARE, t-SNARE, and 
SNAP25 are sufficient to mediate vesicle fusion. Vesicle-associated membrane 
protein (VAMP)/synaptobrevin on SVs is an essential component for exocytosis 
(Igarashi and Watanabe, 2007; Kim and von Gersdorff, 2009). During the 
exocytosis of the SVs, the v-SNARE VAMP/synaptobrevin is transiently 
incorporated into the PM (Igarashi and Watanabe, 2007). VAMP/synaptobrevin 
in SVs does not readily react with syntaxin or SNAP-25 (Darios et al., 2009). 
Syntaxin the t-SNAREs, an integral membrane protein, and SNAP-25, which is 
attached to the PM by a hydrophobic lipid anchor, palmitoylated cysteines (Fdez 
et al., 2008).  
Repeating heptad sequence is present in the cytosolic regions of these four 
SNAREs i.e. one from VAMP/synaptobrevin, one from syntaxin, and two from 
SNAP-25; which allows them to form four α helices (Fdez and Hilfiker, 2006; 
Xue et al., 2010). These helices coil around each other to form a four-helix 
bundle. It is believed that the four-helix bundle helps the SVs and the PM to come 
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into the proximity of the embedded transmembrane domains of the 
VAMP/SYNAPTOBREVIN and syntaxin, thereby mediating fusion of SVs into 
the PM (Ohyama et al., 2002). SNARE complexes are thought to assemble by 
“zippering” in an N- to C-terminal direction, thereby forcing their resident 
membranes closely together (Fdez et al., 2008). 
After the fusion of the SVs occurs, the SNARE complexes need to dissociate in 
order for them to be available for additional fusion events. As the SNAREs are 
highly stable molecules, additional proteins and energy are required for its 
dissociation. One of the cytosolic proteins required is NSF, a tetramer of identical 
subunits that binds and hydrolyzes ATP (Sudhof and Malenka, 2008). Other 
proteins, called α-, β-, and γ-SNAPs (soluble NSF attachment proteins) are 
required for NSF to link to the SNARE proteins. It is now the consensus that NSF 
and α-SNAP are not necessary for the vesicle fusion but are required for the 
regeneration of free SNARE proteins following the conversion of a trans-SNARE 
complex (where v and t-SNAREs are in distinct membranes) to a cis-SNARE 
complex (where v- and t-SNARES are in the same membrane) (Refer Figure O). 
SNARE proteins not only provide sufficient energy to initiate exocytosis, but also 
to accelerate merger of membranes (Kesavan et al., 2007). 
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Figure O. Schematic model depicting the organization of the non-releasable and 
releasable vesicles vis-à-vis the voltage-gated calcium channel, syntaxin 1A, SNAP-25, 
and synaptotagmin: (A) At rest, Ca
2+
-independent interactions between the calcium 
channel with the SNARE binary-complexes (syntaxin 1A, SNAP-25) and synaptotagmin 
(syt1), assembled into the heteroprotein excitosome complex, hold the vesicles close to 
the channel. These vesicles cannot fuse in part, due to the repulsion between the negative 
charges of the syt1 C2 Ca
2+
-binding site and the negatively charged phospholipids, which 
prevent syt1's conserved basic residues from interacting with the membrane. Prior to 
Ca
2+
 binding to syt1 insertion at the membrane there would be no buckling of the vesicle 
to the membrane. (B) The final structural configuration of the excitosome, prior to the 
fusion event, is accomplished when Ca
2+
 is bound to the syt1 C2 domains. Subsequent to 
a transient elevation in the [Ca
2+
]iconcentration, the Ca
2+
 binding loops of the C2B 
domain rapidly insert into the target membrane, pinning the vesicle at the bilayer (black 
pins). Consequently, the Ca
2+
-dependent changes in syt1 orientation vis-à-vis the 
membrane, modify the interplay within the excitosome proteins and transform the vesicle 
to a releasable state. As depicted, the PM is bent towards the vesicle membrane due to 
concerted actions of multiple C2B domains that could serve to bring the two membranes 
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into closer proximity. The excitosome complex is now associated with a releasable 
vesicle that underwent significant changes at the membrane, including minimizing the 
repulsive hydration force, and significantly lowering the energy barrier for bilayer 
merger (Atlas, 2010). 
For a synapse to function, the proper balance of proteins must localize to the 
presynaptic release machinery, and the protein composition at the release site is a 
likely determinant of its synaptic efficacy. While the general properties of 
synapses formed by a single axon are similar, the release probability of such 
synapses can vary dramatically. This heterogeneity of presynaptic terminals is 
possibly due to mechanisms that control synapse specific plasticity and may 
represent one aspect of the molecular basis of learning and memory (Graf et al., 
2009).  
I.9 Secondary messengers  
I.9.1 Calcium/calmodulin dependent kinase  
Rise in the [Ca
2+
]i ions induces complex formation with calmodulin (CaM: a 
cytosolic Ca
2+
 binding protein) and this can help regulate SV fusion. The activity 
of PM ATPases is regulated by CaM (Pang et al., 2010). CaM is composed of 
148 conserved amino acids and has four Ca
2+
-binding sites (Igarashi and 
Watanabe, 2007). Small changes in the level of [Ca
2+
]i give rise to a variety of 
cellular responses (Ohyama et al., 2002). When the level of Ca
2+ 
increases above 
0.1-0.2µM during stimulation it binds to the four sites on CaM, which results in a 
complex that interacts and alters the activity of various enzymes and other 
proteins (Lodish et al., 2008). CaM is the Ca
2+
sensor for Ca
2+
-triggered 
endocytosis. Data by Wu et al., (2009) suggests that Ca
2+
/binding with CaM 
initiates endocytosis. CaM forms a physical complex with VGCCs and its N and 
C lobes may sense different Ca
2+
concentrations, allowing CaM to mediate 
multiple forms of endocytosis. Additionally, fused vesicle membrane is the 
substrate used by Ca
2+
/CaM to initiate endocytosis (Wu et al., 2009).   
CaMKII is one of the most abundant proteins in neurons, expressed both in the 
pre- and postsynaptic density (Sunyer et al., 2008). CaMKII has α, β, γ, and δ, 
isoforms. The α and β isoforms are dominant in neurons, whereas the γ and δ 
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isoforms are distributed among various tissues. Both α and β isoforms of CaMKII 
bind syntaxin in vitro. CaMKIIα is mainly expressed in glutamatergic neurons 
(Pang et al., 2010).  
Neuronal CaMKII regulates important neuronal functions, including NT 
synthesis, NT release, modulation of ion channel activity, cellular transport, cell 
morphology and neurite extension, synaptic plasticity, learning and memory, and 
gene expression (Yamauchi, 2005). Stimulation of CaMKII, which endogenously 
phosphorylates synaptotagmin in SVs, increased the interaction of syntaxin and 
SNAP-25 with synaptotagmin suggesting that, Ca
2+
/CaMKII
 
can increase the 
synaptotagmin–t-SNARE interactions after phosphorylation (Verona et al., 2000). 
VAMP-2 binds to CaM in a Ca
2+
-dependent manner and this can regulate the 
phospholipid-binding activity of VAMP/synaptobrevin. Additionally, CaM 
binding can prevent VAMP/ synaptobrevin from participating in the formation of 
the SNARE complex (Igarashi and Watanabe, 2007). CaMKII may also play 
some scaffolding roles in addition to its kinase activity. It was proposed that 
CaMKII regulates presynaptic short-term plasticity in the absence of its kinase 
activity (Pang et al., 2010). Figure P shows a schematic representation of the 
activation of CaMKII and of the regulation of neuronal functions. 
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Figure P. Schematic Representation of Activation and Role of CaM Kinase II in 
Neuronal Cells: [Ca
2+
]i is increased by extracellular stimuli, binds to calmodulin, and 
activates CaMKII. CaMKII phosphorylates various kinds of proteins and regulates 
physiological processes. CaMKII protein is induced by the stimuli of differentiation. 
(Yamauchi, 2005). 
Hyper-activation of CaV1.2 L-type VGCCs by CaMKII is associated in Timothy 
Syndrome, a multi-organ human genetic disorder whose symptoms include 
mental retardation and cardiac disease (Yamauchi, 2005). Phosphorylation of the 
N-type Ca
2+
 channel by CaMKII or PKC decreases its interaction with syntaxin 
and SNAP-25, providing a possible regulatory mechanism that may decrease an 
inhibitory constraint of SNAREs on channel function and facilitate release 
(Verona et al., 2000). 
All the CaMKII isoforms are believed to have syntaxin 1A-binding ability and 
these interactions may induce CaV2.1 channels presynaptic regulation (Pang et 
al., 2010). CaMKII is a key downstream effector of L-type VGCC signals.  
CaMKII may bind to and/or phosphorylate the CaV1.2 α1 subunit to support 
multiple forms of L-type VGCC facilitation. CaMKII was also shown to regulate 
excitation-transcription coupling in neurons (Abiria and Colbran, 2010). 
CaM is thought to regulate the asynchronous release, which is not mediated by 
synaptotagmin. It may also play a role in refilling the RRP and/or modulate 
presynaptic release by activating CaMKIIα and CaMKIIβ (Munton et al., 2007). 
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CaM is also thought to control pre- and postsynaptic Ca
2+
-channel function, 
mediates postsynaptic long-term plasticity by activating CaMKIIα and 
calcineurin, and alters neuronal gene expression (Pang et al., 2010).  
CaM regulates NT release by multiple mechanisms, including a direct modulation 
of Ca
2+
 channels, activation of protein kinases, regulation of SV priming via the 
cytoskeleton and a process involving binding to the Munc13-1 and Munc13-2 
isoforms (Shin et al., 2010).  
The CaMK inhibitor 2-[N-(2-hydroxyethyl)]-N-(4- methoxybenzenesulfonyl)] 
amino-N-(4-chlorocinnamyl)-N-methylbenzylamine, KN93, (but not its inactive 
congener M2-[N-(4-methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-
methylbenzylamine, phosphate, KN92) blocked signalling in Sprague-Dawley 
superior cervical ganglion neurons (Wheeler et al., 2008). KN93 exerts its effect 
by competing for the CaM binding site of CaMKII (Rezazadeh et al., 2006).  
Ca
2+
 influx also recruits an adenylyl cyclase, which activates the cAMP-
dependent PKA leading to its translocation to the nucleus, where it 
phosphorylates the cAMP response element-binding (CREB) protein. CREB 
activates targets that are thought to lead to structural changes leading to the late 
phase of LTP (Sunyer et al., 2008).  
I.9.2 Protein Kinase C  
The second-messenger dicaylglycerol (DAG) activates PKC, and this activation 
can take place when PKC attaches to the cell membrane.  Physiological activation 
of PKC is normally associated with rise in presynaptic [Ca
2+
]i through inositol 
triphosphate receptor activation and increase in DAG (Chang and Mennerick, 
2010). These two secondary messengers are produced when phospholipase C is 
activated normally through G-protein coupled receptor activation. PKC can be 
activated either by Ca
2+
 binding to PKCs C2 domains and/or by binding of DAG 
to C1 domains. However, the signalling pathways leading to an increase in DAG 
by presynaptic activity are unclear (Wierda et al., 2007). DAG is responsible for 
activating PKC function by increasing its affinity for phospahtidylserine (PS)-
containing membranes. Upon activation, PKC enzymes are translocated to the 
PM, where it activates various other signal transduction pathways (Wierda et al., 
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2007). Activated PKC may phosphorylate a target protein in the vesicle fusion 
machinery, like munc-18, which in turn may result in an increase in the Ca
2+
 
sensitivity of vesicle fusion (Rizo and Rosenmund, 2008). Other presynaptic 
proteins, like SNAP25 and synaptotagmin-1, also have PKC phosphorylation 
sites (Korogod et al., 2007; Wierda et al., 2007). PKC activation changed release 
kinetics and decreased quantal size by shortening the release period (Graham et 
al., 2002).  
Studies have shown that stimulating chromaffin cells in elevated [Ca
2+
]i increases 
the quantal size, and pharmacological activation of PKC increases the rate of 
catecholamine release. Additionally, the physiological stimulation is competent 
enough to raise cytosolic Ca
2+
 to levels adequate to activate conventional 
isoforms of PKC, causing its translocation to the cell membrane, where it acts to 
alter the kinetics and magnitude of exocytosis (Fulop and Smith, 2006). Data by 
Graham et al., (2002) suggests that during PKC activation, a dynamin-
independent fusion pore closure limits release (Graham et al., 2002). PKC also 
play important roles in spatial memory. 
Phorbol 12-myristate 13-acetate (PMA) is an active phorbol ester that activates 
presynaptic PKC-dependent and independent mechanisms to potentiate 
transmitter release. PMA are amphiphillic molecules and have tendency to bind to 
biological phospholipid membrane receptors. They are functional analogues of 
the lipid-signalling molecule DAG that activates C1-domain of PKCs (Lou et al., 
2008a). PMA by activating PKC can enhance the Ca
2+
 sensitivity of vesicle 
fusion (Korogod et al., 2007) and results in increase of the fusion probability of 
RRPs (Lou et al., 2008a).  
Fulop & Smith, (2006) proposed a cellular mechanism whereby increased cell 
firing increases cytosolic Ca
2+
 and this or the PMA activation of PKC may result 
in the dilation of fusion pore, thereby switching from K&R to FF mode of 
exocytosis. This may depend upon the model of exocytosis being studied and also 
the level of [Ca
2+
]i achieved. This mode shift forms the basis for activity-
dependent differential transmitter release (Fulop and Smith, 2006).  
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I.9.3 Protein Phosphatases  
The serine/threonine protein phosphatase family members include protein 
phosphatases 1 (PP1), 2A (PP2A), and 2C (PP2C). These phosphatases are 
essential for a number of signal transduction pathways in eukaryotic cells 
(Rusnak and Mertz, 2000). A difference in divalent metal ion dependence lead to 
the resolution of the type 2 enzymes into PP2A, PP2B (calcineurin), and PP2C. 
PP2A was originally described as having no requirement for divalent metal ions, 
calcineurin is regulated by CaM, and PP2C is Mg
2+
 dependent.  
I.9.3.1 PP2A  
PP2A is a heterotrimer consisting of three unrelated subunits, the catalytic subunit 
(C), a 65kDa regulatory subunit (A), and a variable regulatory subunit (B). The A 
and C subunits are tightly associated and are generally present in the cell as an 
invariable holoenzyme; substrate specificity and subcellular localization are 
conferred by the binding of one of a wide variety of related B subunits (Hill et al., 
2006).  
Okadaic acid (OA) is a widely used small-molecule phosphatase inhibitor that 
under some circumstances can be regarded as a selective inhibitor of PP2A (Hill 
et al., 2006). OA, a polyether fatty acid isolated from the black sponge 
Halichondria okadai and under particular conditions is a potent inhibitor of both 
type-1 and type-2 phosphatases (Morimoto et al., 2000; Rusnak and Mertz, 2000). 
The phosphatase inhibitor OA, alters the phosphorylation state of synapsin and 
increases vesicle mobility and NT release under certain stimulation conditions 
(Fernandez-Busnadiego et al., 2010).  
I.9.3.2 PP2B/Calcineurin  
Calcineurin (CaN) is a heterodimer consisting of a catalytic subunit, CaN A, and 
a “regulatory” subunit, CaN B. The active site of CaN is located on the A subunit 
(Rusnak and Mertz, 2000).  
CaN can be phosphorylated by PKC, casein kinase I, and casein kinase II in vitro. 
Even though phosphorylation can be blocked by CaM, the kinetic properties of 
the phosphorylated and dephosphorylated forms are similar. CaN is a Ca
2+
-
dependent protein phosphatase, which has been implicated in the regulation of 
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endocytosis (Igarashi and Watanabe, 2007), due to the fact that CaN 
dephosphorylates various synaptic proteins (Kumashiro et al., 2005). Ca
2+
 influx 
in nerve terminals activates CaN and enzyme dephosphorylates a set of proteins 
involved in endocytosis: these are called the dephosphins. The dephosphins are 
grouped together by their capacity to be dephosphorylated by CaN upon nerve 
terminal stimulation, and by the fact that they are all essential for SV endocytosis. 
The dephosphins include; dynamin I (Kumashiro et al., 2005), the AdP AdP180, 
and the accessory proteins amphiphysin I/II, synaptojanin, epsin, esp15 and 
phosphatidylinositol phosphate kinase type Iγ (PIPKIγ). After the stimulus-
dependent dephosphorylation, the dephosphins are then rephosphorylated by their 
individual protein kinases e.g. cyclin-dependent kinase 5 (cdk5) rephosphorylates 
dynamin I, synaptojanin and PIPKIγ in vivo (Clayton et al., 2007).  CaN mediates 
downstream effect on CaM (Yamashita et al., 2010) on vesicle endocytosis in 
mammalian neurons (Kumashiro et al., 2005). Kumashiro et al., (2005) also 
demonstrated that CaN was required for endocytosis to the RP, but not for the 
RRP under particular recycling conditions (Kumashiro et al., 2005).  
Cyclosporine A: 
 CaN is specifically inhibited by the immunosuppressant drug cyclosporine A 
(Cys A). Cys A binds to cyclophilin (CyP), a ubiquitous intracellular protein, and 
undergoes a conformational change. The Cys A-CyP complex binds to CaN and 
inhibits its serine/threonine phosphatase activity (Batiuk et al., 1995).  
I.9.4 Myosin Family   
Myosins are a family of molecular motors that bind to actin (Bhat and Thorn, 
2009). Experiments have indicated that members of this protein family account 
for some vesicle dynamic properties. E.g.1 myosin Va contributes in DCV 
transport and plays a role in the docking process. E.g.2 Myosin VI is involved in 
endocytosis by associating with CCVs and is the only known motor protein that 
transports cargoes to the minus ends of the actin filament (Bhat and Thorn, 2009).  
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I.9.4.1 Myosin-II 
Myosin II is a conventional myosin enriched in neurons, where it is thought to 
play a role in exocytosis (Igarashi and Watanabe, 2007). Myosin II can control 
regulated secretion in certain tissues (Bhat and Thorn, 2009). There is extensive 
evidence that myosin II plays a role in the secretory processes of a variety of 
cells, including: mast cells, natural killer cells, hippocampal and sensory neurons, 
chromaffin cells, β-cells, exocrine cells, and oocytes (Bhat and Thorn, 2009). It is 
thought that myosin II contributes to earlier exocytotic steps, such as vesicle 
transport in a motor activity-dependent manner.  
Myosin II is an ATP-driven molecular motor forming an essential part of the 
motile machinery of most eukaryotic cell (Kovacs et al., 2004). In sympathetic 
neurons, inhibiting myosin II decreases synaptic transmission (Tokuoka and 
Goda, 2006) by inhibiting SV transport. Additionally, it has been shown in PC12 
cells that myosin II plays important roles under certain conditions in shifting the 
exocytotic mode from K&R to FF and increases the speeds of release of the 
catecholamine (Aoki et al., 2010). Additionally, CaM regulates myosin light-
chain kinase (MLCK), which in turn regulates the motor activity of myosin II. 
CaM may contribute to vesicular recycling by interacting with actomyosin 
(Igarashi and Watanabe, 2007). Ca
2+
 signalling in presynaptic terminals, 
therefore, may serve to regulate SV mobility along actin filaments via MLCK 
(Tokuoka and Goda, 2006; Bhat and Thorn, 2009). 
Structurally myosin II has two functional domains; the head domain, which has 
ATPase activity and is required for motor activity and the other, a long-rod 
domain, which is required for the assembly of myosin II monomers into bipolar 
filaments (Aoki et al., 2010). In the research carried out by Aoki et al., (2010), it 
was found that under the conditions of their experiments myosin II was involved 
in the modulation of internalization kinetics rather than in the release kinetics. 
Additionally, they concluded that, the co-localization of myosin II with PM-
docked vesicles was retained even with myosin II that lacked ATPase activity, as 
it was still able to bind actin filaments and bundle them, and the rod domains of 
myosin II could still interact with the lipid membrane. Thus, myosin II could 
participate in the transport step of exocytosis via its adaptor function rather than 
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through it ATPase motor activity (Aoki et al., 2010). However, a study by Bhat 
and Thorn (2009) on pancreatic cells suggest that inhibition of myosin II ATPase 
activity affects post fusion events, slowing the opening of the fusion pore  and 
plays a role in promoting vesicle FF (Bhat and Thorn, 2009).  
Blebbistatin is permeable to cell membranes. It is a potent inhibitor of skeletal 
muscle and non-muscle myosin II isoforms (Kovacs et al., 2004). Blebbistatin 
(Bleb) has a high affinity and selectivity to inhibit of class-II myosin ATPase 
activity and is used to identify and study myosin II-dependent processes in cells 
(Shu et al., 2005). It preferentially binds to the ATPase intermediate with ADP 
and phosphate bound at the active site, and slows down phosphate release. Bleb 
does not interfere with binding of myosin to actin or with ATP-induced 
actomyosin dissociation. Instead, it blocks the myosin heads in a products 
complex with low actin affinity. Bleb binding site of the myosin head is within 
the aqueous cavity between the nucleotide pocket and the cleft of the actin-
binding interface. Bleb binds to a nucleotide-bound enzyme intermediate with 
highest affinity and does not compete with substrate for binding sites on the 
enzyme. It blocks ATP hydrolysis and motor activity (Doreian et al., 2009).  
I.10 Synaptic plasticity  
Synaptic plasticity is defined as an activity-dependent change in synaptic 
transmission. Transient modifications of synapses have been associated with 
short-term memory (STM) and more lasting changes have been associated with 
long-term memory (LTM) in the mature neuron (Yamauchi, 2005). Learning can 
be described as the mechanism by which new information about the environment 
is acquired; memory represents the mechanism by which that knowledge is 
retained (Sunyer et al., 2008). Learning and memory rely upon the molecular 
mechanisms associated with the protein machinery. Stable synaptic changes 
involve post transitional modification (PTM) of proteins during STM and gene 
transcription, while the LTM require the synthesis of protein and synaptic growth. 
Short-term synaptic plasticity has two mechanistic elements: (1) the source and 
regulation of the residual Ca
2+
 that initiates the process and (2) the effector 
mechanism(s) that respond to residual Ca
2+
 and enhance NT release (Catterall and 
Few, 2008). 
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Also the study of LTP and long-term depression (LTD) reveal that, the forms of 
activity-dependent synaptic plasticity in the mammalian CNS play a role in the 
mechanisms underlying learning and memory (Sunyer et al., 2008). LTP is the 
long-lasting strengthening of the connection between two nerve cells, which is 
typically caused by high-frequency stimulation of excitatory input leading to 
rapid elevation of Ca
2+
 in postsynaptic dendritic spines (Sudhof and Malenka, 
2008). Whilst, LTD comprises of persistent activity-dependent reduction in 
synaptic efficacy, that typically occurs following repeated low frequency afferent 
stimulation (Sunyer et al., 2008).  
 
Figure Q. Memory consolidation needs PTMs and protein synthesis (Sunyer et al., 2008) 
I.10.1 Post-Transtional Modification of Endocytotic Proteins 
The change in protein phosphorylation helps in the initiation of endocytosis. 
Protein phosphorylation is required for the induction of many forms of synaptic 
plasticity, including LTP and LTD. Various protein kinases play important roles 
in the regulation of NT release, and candidates for protein substrates essential for 
the regulation have been identified (Sunyer et al., 2008). Recent research have 
suggested that PTMs like phosphorylation of serine, threonine, and tyrosine play 
a major role in the cognitive processes such as synaptic plasticity in the brain, 
release of NT, vesicle trafficking and synaptosomal or synaptosomal-associated 
proteins that are substrates of a series of specific protein kinases and their 
counterparts, protein phosphatases (Sunyer et al., 2008). The serine-threonine 
kinase that phosphorylates the µ-subunit of AP2 and possibly other accessory 
factors is considered to promote coat assembly (Hosoi et al., 2009; Shupliakov, 
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2009). Intriguingly, dephosphorylation of several accessory proteins (Sunyer et 
al., 2008) also known as dephosphins after the Ca
2+
 influx, is also responsible for 
promoting the clathrin mechanism in the synapses (see earlier discussion about 
the dephosphins). It is believed that dephosphorylation triggers the interaction of 
these proteins with the other components of the endocytotic machinery 
(Shupliakov, 2009).  
Researchers have demonstrated that the risk of neurodegenerative disorders 
increases with age. The major changes seen in aging neurons include increased 
Ca
2+
 release from intracellular stores through inositol (1,4,5)-trisphosphate 
receptors (InsP3R) and ryanodine receptors (RyanR), increased Ca
2+
 influx 
through L-type VGCCs, reduced contribution of N-methyl D-aspartate receptor 
(NMDAR)- mediated Ca
2+
 influx, reduced cytosolic Ca
2+
 buffering capacity and 
activation of CaN and calpains. The resulting changes in neuronal Ca
2+
 dynamics 
lead to augmented susceptibility to induction of LTD and an increase in the 
threshold frequency for induction of LTP in aging neurons (Breukel et al., 1997).  
The factors responsible for the age-induced alteration may be defects in 
mitochondrial function due to cumulative oxidative damage or mitochondria are 
depolarized and less competent in handling Ca
2+
 load. 
 I.10.2 Neurotoxicity 
In brain, unregulated enhanced release of excitatory NTs can lead to neuronal 
damage and death. This excitotoxic neuronal death induced by increased synaptic 
glutamate is implicated in the pathology of multiple neurodegenerative diseases 
including Alzheimer‟s and Huntington‟s diseases along with ischaemia and 
epilepsy (Fdez et al., 2008). NMDARs are believed to play a crucial role in the 
process of excitotoxicity and neuronal degeneration. A continuous increase in the 
[Ca
2+
]i concentration is considered to trigger a series of events (including 
persistent activation of Ca
2+
-dependent enzymes, production of toxic 
metabolities, and disruption of the cytoskeletal network) that results in 
cytotoxicity and cell death. It has been demonstrated that, several pathological 
states, such as anoxia, ischemia, or chronic degenerative diseases such as 
epilepsy, amyotrophic lateral sclerosis are associated with modified glutamate 
levels (Bertolino and Llinas, 1992). 
 
 
51 
Extraneuronal concentrations of glutamate in injured brains are dramatically 
increased because of an abnormal release of the transmitter from damaged nerve 
terminals and because of reduced glutamate reuptake. These increased 
extraneuronal glutamate concentrations cause paroxysmal stimulation of 
NMDARs thereby, destabilizing neuronal Ca
2+ 
homeostasis (Bertolino and 
Llinas, 1992).  
Chronic blockade of AP firing in neuronal cultures increases trafficking of the  
AMPA receptor subunits GluR1 and GluR2 to postsynaptic sites, thus increasing 
sensitivity to released glutamate (Fdez et al., 2008). Researchers have also 
demonstrated that as NMDAR channels are highly permeable to Ca
2+
 ions, the 
receptor channel has considered being the central pathway for the Ca
2+
entry in the 
presence of glutamate (Bertolino and Llinas, 1992). Ca
2+ 
influx followed by 
PTMs may also serve as an important signal for the accumulation of key 
endocytic proteins at the periactive zone and serve as an important mechanism to 
initiate endocytosis in synapses.  
Activity-dependent long-term changes in the efficacy of glutamatergic synaptic 
transmission are important in many forms of learning (Fourcaudot et al., 2009). 
The LTP studies of glutamatergic synaptic transmissions in different brain areas 
like cortex, hippocampus, and amygdala unfolded that synaptic strength is 
enhanced by two mechanisms, both dependent on the rise in [Ca
2+
]i. The first is 
by continual increase in the postsynaptic response to a fixed amount of glutamate 
released and the other is due to the dependence of NT release on the Ca
2+
 influx, 
the LTM in the presynaptic Ca
2+
 entry or sensing could cause a persistent 
increase in the release credibility (Fourcaudot et al., 2009). 
In a study done by Fourcaudot et al., (2009), it was concluded that LTP 
expression can be mediated by a persistent development of L-type VGCC 
efficacy. This might involve a PKA-dependent mechanism and/or proteins 
interacting with L-type VGCC such as the presynaptic AZ component RIM1α 
(Rizo and Rosenmund, 2008). They also concluded that the L-type VGCC is 
responsible for presynaptic LTP in LTM formation (Fourcaudot et al., 2009).  
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For an efficient NT release, the formation of SNAP receptor (SNARE) complex 
is necessary. This process involves: (1) binding of the synprint sites on N-type or 
P/Q-type Ca
2+
 channels with presynaptic membrane proteins synaptotagmin and 
t-SNARE (i.e. SNAP25 and syntaxin 1A) (Jackson and Chapman, 2006; Serra et 
al., 2010),  (2) dissociation of Syb/ VAMP2 from synaptophysin I, a small SV 
protein that interacts with Syb‟s transmembrane domain (Darios et al., 2009; 
Hosoi et al., 2009), and (3) association of Syb with  t-SNARE, all of which are 
tightly regulated by [Ca
2+
]i and the phosphorylation of the synprint sites on N-
type and P/Q-type Ca
2+
  channels located within the intracellular loop-connecting 
domains II and III (LII-III) (Refer Figure C)  (Rizo and Rosenmund, 2008; Serra et 
al., 2010).  
CaMKs and PP2B also act as mediators in this regulation (Shupliakov, 2009). 
Reverse phosphorylation is predominantly accomplished by the cdk5. However, 
the step at which the PTM occurs in the SVs recycling still remains unclear. 
Recent research have suggested that some of the enzymes are compartmentalized 
at the synapse, which further implies that PTMs predominantly occur at specific 
synaptic compartments (Shupliakov, 2009).  
The balance of activities of such protein kinases and protein phosphatases 
contribute to the control of synaptic strength and plasticity underlying LTP, 
learning and memory. An imbalance in the regulation of protein kinases and 
protein phosphatases in the affected neurons can cause disease such as 
Alzheimer‟s disease. 
Old neurons are sensitized to cytosolic Ca
2+
 toxicity because Ca
2+
-buffering 
capacity declines with advancing age. The supranormal cytosolic Ca
2+
 signals 
might cause excessive Ca
2+
 handling by mitochondria and induction of apoptotic 
cell death (Bezprozvanny, 2009).  
The regulation of presynaptic Ca
2+
 channels by effectors and regulators of Ca
2+
 
signalling depicts that Ca
2+
 channel play a critical role in regulating 
neurotransmission and presynaptic plasticity. Failure of function and regulation of 
presynaptic Ca
2+
 channels leads to migraine, ataxia, and potentially other forms 
of neurological disease (Peretz et al., 1998). Recent evidence indicates that 
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neuronal Ca
2+
 signaling is abnormal in many of the neurodegenerative disorders 
like, Alzheimer‟s disease (AD), Parkinson‟s disease (PD), amyotrophic lateral 
sclerosis (ALS), Huntington‟s disease (HD) and spinocerebellar ataxias (SCAs) 
(Bezprozvanny, 2009).  
As protein phosphorylation has also been shown to be involved in regulating the 
mode of SV exocytosis, the role of CaMKII in this process has also been studied 
(Catterall and Few, 2008). 
I.11 Background Results 
Studies in a model of type 1-diabetes whose exocytotic activity may involve 
various processes that have been discussed above: Very excitingly, it has been 
discovered by Dr A. Ashton that diabetic nerve terminals behave differently to 
control terminals. Diabetic terminals release exactly the same amount of 
glutamate (Glu) as controls when release was evoked by HK5C (Fig i.A). 
Intriguingly, HK5C induced a larger change in [Ca
2+
]i in diabetic synaptosomes 
than in control synaptosomes (Fig i.C). This result suggests that, there is a 
difference between control and diabetic terminals in the mechanisms that 
contribute to this stimulus induced change in Ca
2+
 levels. Remarkably, whilst 
there is no change in HK5C evoked Glu release, there is a reduction in the 
amount of HK5C evoked FM2-10 dye release in diabetic terminals when 
compared to control synaptosomes (Fig i.B). This result indicates that HK5C 
evokes a greater amount of K&R exocytosis in diabetic synaptosomes. These 
results led to the hypothesis that it is the higher [Ca
2+
]i induced by HK5C in 
diabetic terminals that leads to a larger proportion of exocytosis by the K&R 
mode and this could be due to the diabetic preparations possessing differences in 
components that contribute to this raised [Ca
2+
]i levels.  
 
 
54 
 
Figure i. Comparision between control and daibetic synaptosomes:A) No significant 
difference observed in the amount of glutamate released B) FM2-10 dye study confirms 
that the diabetic terminals undergo more K&Rmode of exocytosis in comparision to the 
control C) Fura-2AM study reveals that application of HK5C induces a larger change in 
[Ca
2+
]i in diabetic synaptosomes compared to control synapatosomes. 
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Since the above biochemical differences were observed in diabetic terminals, 
further studies on other biochemical and behavioural changes were carried out on 
such diabetic rats. 
I.12 Diabetes Mellitus 
Diabetes is from the Greek word meaning "siphon," and "mellitus" comes from 
melliferous, meaning "of or relating to honey." Diabetes has been recognized for 
centuries and was originally diagnosed by testing the urine and finding it sweet 
(melliferous). The World Health Organisation (WHO) defines diabetes mellitus 
(DM) as “a chronic disease, which occurs when the pancreas does not produce 
enough insulin, or when the body cannot effectively use the insulin it produces. 
This leads to an increased concentration of glucose in the blood 
(hyperglycaemia)” (Donath et al., 2005). In diabetes, the patient has a high blood 
glucose level either due to the body being unable to produce sufficient amount of 
insulin (type 1 diabetes) or due to the cells in the body becoming insulin resistant 
(type II diabetes) (Donath et al., 2005).  
The pancreatic islet β-cell regulates cellular fuel metabolism and glucose 
homeostasis by secreting the hormone, insulin (Min et al., 2007). Insulin 
promotes anabolism, and inhibits catabolism in muscle, liver, and fat cells. Its 
functions include the increase in the rate of synthesis of glycogen, fatty acids, and 
proteins. Thus, insulin plays a crucial role in the process of digestion (Donath et 
al., 2005). Abnormal insulin secretion or usage results in DM. Several pathogenic 
processes are involved in the deficiency of insulin (Romero-Aroca et al., 2010). 
These include, autoimmune destruction of the β-cells of pancreas. Also can 
include the tissues/cells (mainly muscle, liver and/or fat cells) becoming insulin 
resistant. Another possibility is a defect in cellular signalling such that there is 
inadequate insulin secretion or inadequate response to insulin secretion. The first 
type is called type 1 diabetes mellitus (T1DM) and the second is called type 2 
diabetes mellitus (T2DM). Liver is an important insulin dependent tissue and 
plays a pivotal role in glucose and lipid metabolism, and is severely affected 
during diabetes (Moller, 2001). In diabetes the levels of hepatic enzymes 
increases (Farswan et al., 2009).  
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I.13 Symptoms for both types of DM include; marked hyperglycaemia (rise in 
blood glucose level), polyuria (frequent urination), polydipsia (increased thirst), 
weight loss sometimes with polyphagia (excessive hunger), and blurred vision 
(Kirpichnikov and Sowers, 2001; Latham et al., 2009). The reason for increased 
amount urine and thirst is because, glucose leaks into urine which 'pulls out' extra 
water through the kidneys. Uncontrolled diabetes leads to acute and life-
threatening consequences like hyperglycaemia with ketoacidosis (a state of 
metabolic dysregulation characterized by the smell of acetone) or the non-ketotic 
hyperosmolar syndrome (due to dehydration). Other symptoms include Kussmaul 
breathing (a rapid, deep breathing), nausea, vomiting and abdominal pain, and an 
altered state of consciousness (Anderson, 2008). Frequent infections, especially 
around genitals such as recurring thrush and, other infections such as developing 
boils are indication for the development of T2DM. 
The late-stage diabetic complications can occur in both types of diabetes. In 
T1DM late stage complications usually develop after 10-15 years after the 
diagnosis of the disease, whereas in T2DM, symptoms may appear close to the 
time of actual diagnosis because the disease may go undetected for longer (Tfayli 
and Arslanian, 2009). Studies show that proper control in glucose level (as close 
to normal level) can significantly reduce or even stop complications.  
Although the pathogenesis of diabetes-related vascular complications is 
composite and multifactorial, they are associated with the level of glycaemia 
(Kirpichnikov and Sowers, 2001). Uncontrolled glucose regulation can result in 
the development of hyperglycaemia (Roy et al., 2010). If persistent and untreated, 
hyperglycaemia can damage many of the body's tissues, particularly the 
vasculature. As a result, diabetes-associated microvascular and macrovascular 
complications occur at advanced stages (Cooper et al., 2001). The major 
microvascular complications are nephropathy, retinopathy, and peripheral 
neuropathy, whereas the macrovascular complications in diabetes is manifested 
by accelerated atherosclerosis, clinically resulting in premature ischemic heart 
disease, increased risk of cerebrovascular disease, and severe peripheral vascular 
disease (Feener and King, 1997). Further, the thesis concentrates on the effects of 
diabetes on the nervous system.  
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I.14 Cognitive Dysfunction 
In addition to its well known adverse effects on the cardiovascular and peripheral 
nervous systems, diabetes appears to negatively affect the brain, increasing the 
risk of depression and dementia. Along with diabetes, cognitive dysfunction is 
also a serious problem and its prevalence is rising worldwide, especially among 
the elderly (Thomas et al., 2001). Diabetes associated cognitive dysfunction, first 
described nearly a century ago (Zhou et al., 2010), occurs in both types of 
diabetes. Recent studies have also confirmed the link between the cognitive 
dysfunction and diabetes, i.e. DM could also be the risk factor for the 
development of cognitive diseases (Allen et al., 2004). Human subjects with 
either T1DM or T2DM typically show impaired cognitive function compared to 
age-matched non-diabetic subjects (Desrocher and Rovet, 2004; Greenwood and 
Winocur, 2005). Latest observations have concluded that, compared to people 
without diabetes, people with diabetes are at a greater rate of decline in cognitive 
function (a 1.5-fold greater risk of cognitive decline; and a 1.6-fold greater risk of 
future dementia). Compared to non-diabetic individuals, diabetes increased the 
risk of vascular dementia and Alzheimer‟s dementia 1.3 and 4.4-fold, respectively 
(Cukierman et al., 2005). In T1DM, the effect on the brain structure and function 
occurs at the extremes of age, i.e. during childhood and during old age (Wessels 
et al., 2007; Biessels et al., 2008; Kloppenborg et al., 2008).  Studies have 
concluded that, neuronal deficits may be associated with impaired neurotrophic 
support, inflammation and oxidative stress. Some studies have also demonstrated 
that, poorly controlled T1DM and fatal brain oedema of ketoacidosis is associated 
with a decreased presence of insulin and IGF-1 receptors and accumulation of 
nitrotyrosine in neurons of affected areas and the choroid plexus leading to 
neuronal deficits (Hoffman et al., 2010). Cognitive deficits have also been 
documented in rodent models of diabetes (Biessels et al., 2008). 
DM has negative impacts on the CNS leading to diabetic encephalopathy and 
concomitant augmented incidence of cognitive problems (Brands et al., 2006), 
which are particularly associated with atrophy of the hippocampal formation that 
is involved in learning and memory processing (Gold et al., 2007). It is also 
associated with other moderate cognitive deficits and neurophysiological and 
structural changes in the brain (Satoh and Takahashi, 2008). A recent study 
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carried out by Stranahan, et al., (2008) confirmed that, diabetes deteriorates 
hippocampus-dependent memory, perforant path synaptic plasticity and adult 
neurogenesis in both insulin-deficient rats and insulin-resistant mice (Stranahan et 
al., 2008).  
It has been observed that, the peripheral nerves in diabetes have an additional 
pathway by which insulin acts on the brain and sends messages via the nervous 
system to exert a higher level of control on glucose output from the liver (van 
Duinkerken et al., 2009). Experimental studies in animal models and in humans 
without diabetes have shown that, poor glucose regulation after a glucose 
challenge test was associated with poorer performance on a variety of cognitive 
tests, the effect being more pronounced in the older age group (Messier, 2004; 
Stranahan et al., 2008). 
Neurons have a constantly high glucose demand. Neuronal glucose uptake 
depends on the extracellular concentration of glucose, and cellular damage can 
ensue after persistent episodes of hyperglycaemia; a phenomenon referred to as 
glucose neurotoxicity (Tomlinson and Gardiner, 2008). Even though quite a few 
studies have found the link between the brain alteration and changes in the level 
of insulin, the role of insulin in the brain is still to be elucidated. It is postulated 
that insulin and its signalling play an important role in neuronal, glial, and overall 
cognitive and memory functioning. Also, recent researches have shown that 
insulin does penetrate the cerebral spinal fluid, probably via receptor-mediated 
transport and reach the rest of the brain. Autoradiography (Autoradiography is the 
use of X-ray (or occasionally photographic) film to detect radioactive materials) studies 
have shown that insulin can cross the blood-brain barrier (BBB), penetrating to 
the circum-ventricular organs, including the arcuate and ventromedial nuclei of 
the hypothalamus (Bingham et al., 2002).  For insulin-stimulated glucose 
metabolism to occur in the brain; insulin, IRs and insulin-sensitive glucose 
transporters are required. Recently studies have proved that, insulin receptors 
(IRs) are present on the endothelium of the BBB, which allow receptor-mediated 
active transport of insulin into the brain (Banks et al., 1997). It has also been 
assumed that, insulin can be synthesised in the brain (Bingham et al., 2002); 
however, most of the brain insulin is thought to originate from the systemic 
circulation. 
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Some studies have also identified IRs in central neurons, astrocytes, synapses, 
and other glia (Zhao et al., 2004). The presence of IR has been confirmed 
throughout the human brain, with particularly high concentrations in the 
hypothalamus, cerebellum, cortex (Hopkins and Williams, 1997) olfactory bulb, 
hippocampus, amygdala and septum (Unger et al., 1991).  
Additionally, before glucose can be delivered to CNS neurons, it must cross the 
BBB (Tomlinson and Gardiner, 2008). Although, brain glucose uptake seems to 
be independent of insulin action, insulin sensitive glucose transporters have also 
been found at the BBB and on glial cells in various studies of animal brain. These 
include both insulin-sensitive GLUT4 and a partially insulin-sensitive GLUT1 
(Ngarmukos et al., 2001). GLUT1 is expressed in the microvessels of brain 
(Tomlinson and Gardiner, 2008). The regional distribution of GLUT4 suggests 
that insulin-dependent glucose uptake might occur in specialized neuronal 
phenotypes but, in general, vascular barriers offer neurons the only protection 
against glucose toxicity during hyperglycaemia. The highest expression of 
GLUT1 and GLUT4 is in the hippocampus, the cerebellum and the olfactory 
bulb; lower expression is reported for the lateral hypothalamus, the arcuate 
nucleus and the globus pallidus (Tomlinson and Gardiner, 2008). mRNAs coding 
for accessory molecules, such as glucokinase and the IRs, are also expressed in 
some of these brain regions, but insulin-regulated glucose uptake has not yet been 
proven to occur in the brain. Recently, GLUT8 has also been identified in the 
brain, localized specifically to the hippocampus, the cerebral cortex and the 
hypothalamus. Studies in hippocampus suggest that it does not respond to insulin, 
but that it is activated by glucose itself, which recruits GLUT8 to the PM 
(Tomlinson and Gardiner, 2008). Even though the regional distribution of 
GLUT4 suggests that insulin-dependent glucose uptake might occur in 
specialized neuronal phenotypes, there is no strong evidence that these systems 
provide protection against hyperglycaemia. Positron emission tomography studies 
in humans, however, have shown no effect of increasing insulin levels on global 
brain glucose uptake (Hasselbalch et al., 1999), and based on the lack of effect of 
hyperinsulinemia, it has been concluded that in human brain glucose metabolism 
is not insulin sensitive. This contrasts with the clear evidence for an effect of 
insulin on brain function mentioned above. The study conducted by Duarte et al., 
(2009) suggested that the neurochemical alterations in the hippocampus of male 
 
 
60 
diabetic Sprague–Dawley rats (tested 4 weeks after STZ administration), are not 
related to defects in glucose transport in the brain, but is likely to reflect 
osmoregulatory adaptations caused by hyperglycaemia (Duarte et al., 2009). The 
published studies testify inconsistent effects of hyperglycaemia on substrate 
transport into the brain. Particularly, glucose transport into the brain was 
suggested to be reduced, augmented (Duelli et al., 2000) or unaffected (Simpson 
et al., 1999) by chronic hyperglycaemia. As mentioned before, hyperglycaemia 
may cause deregulation of brain metabolism involving inadequate glucose 
utilization, the hallmark of diabetic conditions in peripheral tissues. Also, 
hyperglycaemia-induced hippocampal dysfunction and damage may be because 
of the disruption of osmotic balance, which is of fundamental importance for the 
viability of cells, in particular of neurons (Tomlinson and Gardiner, 2008). In one 
study, it was found that chronic hyperglycaemia, induced by STZ administration, 
caused a plethora of metabolic alterations in the hippocampus, most of which 
were normalized upon restoration of euglycemia (Duarte et al., 2009). 
In a recent review, a number of possibilities were considered for the association 
between diabetes and cognitive decline.  
1. Hypoglycaemia may also affect cognitive function; however, it is not fully 
established. Studies have confirmed that intensive treatment regimens that were 
associated with increased hypoglycaemic episodes in individuals with T1DM did 
not adversely affect cognition (Reichard and Pihl, 1994). 
2. Hyperglycaemia may also be a factor for development of chronic cognitive 
impairment (Huang et al., 2002).  
Depression occurs more frequently in people with diabetes (Anderson et al., 
2001) and is difficult to differentiate clinically from dementia and early cognitive 
decline (Swainson et al., 2001). 
I.14.1 Hypoglycemia and brain  
The brain is a very vulnerable organ to any changes in the glucose level. If both 
higher and lower level of glucose persists in the circulatory system, it can lead to 
severe alteration in the brain. In uncontrolled DM, the only treatment is insulin 
therapy. Rise in the level of insulin in the circulatory system, can lead to increase 
the risk of both moderate and severe hypoglycaemia (Puente et al., 2010) and can 
thereby result in the alteration of the brain function (Bingham et al., 2002). 
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Severe and recurrent episodes of hypoglycaemia results in the brain getting 
deprived of glucose, causing brain damage in animal studies,  and leading to 
long-term impairments in learning and memory (Suh et al., 2005). Severe 
hypoglycemia has been shown to alter brain structure and cause significant 
cognitive damage in many but not all studies (Puente et al., 2010).  
I.14.2 Hyperglycaemia and neuronal deficient  
Despite the fact that the underlying neuropathological and biological substrates 
are still not elucidated, hyperglycaemia leading to microangiopathy in the brain is 
thought to be the primary reason for the cerebral complications observed in 
diabetes (Wessels et al., 2007).  Hyperglycaemia induces variety of secondary 
metabolic defects such as, polyol pathway flux, protein glycosylation, oxidative 
stress, and impaired neurotrophic support. These secondary effects have been 
identified as main factors for sensory polyneuropathy in diabetes.  
Some research has demonstrated that, hyperglycaemia can induce cellular damage 
through increased glucose metabolism by aldose reductase (Obrosova, 2005), 
elevated protein glycation (Thornalley, 2002), and increased mitochondrial 
NADH supply, thereby enhancing electron availability and causing partial 
reduction of oxygen to superoxide radicals in the proximal part of the electron 
transport chain (Du et al., 2001). These three mechanisms may combine to trigger 
large elevations in reactive oxygen species (ROS) that induce oxidative stress and 
tissue damage (Calcutt et al., 2009). It is assumed that, the ability of diabetic 
nerves to survive oxidative stress may be impaired because of the suboptimal 
trophic support from insulin, insulin-like growth factors, and neurotrophic factors 
(Calcutt et al., 2009). Although increased oxidative stress has become a widely 
accepted consequence of hyperglycaemia in models of diabetic neuropathy, the 
source of excessive ROS is not defined. Hyperglycaemia may also responsible for 
triggering the other cascade of changes, such as glycation end products (Huang et 
al., 2002), activation of the hypothalamic-pituitary-adrenal axis (HPA), which 
could have an effect on the brain (Chowdhury et al., 2010). In a research carried 
out by Messier et al., (2005), it was found that humans with poorly controlled 
diabetes show hyperactivation of the HPA, resulting in elevated circulating 
cortisol and cognitive dysfunction in diabetes. The role of glucocorticoids in 
cognitive dysfunction in diabetes is still unknown but, high levels of cortisol has 
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been associated with poor cognitive ability in humans subjected to psychosocial 
stress, during normal aging and in AD (Stranahan et al., 2008). It has also been 
demonstrated that, hypergylcemia results in increased corticosterone, and 
impairments in hippocampal neurogenesis, synaptic plasticity and learning 
(Stranahan et al., 2008).  
Post mortem studies of senile plaques from the brains of people with Alzheimer‟s 
dementia found metabolic oxidation products associated with hyperglycaemia 
(Horie et al., 1997). Changes in the strength of synapses between groups of 
neurons within the hippocampus are critical in certain types of learning and 
memory (Stranahan et al., 2008). The regulation of synaptic connectivity at the 
level of the dentate gyrus extends beyond changes in the number and strength of 
synapses to the de novo addition of new neurons in adulthood (Leuner et al., 
2006). Recent studies of animal models suggest impairment of both synaptic 
plasticity and adult neurogenesis in diabetes. Streptozotocin (STZ)-induced 
diabetic rats, a frequently used model of T1DM, is characterized by chronic 
hyperglycaemia associated with impaired hippocampal-dependent learning and 
memory as well as defective synaptic plasticity in the hippocampus (Biessels et 
al., 2008; Duarte et al., 2009). 
The cellular mechanism of learning and memory depends on LTP of synaptic 
transmission, is believed to be impaired in the dentate gyrus of rats with STZ-
induced diabetes (Kamal et al., 2006).  
Duarte et al., (2009) reported that, chronic hyperglycaemia triggers astrocytosis in 
the hippocampus, and increased glial fibrillary acidic protein immunoreactivity in 
hippocampal membranes of STZ-induced diabetic rats, when compared to 
controls (Duarte et al., 2009). It is believed that astrocytic proliferation may be 
due to the neuronal damage, as observed in other neurodegeneration such as 
amyotrophic lateral sclerosis, AD (Lauderback et al., 2001) and Lewy-body 
dementia, and may contribute for diabetes-induced hippocampal deterioration as 
reactive astrocytes are known to produce free radicals (Chao et al., 1996) and 
apoptotic factors (Ferrer et al., 2001).  
Both pre- and postsynaptic deficits have been associated with impaired LTP in 
the diabetic hippocampus. Synaptic transmission changes in the pyramidal cells 
of the hippocampus in STZ-induced DMin rats (Kamal et al., 2006). Short-term 
replacement of insulin in STZ-treated rats from the onset of diabetes prevents 
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cognitive decline and protects against hippocampal potentiation deficits (Francis 
et al., 2008). 
The affect of all physiological fates due to the increased glucose level is 
highlighted in Figure R. 
 
Figure R: Physiological fates due to the increased glucose level: a | The major damaging 
metabolic pathways driven by raised glucose levels and their damage targets (indicated 
by the round-ended arrows) in a primary afferent neuron and its accessory cells 
(astrocytes, microglia and Schwann cells). b | The processes that are disturbed by these 
metabolic impacts include spinal sensitization, dysfunction of descending inhibitory 
pathways, muted response to injury, demyelination and altered axonal transport, among 
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others. (AGE, advanced glycation end-product; ECM, extracellular matrix; MAP kinase, 
mitogen-activated protein kinase) (Tomlinson and Gardiner, 2008). 
I.14.3 Hyperglycaemia and neuronal regeneration   
The ability of nerves to regenerate is inversely proportional to the duration of the 
diabetes (Duarte et al., 2009). Axonal regeneration is impaired after nerve cut or 
crush injury in the STZ model of diabetes (Tomlinson and Gardiner, 2008).  
Experiments have confirmed that, selective synaptic degeneration occurs in 
diabetic rodents due to reduction of the density of synaptic proteins such as 
syntaxin, SNAP25 and synaptophysin, in the hippocampus. The number of the 
postsynaptic protein, PSD95 was unaltered in the hippocampus of STZ-treated 
rats, when compared to the control rats, suggesting that diabetes mainly affects 
the presynaptic component of the synapse following long-term illness (Duarte et 
al., 2009). Eventually, these modifications in nerve terminals may be responsible 
for some of the altered synaptic plasticity in the hippocampus and thus memory 
impairment observed in STZ-induced diabetic rats (Biessels, 1996).  
Experiments using Ca
2+ 
ionophore in mouse motor nerve endings have illustrated 
that synaptic fusion can be directly regulated by the redox state. In these nerve 
endings, evoked and spontaneous quantal release was reduced by physiological 
levels of ROS (Giniatullin et al., 2006). When the neuronal proteins were studied 
to check their sensitivity to the oxidative stress, it was foud that, SNARE proteins 
are sensitive to oxidative stress, with SNAP25 being the most sensitive 
(Giniatullin, 2006). The redox state is known to affect cysteine residues. Specific 
cysteine residues in SNAP25 play a role for the disassembly of SNARE and 
exocytosis and not for membrane targeting. During oxidative stress in motor 
nerve endings, crucial alterations in SNAP25 structure (cysteine residues) may 
underlie the lack of SNARE complex assembly and reduced exocytosis. 
Interestingly, the expression of some exocytotic proteins, including SNARE 
proteins, is altered in disease-relevant brain areas in neurodegenerative diseases 
such as AD and HD (Sze, 2000; Morton, 2001; Suh et al., 2005). The redox 
modulation of SNARE complex formation is therefore another mechanism by 
which mitochondrial dysfunction occurs early in some neurodegenerative 
diseases and might reduce synaptic activity (Keating, 2008). 
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Experiments on STZ-diabetic rat‟s hippocampus have demonstrated that, 
neurological dysfunction and impaired learning with diabetes are correlated with 
reduced expression of the presynaptic protein synaptophysin in the absence of 
neuronal loss. A decrease in basal synapsin I phosphorylation, which mediates the 
fundamental initiating event in regulating the release of NT from the 
cytoskeleton, may hinder the mobilization of vesicles within the presynaptic 
terminal. This phosphorylation event is affected by CaMKII. CaMKII content and 
activity are reported to be decreased by diabetes in the hippocampus, which also 
exhibits electrophysiological abnormalities and synaptic protein loss. Insulin 
replacement therapy partially rectified CaMKII activity in STZ-diabetic rat brain 
(VanGuilder et al., 2008). Additionally, it has been found by Ramakrishnan et at., 
(2005) that diabetes have increase in CaMKII expression and enzyme activity in 
different brain regions that in most instances are correlated with increased 
serotonine levels, thereby suggesting that CaMKII may be involved in the 
regulation of indolamines in diabetic animals (Ramakrishnan et al., 2005). 
As explained earlier, as ageing in the brain takes place, various changes in 
numerous aspects of NT signalling occurs. Recent researches have indicated 
gross imbalances in NTs occurring during brain aging and age-related diseases of 
the brain (Uranga et al., 2010). For instance, the levels and density of key NTs 
such as dopamine have been demonstrated to be decreased in the aging brain 
(Meng, 1999). Moreover, the levels of NTs such as acetylcholine decreases and is 
accepted in the aging brain and age-related neurodegenerative disorders such as 
AD (Terry and Buccafusco, 2003; Hynd, 2004).  Along with the changes in the 
level of NT, changes in the levels of key NT receptors have also been reported. 
The glutamate receptor subunits NR1, NR2A, and NR2B; and the AMPAR 
decline with age (Adams, 2008; Newton, 2008).  There is also significant age-
related decrease in the levels of dopamine receptors D1, D2, and D3 (Kaasinen, 
2000). The effects of aging on the levels of cholinergic receptors, however, are 
still unclear (Uranga et al., 2010). 
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I.15 Behavioural Studies 
In all the living organisms, natural actions are due to the synchronized 
coordination of various complex sequences of patterns such that, each pattern 
must be connected to another in a well-organised fashion (Berridge, 1989). 
Behaviour is one of the most important properties of animal life. It plays a critical 
role in biological adaptations, and is believed to be the bridge between the 
molecular and physiological aspects of biology. Experiments on learning, 
memory and perceptual processes are revealing new insights into neural plasticity 
and developmental influences on the brain. Today the behavioural study is not 
only important to understand how the brain works but also is significant to 
elucidate the neural disorder during diseases like AD.  Cognitive neuroscience, a 
discipline aimed at understanding the functioning of the brain, encompasses 
approaches ranging from behaviour to molecular.  
Studies monitor animals‟ behavioural patterns in order to gain comprehensive 
understanding of their behaviour and also to determine the effects of the 
environmental changes, drugs or to have a detailed insight in the neuronal 
regulation of the behaviour (Van de Weerd et al., 2001). Each species-specific 
behaviour provides basic understanding of how the brain organizes elemental 
actions into patterned sequences. These actions allow syntactic processes of 
sequence control to be isolated and examined, without the use of training 
procedures, and relatively independent of the learning and memory processes on 
which trained action sequences depend.  
This laboratory investigates the molecular mechanisms of NT release and its 
perturbation in diseased states. However, after examining the diabetic 
synaptosomes, it has been established that the basic neuronal machinery is 
affected. Therefore, the present behavioural study was undertaken with the 
intention of establishing the biochemical changes and the behavioural changes 
that occurs in the diabetic animals in order to elucidate the co-relation between 
the behavioural patterns to the biochemical changes that occurs in these animals.  
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I.16 Rationale Behind the methods used   
Experiments reported herein used the well-established model system consisting of 
pinched off nerve terminals (synaptosomes) prepared from the cerebral cortex of 
rat brain. These allow the study of the various pools of SVs from adult tissue.  
I.16.1 Synaptosomes  
Synaptosomes are a well-established model for NT release and are susceptible to 
pharmacological manipulations (Fernandez-Busnadiego et al., 2010). They were 
first isolated by Whittaker in 1958 (Breukel et al., 1997). Synaptosomes are intact 
nerve terminal particles with small, clear vesicles, signifying their presynaptic 
origin. Clearly, synaptosomes contain all the components necessary to store, 
release, and retain NTs. They also contain viable mitochondria with ATP and 
active energy metabolism. They maintain resting [Ca
2+
]i concentrations of 100-
200 nM in the presence of 2 mM [Ca
2+
]e. Resting membrane potential (which is 
regulated by a Na
+
/K
+
-ATPase) is maintained and they express functional uptake 
carriers and ion-channels in their PM. On application of diverse depolarizing 
stimuli (e.g. potassium and 4-aminopyridine), Ca
2+
 enters synaptosomes via 
VGCCs or one can use ionomycin which allows Ca
2+
  entry due to its ionophore 
transport properties and these three stimuli triggers exocytosis of docked vesicles, 
thereby releasing various NTs (Breukel et al., 1997) .  
I.16.2 Glutamatergic synaptic transmission 
 Glutamate is the main NT present in mammalian synaptosomes (Nicholls et al., 
1987).  It plays a critical role in many neuronal functions (as discussed above) 
(Satoh and Takahashi, 2008). Various types of glutamate receptors are present in 
the CNS. Ionotropic glutamate receptors (iGluR), i.e. NMDA, AMPA and 
kainate, are responsible for mediating fast synaptic transmission, whereas 
activation of metabotropic receptors (mGluRs) modulates neuronal excitability 
and transmission (Woolley et al., 2008). About eight mGlu types of receptors 
have been identified so far. It is believed that, mGlu2 receptors are located 
presynaptically at the periphery of the synaptic area, where they function to 
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monitor excessive glutamate that has escaped from the synaptic space and 
provide negative feedback to prevent excessive glutamate release (Woolley et al., 
2008). It was demonstrated that, physiological concentrations of transmitter in the 
synaptic cleft were insufficient to activate all the postsynaptic receptors 
suggesting that glutamate concentrations during synaptic transmission could 
possibly be the regulatory function of synaptic strength. Because of its role in 
synaptic plasticity, glutamate is involved in cognitive functions like learning and 
memory (Meldrum, 2000). Glutamatergic vesicles are defined by their ability to 
pack glutamate (Glu) for release, a property conferred by the expression of a 
VGLUT. VGLUTs are subject to regional, developmental, and activity-dependent 
changes in expression.  
Since >80% of all cerebral cortical synaptosomes are glutamatergic, the release of 
endogenous Glu at 22°C (determined using a glutamate dehydrogenase coupled 
assay and measuring fluorescence of NADPH product) was studied in this thesis.  
I.16.3 FM2-10 dye assay to study the modes of exocytosis 
Applications of styryl dye staining and destaining during endocytotic and 
exocytotic processes have been used to study the kinetics of vesicle cycling and 
the prevalence of different exocytotic modes of release i.e FF versus K&R 
exocytosis (Omiatek et al., 2010). Fluorescent styryl dyes (e.g. Fei Mao), 
enduring both lipophilic and divalent cation groups, are widely used to label 
membranes for fluorescence microscopy investigations of vesicular exocytosis. 
Styryl dyes like Fei Mao (FM) fluoresce brightly when harboured in the 
hydrophobic vesicle membrane, but not in aqueous solution, and thereby report 
vesicle fusion events (Zhang et al., 2007). Upon stimulation, when the SVs that 
undergo exocytosis in the presence of the styryl dye, the dye molecules are 
subsequently integrated into the vesicular domain following endocytosis. This 
dye molecule partition easily and reversibly inside of the cell membrane, and 
increases the fluorescence intensity significantly by 20 fold (Omiatek et al., 
2010).  This dye cannot escape through a flickering proteinacious pore (Henkel et 
al., 2001).  FM dye can leave the vesicle membrane by lateral diffusion away 
from fused membrane upon FF (Zhang et al., 2007). Zhang et al., (2009) 
hypothesized that the nanoparticles of the stryl dye are small, which allows them 
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to be transported into the vesicle (interior lumen space estimated as about 24 nm 
diameter), but are spatially excluded from the narrow fusion pore (1-5 nm 
diameter) formed during K&R (Zhang et al., 2009).  
To remove non-specific binding of FM dye to the PM, Advasep-7 is utilized. 
Advasep-7 has a higher affinity for the dye than membranes. The dye inside the 
membrane is not disturbed as advasep-7 cannot cross the PM. Upon a subsequent 
stimulation, the SVs re-exocytose and depending on the mode of exocytosis, the 
dye will or will not de-partition from the membranes. The FM dye should be 
discharged during FF mode of exocytosis and the membrane will completely lose 
its fluorescence. This would allow direct interrogation of the mechanism of 
release (Figure S). Whilst in K&R mode of exocytosis, the SVs do not fully 
collapse and so the FM dye is still trapped within the luminal domain of the SV. 
Previous studies have suggested that the K&R mode of exocytosis dominates at 
the onset of stimulation, and that FF prevails following continuously repeated 
stimulation. The results in this thesis re-inteprets the significance of this finding 
since it relates to the pools of SVs. The use of lipophilic FM dyes to follow 
vesicle cycling has also suggested the existence of fast K&R exocytosis in 
synaptosomes (Graham et al., 2002; Richards, 2009). 
Optimal stimulation conditions that produce maximum NT release will enable all 
releasable SVs to be loaded with FM dye, and subsequently such SVs can be 
released upon the application of a stimulus. Sub-optimal conditions for dye 
loading will make it difficult to compare endogenous NT release because dye free 
vesicles will still be able to release NT. Maximum stimulus is required to be 
applied for the study of the FM dye release as all the vesicles (RRP and RP) 
needs to be labelled. Drugs that perturbed Glu release, and therefore reduce the 
number of SV exocytosing cannot be used for such experiments.  
In  FM dye studies, the application of a depolarizing stimulus with 30mM K
+
 plus 
5mM Ca
2+
 (HK5C) produced maximal synaptosomal NT release, and the 
inclusion of a 5min post-stimulus incubation, both carried out in the presence of 
100µM FM2-10 dye, ensured that all releasable vesicles were fully labelled. All 
loading of FM dyes, washing and release were performed at RT (22°C). 
Exocytosis was studied by measuring the decrease in fluorescence in response to 
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optimal concentrations of secretagogues and Ca
2+
 known to induce maximal 
release. The size of the releasable pool(s) is reflected by the terminals‟ response 
to a single application of the strongest release stimulus.  
Such conditions have been established herein and furthermore all three stimuli 
employed only induce one round of release of the SV pools such that one can 
correlate release of Glu with FM dye. 
 
Figure S. Dynamics of FM-dye terminal staining in the two models of NT release: A. 
K&R mode of exocytosis where the FM dye (green spots) do not dissociate when 
glutamate (red spots) are released. B. FF mode of exocytosis where both the FM dye and 
Glu is released as the vesicle completely fuses with the PM (Krupa and Liu, 2004). 
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I.16.4 Fura-2AM experiments  
Fura-2, a Ca
2+
-indicators is used for measuring of [Ca
2+
]i concentration. Cells are 
loaded by immersion in a solution of the permeant acetoxymethyl ester form 
(Fura-2AM), which is fluorescent but Ca
2+
-insensitve. Following cleavage by 
intracellular esterases liberates Fura-2AM (the pentacarboxylate Ca
2+
indicator), 
and thereby being trapped into the cell. Measurement of Ca
2+
-induced 
fluorescence at excitation wavelength 340 nm and 380 nm allows for calculation 
of Ca
2+ 
concentrations based 340/380 ratios with an emission wavelength 535 nm 
(here the wavelengths of emission was at 535 nm and excite at 340 nm and 390 
nm were measured but for results, it is often refered to the 340/390 ratio as the 
340/380 ratio). The use of the ratio automatically cancels out certain variables 
such as local differences in Fura-2AM concentration or cell thickness that would 
otherwise lead to artifacts when attempting to image Ca
2+
concentrations in cells.  
[Ca
2+
]i is calculated from the ratio (R) of fluorescence intensities obtained using 
the formula of Grynkiewicz, et al., (1985): 
[Ca
2+
]i = Kdβ(R – Rmin)/ (Rmax – R). (Gillis et al., 1994). 
where, Rmax values obtained by permeabilizing PM with 0.3% Triton X-100 in 
the presence of 7mM Ca
2+
 and Rmin values measured by permeabilizing PM with 
0.3% Triton X-100 in the presence of 15mM EGTA at pH 7.4 to chelate the 
available Ca
2+
ions.  
Studies by others and by Ashton and Ushkaryov, (2005) illustrate that measuring 
the 340 nm/390 nm ratio removes artifactual variations in the fluorescence 
measured due to changes in dye concentration and instrument efficiency (Ashton 
and Ushkaryov, 2005). 
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I.16.5 Three stimuli employed in this study: HK5C, ION5C and 4AP5C.  
K
+
 was raised (with a corresponding reduction in Na
+
 ions) to 30mM (HK). This 
causes clamped depolarization at the nerve terminal membrane whichactivates 
various Ca
2+
 channels and causes a large increase in [Ca
2+
]i (depending upon the 
[Ca
2+
]e employed) at the AZ and a subsequent generalized lower increase in Ca
2+
 
throughout the nerve terminal. 
The application of a potent and selective Ca
2+
 ionophore, ionomycin (ION) (Yoon 
et al., 2008) (in the presence of extracellular Ca
2+
) to cells leads to influx of 
[Ca
2+
]e, and results in a large increase in the [Ca
2+
]i, which can induce SV 
exocytosis and triggers secretion. The molecule acts as a motile Ca
2+
 carrier and 
enhances Ca
2+
 influx by direct cation entry across biological membranes. Please 
note that ION5C works throughout the nerve terminal (not just at the AZ) and the 
amount of Ca
2+
 at the AZ is not same as that for HK.  
The addition of 1mM 4-aminopyridine (in the presence of extracellular Ca
2+
) 
(4AP) causes the prolonged opening of VGCCs at the AZ due to its action on K
+
 
channels (note others believe that 4AP also has actions that are independent of the 
K
+
 channels). However, this does not cause a clamped depolarization, unlike HK, 
and so the actual increase in the [Ca
2+
]i at the AZ and throughout the nerve 
terminal will not be as great as that for HK. 
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I.16.6 STZ as a model  
Streptozocin (STZ), which has been proven to be toxic only to the β-pancreatic 
cells in rodents; and STZ-induced diabetes is a well established model for TIDM. 
STZ (an alkylating agent) is a naturally occurring chemical, which is derived 
from the soil microorganism Streptomyces achromogenes. It is a cytotoxic 
glucose analogue, which preferentially accumulates in pancreatic β-cells via low-
affinity GLUT2 glucose transporter in the PM causing necrosis of β-cells. 
However, STZ has no immediate, direct inhibitory effect upon glucose transport 
or on glucose phosphorylation by glucokinase (Lenzen, 2008).  
When STZ enters the β-cells of pancreas, it breaks into its glucose and 
methylnitrosourea moiety. The alkylating property of methylnitrosourea modifies 
biological macromolecules, fragments DNA and destroys the β-cells, causing a 
state of insulin-dependent diabetes (Lenzen, 2008). It works by transferring the 
methyl group from STZ to the mitochondrial DNA, thereby impairing the 
signalling function of β-cell mitochondrial metabolism, causing inhibition of 
glucose-induced insulin secretion. As a result of this, poly (ADP-ribose) 
polymerase is overstimulated in order to repair DNA. This results in diminishing 
cellular NAD
+ and ATP stores, which ultimately causing β-cell necrosis. It causes 
further damage by protein glycosylation. Although STZ also methylates proteins, 
DNA methylation is ultimately responsible for β-cell death, but it is likely that 
protein methylation contributes to the functional defects of the β-cells (Lenzen, 
2008).  
Due to STZ‟s chemical properties (As presented in Figure T), mainly due to its 
greater stability, it is the agent of choice for reproducible induction of a diabetic 
metabolic state in experimental animals (Lenzen, 2008). Significant and rapid 
hyperglycaemia is observed at 1wk post-STZ (Tomlinson and Gardiner, 2008). 
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Figure T. Schematic representation of the toxic effects of the glucose STZ in β-cells, 
which produce chemical diabetes (Lenzen, 2008). 
 
Studies have confirmed that STZ itself does not induce neurotoxicity in insulin-
deficient diabetes (Davidson et al., 2009). The mouse/rat model of STZ-induced 
diabetes has peculiar features that are observed in humans with respect to non-
ischemic systolic and diastolic performance and microvascular rarefaction, which 
are associated with changes in VEGF isoform expression and redox imbalance in 
the myocardium (Stranahan et al., 2008). Slowing of motor and sensory nerve 
conduction velocity is a common feature in animal models of STZ-induced 
diabetes (Thomas et al., 2001). In TIDM rats it has been demonstrated that, 
impaired vascular reactivity precedes the development of nerve dysfunction as 
identified by reduced nerve conduction velocity. Reduced conduction velocity 
develops in motor and sensory nerves in STZ animals (Tomlinson and Gardiner, 
2008). In addition to this, studies have demonstrated that 5wk of STZ-induced 
diabetes caused significant oxidative stress (Han et al., 2009). In an experiment 
conducted by Davidson et al., (2009), mice displayed hypoalgesia 4-12wks after 
injection of STZ and subsequent induction of diabetes (Davidson et al., 2009). 
However, Beiswenger et al. reported that thermal hypoalgesia developed after 
only 2 weeks of diabetes (Beiswenger et al., 2008).  
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I.17 Aims and Hypothesis of the Research 
Hypothesis 
Intracellular Ca
2+
 plays an important role in modifying specific nerve terminal 
proteins via Ca
2+ 
dependent phosphorylation and this determines whether the SVs 
undergo FF or K&R in nerve terminals prepared from either control or STZ-
induced diabetes. Interestingly, higher [Ca
2+
]i levels result in more of the K&R 
mode of exocytosis and less FF and such conditions prevail in diabetic terminals. 
It is hypothesized that compared to control animals, diabetic animals may have a 
larger activation or smaller inactivation of a specific Ca
2+ 
channel subtype. 
Furthermore, this may regulate a larger change in phosphorylation of specific 
proteins compared to control terminals and this will play a role in the increased 
amount of K&R in the diabetic terminals. Further correlation of such changes will 
be compared to the behavioural changes observed in STZ-induced diabetic rats.  
Main aim: The main aim of the study is to investigate the role of Ca2+ and 
protein phosphorylation in the switching of mode in control and diabetic nerve 
terminals. Additionally, to determine the behavioural changes that may occur in 
diabetic rats.  
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Specific Aims: 
1. To determine the reason for the higher level of [Ca2+]i present in the 
diabetic animals by using P-, L-, N- and Q-type Ca
2+ 
channel blockers, as 
these channels may play important physiological roles in the determining 
the mode of exocytosis. 
2. To investigate the role of CaMKII in switching of the exocytotic modes of 
SVs in both diabetic and control animals by using specific inhibitors. 
3. Determining the contribution of dynamin in the switching of the mode of 
exocytosis in diabetic terminals. 
4. Investigating the involvement of PKC in the regulating the modes of SV 
exocytosis.  
5. Determining the role of myosin II in the distinct modes of exocytosis in 
both diabetic and control terminals by blocking this enzyme with Bleb. 
6. Determine the difference in the STZ-induced diabetic rat‟s behaviour in 
comparison to the age-matched control rats, thereby finding the link 
between biochemical and behavioural aspects.  
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II. Regulation of the Mode of Exocytosis in Control and 
Diabetic Terminals 
II.1 Materials and Methods  
All experiments were conducted according to the requirements of the United 
Kingdom Animals (Scientific Procedures) Act (1986) and approved and 
supervised by University of Central Lancashire Science and Technology ethical 
approval committee. The diabetic animals used were under the license of Prof. Jai 
Paul Singh (License number- PIL 50/824) 
II.1.1 Animal house 
Male Wistar rats (Charles River, UK) weighing approximately 160-200grams at 
the time of arrival were used throughout the experiment. The animals were kept 
in the cage in groups of 2-4, in a temperature (22±2
o
Celcius) and humidity 
(55±2%) controlled environment, with ad libitum access to food pellet and tap 
water on a 12hour light/dark cycle (lights on 07.00-19.00h). The control animals 
were housed with wood shaving bedding and the diabetic rats were kept in 
sawdust bedding in a rectangular wire topped RC2R cages from North Kent 
Plastics with overall dimensions 56 × 38 × 22cm and internal size 1575cm
2
 × 
22cm. All the principles for laboratory animals were followed and all the 
procedures were carried out in accordance with the standard University of Central 
Lancashire Procedures and Home office guidelines. 
The rats rendered to be diabetic (approximately when they were 200-250grams)  
received single intraperitoneal injection of 150mg/kg of STZ (Sigma, St. Louis, 
MO, USA) dissolved in 0.05M citrate buffer, pH 4.5. STZ was administered 
within 10mins after preparation, in the caudal abdominal cavity using sterile 
25grams needle by holding the rat in one hand in dorsal position. The injection 
site was swabbed using povidone-iodine solution and the designated amount of 
STZ was injected (according to the weight of the animal). During the following 
four days, the rats were tested for diabetes using glucometer. Animals whose 
blood glucose level exceeded 200mg/dL after treatment were considered diabetic 
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(generally, the blood glucose level above 12mM was considered to indicate 
diabetes but most animals had blood sugar levels averaging about 25mM). 
Severity of the induced diabetic state was assessed by daily monitoring of blood 
glucose levels. At the time of the experiments, the diabetic rat brains were the 
same size as the control and no obvious neuronal dysfunction were observed. 
II.1.2 Biochemical Assays 
The chemicals that were purchased from Sigma-Aldrich Co. Ltd. (UK) are NaCl, 
KCl, MgCl2, hepes, glucose (used for the preparation of the L0 physiological 
buffers), sucrose, calcium, glutamic acid, dimethyl sulphoxide (DMSO), HCl, 
dynasore, glutamate dehydrogenase type II, NADPH, advasep-7. Ionomycin, 
okadaic acid, blebbistatin, cyclosporin A, phorbol-12-myristate-13-acetate were 
purchased from Tocris Bioscience (UK). FM2-10 dye and Fura-2AM were 
purchased from Invitrogen Ltd. (UK).  
A motor driven Potter homogenizer, specifically designed for synaptosomal 
preparation was used for the homogenization procedure of the brain tissue. For 
initial centrifugation Beckman centrifuge with a JA17 rotor was used. Tecan 
GENios Pro
TM
 microplate reader (Figure U) was used for measuring release in the 
different assays used.  XFluor™ software based on Microsoft Excel® was used 
by the plate reader, thereby providing basic instrument handling and display of 
raw data in an Excel® spread sheet. Greiner 96 well, flat (black and transparent) 
bottom microplates were purchased from Greiner Bio-one (UK). 
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Figure U. The Tecan GENios Pro: A) The Tecan GENios Pro advanced 
multifunctional injector Reader B) Loading of micotitre plate C) Compact 
injector system with high-precision pumps D) Patented injector carrier. 
           Photos courtesy of http://www.labx.com/v2/adsearch/detail3.cfm?adnumb=367614 
II.1.3 Preparation of Synaptosomes 
Following injection with STZ, male Wistar rats were used within 4-12 weeks for 
all the experimental procedures unless specified. The rats were humanely killed 
by a blow on the head, followed by cervical dislocation. Thereupon, the skull was 
carefully cut open and the cerebral cortex was removed and placed in ice-cold 
sucrose buffer- 0.32M sucrose and 0.1M hepes pH 7.4 (maintained at 1-4˚Celcius 
on ice). The cortex obtained was homogenised in the sucrose buffer and 
centrifuged in Beckman centrifuge at 4,500rpm [relative centrifugal force (RCF) 
2030 × g] for 10minutes (mins) at 4˚C. The supernatant obtained was 
subsequently centrifuged at 14,500rpm (RCF- 21,075 × g) for 20mins at 4˚C and 
the pellet was discarded. After the centrifugation, the supernatant was removed 
whilst the pellet was resuspended in L0 buffer (125mM NaCl, 5mM KCl, 1mM 
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MgCl2, 10mM glucose, 20mM Hepes; pH 7.4). The homogenized sample was 
further centrifuged at 14,500rpm at 4˚C for 20mins. This step is done to get rid of 
all the cellular debris and to obtain crude P2 synaptosomes. This P2 synaptosome 
pellet was used in all the experiments as the contaminating inactive mitochondria 
and myelin did not interfere with any of the assays, and further purification of 
synaptosome to remove these contaminants produce synaptosomes that had a 
shorter time of viability than the P2. The resultant pellet obtained is homogenized 
in 12ml of ice-cold L0 buffer which was gassed with pure oxygen. The 
resuspended synaptosomes obtained were kept on ice and continuously gassed 
with pure oxygen. These synaptosomes were utilized for various different assays 
such as, glutamate assay, FM2-10 dye assay or Fura-2AM assay. The 
synaptosomes were used within 6hrs following their preparation. In order to make 
direct comparisons between the different assays, the synaptosomes were pre-
treated identically for the three assays. Relevant controls were carried out in 
every experiment in order to compare results from different experiments. 
The assays for glutamate release, FM2-10 dye release and Fura-2AM 
measurement of [Ca
2+
]i, were used with synaptosomes in the presence or absence 
of nifidepine, ω-agatoxin TK, ω-conotoxin GVIA, ω-conotoxin MVIIC, KN93, 
KN92,  dynasore,  cyclosporine A,  blebbistatin, okadaic acid and active phorbol 
ester. Some of these drugs were used in combination (double drug treatment) in 
certain experiments. In most of the assays, the drug was initially added during a 
5min 37°C incubation and was reapplied during the final resuspension step 
(following washing steps) just prior to the synaptosomes being transferred to the 
wells of a microtitre plate. However, blebbistatin and dynasore were not added in 
the last step as mentioned above, but were included in an initial washing step. 
This procedure was undertaken because preliminary experiments with dynasore 
and blebbistatin indicated that the presence of the drugs during the measurement 
stage of the assays interfered with the actual assays. However, both these drugs 
were known to be still active following their initial removal as indicated by the 
results. Eventually, such removal of these drugs could lead to reversibility of their 
effects but this takes longer than the time scale of the experiments conducted. Part 
of the disturbance may be due to the drugs themselves interfering with the 
fluorescence signals.  
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The synaptosomes were stimulated to evoke exocytosis using varying 
concentration of Ca
2+
 and distinct stimuli; including HK, 4AP, and ION. All the 
above mentioned assays involve the measurement of fluorescence changes. All 
these methods are routinely employed in the laboratory of Dr. A. Ashton (see 
Ashton and Ushkaryov, 2005). 
II.1.4 Glutamate Assay 
Rat synaptosomes prepared were used in the following procedure for measuring 
evoked glutamate release under various conditions. 2 × 1ml aliquots of 
synaptosomes were added to microcentrifuge tubes and 2 × 0.25ml of HK and 
Ca
2+
 (HK5C final) containing buffer (130mM K
+
, 25mM CaCl2) were added to 
them. The mixture was incubated at RT for 90seconds (s). Thereafter, the tubes 
were centrifuged in an Eppendorf bench top centrifuge at 11,500rpm (RCF 
11,000 × g) for 40s. The supernatant was discarded and the pellets obtained were 
resuspended in gassed 2 × 0.22ml L0 and pooled (final volume 0.5ml as the 
pellets had some volume) and incubated for 10mins at RT. Thereafter, desired 
drug or solvent i.e. DMSO (for control samples) was added to the synaptosomes 
and further incubated for 5mins at 37˚C.  Then the sample was spun down and the 
pellet obtained was resuspended in 1ml of L0. Finally, the pellet obtained was 
resuspended in 1.6ml L0 with the relevant amount of drug or DMSO. Then 
0.121µl aliquots of synaptosomes samples were added to 12 wells in a row of a 
Greiner 96 well microtitre plate (black with transparent bottom) after adding 20µl 
of L0 to each well. This was followed by adding 10µL of 20mM NADP
+
 and 9µL 
of glutamate dehydrogenase (GDH type II: 4 units per mL and so 36mUnits 
added) to all the wells. Then the plate was incubated for 10mins. In the mean 
time, synaptosomes for the next part of the experiments were prepared. Following 
the 10mins incubation, 40µl HK or 5mM 4AP or basal buffer without Ca
2+
 was 
added to wells 6-12 inclusive and wells are thoroughly mixed. 40µl of HK with 
5mM Ca
2+ 
(HK5C) or 4AP with 5mM Ca
2+ 
(4AP5C) or 5µM ION with 5mM 
Ca
2+ 
(ION5C) are added to wells 1-5 Wells 1-9 are then measured immediately in 
Tecan GENios Pro
TM
 microplate reader. The fluorescence was measured for 21 
cycles. The relevant settings for the microplate reader are specified in appendix 
(table VI.1.1). Following the measurement of glutamate release from the 
synaptosomes, (as determined by changes in the fluorescence signal), the 
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response to the addition of a standard amount of Glu was measured. 10µL of L0 
was added to wells 7-9 and 10µL of 1mM (10 nmol) freshly prepared stock 
glutamate was added to wells 10-12 and following mixing. The change in 
fluorescence was measured over 15 cycles.  
II.1.5 FM2-10 Dye Assay 
The assay for FM2-10 dye release was carried out under similar conditions as for 
the glutamate assay, in order to make a direct comparison between both the 
assays. However, if a drug was found to perturb Glu release, then it was not tested 
in the FM2-10 dye assay because one would not be able to interpret results if all 
SVs were not being released. 
Synaptosomes were prepared (See section II.1.3 above) and resuspended in 16mL 
of L0 buffer. Before the treatment for each set of measurements, 2mL of 
synaptsomes were oxygenated at RT for 15mins. This step was undertaken to 
ensure that the terminals had equilibrated properly at this temperature and this 
would enable maximal FM2-10 dye uptake. After the 15mins incubation 2 × 1mL 
of aliquots were spun down in microfuge tubes in an Eppendorf bench top 
centrifuge at 11,500rpm (RCF 11,000 × g) for 40s. The pellets obtained were 
resuspended in 2 × 0.5mL of L0 buffer and pooled together (final volume was 
1.1ml as pellets have some volume). Into this mixture, 2.2µL of 50mM FM2-10 
dye (100µM final concentration) was added and incubated for 60s. Then, 
0.275mL HK5C was added and stimulated synaptosomes were incubated for 90s. 
This step is very important, as this stimulus exposes the lumenal membrane 
domain of exocytosing SVs to FM2-10 dye, which then binds to these membranes 
and when the SVs re-internalized the dye is also internalized. Following this, the 
synaptosomes were centrifuged for 40s, and the pellet obtained is resuspended in 
1mL of L0 with 2µL of 100mM FM2-10 dye and the sample is incubated for 
5mins at RT whilst being oxygenated. This is to assure that all the SVs are 
labelled with the dye as some vesicles take several minutes to internalize and 
removal of the extracellular dye before this time could lead to wash out of dye 
from these non-internalized vesicles and as a result not all releasable vesicles 
would be labelled. Subsequently, specific concentration of drug or DMSO (in 
case of control samples) was added to the synaptosomes and these were further 
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incubated for 5mins at 37
o
C. Following this step, 4µL of 250 nM stock advasep-7 
(final concentration 1mM) was added to the terminals. Advasep-7 removes FM2-
10 dye from the PM of the synaptosomes; since it has a higher affinity for the dye 
than the hydrophobic phospholipid bilayer (this reduces the background 
fluorescence). Such synaptosomes are spun down and the pellet is resuspended in 
1ml of L0 buffer. This sample is again centrifuged and resuspended in 1mL of L0 
buffer. 5 × 0.2mL of these synaptosomes are prepared and 5 × 1mL of L0 buffer 
is added to each. This step is done to ensure the maximum amount of dye is 
removed from the outside of the membrane. These samples are then centrifuged 
and each aliquoted pellet is resuspended in 0.28ml of L0 containing the desired 
drug or DMSO. These samples are pooled and 160µL of aliquots were added to 
each of the 8 wells of Greiner 96 well microtitre plate (flat black bottom). The 
fluroimeter measurement settings are specified in appendix VI.1.2.  For each row 
of 8 wells (labelled 1-8), 4 wells were injected with 40µL of either HK5C or 
4AP5C or ION5C for evoked FM2-10 dye release measurement, whereas the 
other 4 wells were injected with 40µL of L0 buffer to produce the values for basal 
release of dye. Each well was measured separately for 2mins (461 cycles). As the 
individual wells are being measured separately (unlike for the Glu assay), the first 
well of the series (well 1) will be measured about 16mins prior to the last sample 
being measured (well 8). It is essential to take this into account and so each type 
of experiment was repeated twice within the same experiment, such that in one of 
8 wells, the first 4 wells were exposed to stimulus and the last four wells had 
basal buffer added; whilst in the other row, the first 4 wells had basal buffer 
added whilst the last four wells had the stimulus. The data was averaged for all 
the 8 wells exposed to the stimulus and for the 8 wells exposed to basal buffer, to 
avoid the time dependent difference in the measurements. Each experiment was 
repeated at least four times to allow us to carry out statistical analysis. 
Furthermore, the experiments were designed such that the order of the particular 
drugs treatment was varied in between these distinct experiments to ensure that 
the age of the synaptosomes (since their preparation) did not play a role in the 
observed action of a particular drug treatment. 
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II.1.6 Fura-2-acetoxymethyl ester Assay 
Following the synaptosomes preparation (Refer Section II.1.3), they were 
resuspended in 10mL of L0 buffer. 50µL of 50mg Fura-2AM in DMSO (1mM 
stock: 5µM final) was added and the sample was incubated for 30mins at 37°C 
with oxygen. After incubation, 3mL of L0 buffer was added and 12 × 1mL of 
aliquots were transferred to microfuge tubes. These were spun down in an 
Eppendorf bench top centrifuge at 11,500rpm (RCF 11,000 × g) for 40s. Each of 
the synaptosomal pellets obtained were further washed in 1mL of L0 buffer (this 
step was undertaken to remove any extracelluar Fura-2AM) and resuspended in 
1.1mL of L0 buffer. These samples were then pooled and kept oxygenated on ice 
until required.  
2 × 0.8mL of aliquots were placed in the Eppendorf tubes and 2 × 0.2mL of 
HK5C was added. These samples were incubated for 90s before they underwent 
centrifugation with the corresponding pellets being resupsended in 2 × 0.5mL of 
L0 buffer.  The aliquots obtained were pooled together and transferred to test 
tubes. These synaptosomes were incubated at room RT for 10mins whilst being 
oxygenated. Thereafter, the required concentration of the selected drug/ DMSO 
was added and the synaptosomes were further incubated at 37°C for 5mins. Then 
the sample was transferred to the micofuge tube and was spun down. The pellet 
was resuspended in 1mL L0 buffer prior to recentrifugation. Finally, the sample 
was resuspended in 1.6mL of L0 buffer containing the relevant concentration of 
the desired drug/DMSO. 0.12mL of this synaptosomal suspension were added to 
each of 12 wells of a Greiner 96 well microtitre plate (black flat bottom) for 
measuring the Fura-2AM fluorescence. The settings for the measurement of Fura-
2AM fluorescence is detailed in Appendix VI.1.3. 
Fluorescence measurements were measured from the top of the plate. Each well 
was measured twice. Firstly, the samples were measured at the excitation 
wavelength of 340 nm and emission wavelength of 535 nm for 40 cycles without 
any stimulus or basal buffer being injected by the integral injector present within 
the plate reader (Refer Figure U). Thereafter, the settings were changed to 
measure 160 cycles with a 40µL injection of either the selected stimulus or L0 
(basal buffer). This double measurement procedure was then repeated with the 
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next adjacent well except that the samples were measured at the excitation 
wavelength of 390 nm and emission wavelength of 535 nm. The results for these 
two adjacent wells were lined up and the 340/380 ratios (actually 340/390) for the 
time courses could be ascertained (e.g. well 1 at 340 and well 2 at 390 were 
combined). This procedure was then repeated for wells 3, 4, 5, and 6. In one row, 
wells 1-6 had Ca
2+
 containing stimulus injected whilst wells 7-12 had basal buffer 
injected. The wells with L0 buffer act as a measure of the basal change in 
340/380, which can be utilized to determine the specific change in [Ca
2+
]i induced 
by the stimulus. This procedure was continued until all the 12 wells were 
measured. Following this, a maximum and minimum Ca
2+
 signal was calculated, 
by introducing 16µL of 33.75mM Ca
2+
 with the detergent - 4.05% Triton X-100 
to the synaptosomes with the stimulus (i.e. that already contained extracellular 
Ca
2+
) to observe maximum signal for Ca
2+
. Likewise, 16µL of L0 buffer was 
added to the samples with the basal buffer, followed by 24µL of a solution 
containing ethylene glycol tetraacetatic acid (EGTA) (Ca
2+
 chelating agent; 
giving a 15mM final concentration) plus 3% Triton X-100 which was used to 
determine the minimal signal for Ca
2+
. All the wells were then measured together 
firstly at 340 nm and then at 390 nm respectively for 40 cycles each. A repeat of 
this procedure was carried out in a subsequent row except wells 1-6 had basal L0 
buffer injected whilst wells 7-12 had the relevant stimulus injected. The results of 
these two sets of measurements were averaged to take into account any difference 
due to the age of the synaptosomes in the wells. 
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II.1.7 Statistical Analysis 
Independent experiments carried out in set of 2-4 were averaged and all the 
calculations and statistical analyses were performed using Microsoft Excel and 
GraphPad Prism software. The level of significance for the data was obtained by 
analysing a few points between the two sets of data being compared. The values 
were statistically analysed using unpaired student’s t-test. The results are 
presented as the average and the error bars are the standard error of the mean 
(SEM) for the data points obtained. The results with probabilities less than 0.05 
were considered to be statistically significant for all the experiments. 
Many data points were obtained during the FM2-10 dye assay. Therefore, graphs 
obtained had the data points too close together and the SEM obtained was fused 
together such that the line appears as a nearly continuous thickened curve. For 
presentational purposes some SEM are deleted so that distinct points can be 
visible.   
The legends in the graphs indicate the number of independent experiments and 
the number of times each condition is measured. The glutamate assay results are 
presented as the percentage of the maximum Glu released in order to compare the 
experiments performed on different days and with different conditions. It is to be 
noted that, even though the weight of the diabetic animals used during the 
experiments were just more than half the weight of the control rats (presented in 
Chapter III), the weight of the cortex was similar in both the rats. Therefore, 
direct comparisons could be carried out between the two rat terminals. The yield 
of synaptosomes was equivalent for both control and diabetic animals. 
The wavelengths for the three assays performed are indicated in the table below 
(table 3.A). The emission fluorescence obtained is that which is used in the Y-
axis in all the graphs accordingly. 
Table II.A: Wavelengths used for experimental study 
Assay Excitation Wavelength (nm) Emission Wavelength (nm) 
Glutamate assay 340 465 
FM2-10 dye assay 485 555 
Fura-2AM assay 340 and 390 535 
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II. 2 Results  
As stated in the introduction, the level of the evoked change in [Ca
2+
]i was higher 
in the diabetic nerve terminals in comparison to the control terminals (Figure i.C). 
It was speculated that this might be because of differences in the properties of the 
VGCCs between control and diabetic terminals. Therefore, various Ca
2+ 
channel 
blockers were tested to see whether difference in the activity of distinct VGCCs 
could account for the differences in the two terminals and whether such channels 
may play a role in the switching of the modes of exocytosis. 
II.2.1 Role of P-type VGCCs  
ω-Agatoxin TK (Aga TK) is a potent P-type VCGGs blocker (Wright and Angus, 
1996; Serulle et al., 2007) at 50 nM and synaptosomes were incubated with this 
concentration. 50 nM Aga TK failed to block Glu release in both control and 
diabetic synaptosomes, indicating that all the releasable SVs have been 
exocytosed (Figure 1). 
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Figure 1: No effect of HK5C evoked Glu release ± 50 nM Aga TK on (A) 
Control synaptosomes and (B) Diabetic synaptosomes.   
Although, this toxin does not block the Glu release when evoked with HK5C, 
some of the P-type channels were significantly blocked as when evoked changes 
in [Ca
2+
]i
 
were measured (using Fura-2AM), there was reduced Ca
2+
 entry. This 
was the case for both the control (Figure 2A) and diabetic synaptosomes (Figure 
2B).  
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Figure 2: 50 nM Aga TK significantly perturbs HK5C evoked [Ca
2+
]i release 
using Fura-2AM on (A) Control synaptosomes and (B) Diabetic synaptosomes.   
Please note that the above experiments were carried out at different times. 
Further, such measurements were only performed once on diabetic terminals so 
the actual levels of ∆[Ca2+]i for control and diabetic nerve terminals in these 
figure cannot be compared.   
Results observed from Figures 1 and 2 suggest that blockage of P-type VGCCs 
does not reduce the HK5C evoked changes in [Ca
2+
]i  sufficiently enough at the 
AZ to reduce the maximum Glu release. A supra-maximum Ca
2+
 concentration is 
employed when using HK5C, such that there is more Ca
2+
 entry than is needed to 
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induce maximum Glu exocytosis, so that even a reduction in this (as seen with 
treatment with Aga TK) is still sufficient to induce maximum Glu release.  This 
demonstrates that there is sufficient Ca
2+
 entry through other Ca
2+
 channel 
subtypes for maximum Glu release. At lower [Ca
2+
]e concentration researchers 
have suggested that P-type channels play a role in Glu release (Wykes et al., 
2007; Ladera et al., 2009).  
To verify this, the nerve terminals were stimulated with HK in the presence of 
1.25mM of Ca
2+
. Under such conditions, Glu release was significantly decreased 
in control synaptosomes using 50 nM Aga TK (Figure 3A), thereby proving that 
P-type channels do play a role in Glu release. However, Figure 3B indicates that 
50 nM Aga TK still does not affect the Glu release in diabetic terminals. This data 
leads us to make an initial conclusion that P-type channels do not appear to 
contribute to Glu release in the diabetic terminals. 
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Figure 3: 50 nM Aga TK action on HK1.25C evoked Glu release is significant 
in(A) Control synaptosomes , but has no effect in (B) Diabetic synaptosomes.   
As P-type channel blockade did not affect the total number of SVs exocytosing 
upon application of HK5C (as Glu release was not perturbed) in control 
synaptosomes, the role of such channels in switching of the mode of exocytosis 
was tested using the FM2-10 dye assay. A pre-requisite for relating any changes 
in FM2-10 dye release to changes in exocytotic mode is that all the releasable 
SVs must undergo exocytosis (i.e. need maximum amount of Glu release for any 
particular stimulus).  
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Figure 4 reveals that blockade of P-type channels with 50 nM Aga TK does not 
play a role in switching of the mode of exocytosis since there was the same 
amount of FM2-10 dye release with or without Aga TK treatment.  
 
Figure 4: No change in HK5C evoked FM2-10 dye release in control 
synaptosomes treated with 50 nM Aga TK  
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II.2.2 Role of L-type channel   
Experiments carried out in Dr. Ashton‟s laboratory show that 1µM of the L-type 
VGCCs blocker nifidipine (Nif) (Dolphin, 2006; Yang et al., 2009) does not 
affect the HK5C evoked Glu release in control (5A) and diabetic (5B) nerve 
terminals.  
 
Figure 5: 1µM Nif fails to perturb the  Glu release evoked by HK5C in (A) 
Control synaptosomes and (B) Diabetic synaptosomes (Barba, 2010).   
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Therefore, the role of L-type VGCCs in Glu release was examined using sub-
maximal Ca
2+
 concentration i.e. HK with 1.25mM Ca
2+
 (HK1.25C) on control 
and diabetic synaptosomes. Figure 6A demonstrates that 1µM Nif perturbed 
substantial amount of Glu release in comparison to non-treated terminals in the 
control synaptosomes. However, like the results with Aga TK, no effect was 
observed with Nif on the diabetic synaptosomes stimulated with HK1.25C 
(Figure 6B). Clearly, the contribution of Ca
2+
 channels to evoked release seems to 
be distinct between control and diabetic terminals.  
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 Figure 6: (A) Significant amount of Glu release perturbed when evoked with 
HK1.25C in control synaptosomes treated with 1µM Nif (Barba, 2010) (B) No 
difference observed when similar treatment applied on Diabetic synaptosomes. 
As the amount of Glu released was not perturbed using HK5C evoked release, the 
FM2-10 dye assay was carried out to study the role of L-type channels in the 
switching of the modes.  
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Figure 7: HK5C evoked FM2-10 release is increased in the presence of 1µM Nif 
in (A) Control terminals but is not changed in (B) Diabetic terminals.  
Remarkably, 1µM Nif exhibits distinct effects on the control and diabetic 
synaptosomes. Figure 7A demonstrates that the blockage of L-type VGCCs 
causes a switch in the mode from K&R mode of exocytosis to FF in control nerve 
terminals. However, Figure 7B shows that 1µM Nif does not affect the mode of 
exocytosis in the diabetic terminals. This suggests that, L-type channels in 
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diabetic terminals do not play the same role as they play in control terminals. For 
control terminals, this result is important, as for the first time it is demonstrated 
that, Ca
2+ 
going through specific VGCC, in this case L-type VGCCs, can play a 
role in the regulating the mode of exocytosis. Therefore, Ca
2+
 going through the 
L-type channels would allow the RRP to undergo K&R mode of exocytosis, and 
when this channel is blocked, the mode is switched to FF. 
Figure 8 displays the comparison between FM2-10 dye release with 1µM Nif and 
0.8µM OA (okadaic acid), which is known to switch all RRP from K&R mode of 
exocytosis to FF (Dr. Ashton‟s unpublished data). The two curves look almost 
similar, thereby suggesting that Nif also switches all the RRP from K&R to FF 
mode of exocytosis. Please refer later for more experiments involved with OA. 
 
Figure 8: Similar amount of FM2-10 dye release observed in Control terminals 
evoked with HK5C and treated with 0.8µM OA or 1µM Nif  
Finally, figure 9 show that 1µM Nif reduces some Ca
2+
 entry in control 
synaptosmes stimulated with HK5C. This indicates that, there must be supra-
maximum Ca
2+
 present in the extracellular space, such that Ca
2+ 
entry through the 
other VGCCs types, is sufficient to permit maximum Glu release (Figure 5A: see 
similar arguments above for Aga TK), although blockade of L-type channels does 
cause a change in the mode of fusion.  
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Figure 9: Application of 1µM Nif significantly decreases HK5C evoked [Ca
2+
]i 
in control terminals 
II.2.3 Role of N-type VGCCs 
After studying P- and L-type VGCCs, the role of N-type VGCCs were elucidated 
by using N-type channel blocker 1µM ω-conotoxin GVIA (GVIA) (Wright and 
Angus, 1996) on the control and diabetic nerve terminals.  
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Figure 10: 1µM GVIA has no effect on HK5C evoked Glu release 1µM GVIA in 
(A) Control synaptosomes but has an effect in (B) Diabetic synaptosomes.  
When N-type VGCCs are blocked using 1µM GVIA, the stimulated HK5C Glu 
release in control nerve terminals is not altered (Figure 10A). Interestingly, 
however, 1µM GVIA inhibits some of the HK5C Glu release in diabetic terminals 
(Figure 10B).  
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Figure 11:  There is a significant decrease in HK5C evoked change in [Ca
2+
]i 
upon addition of 1µM GVIA in (A) Control synaptosomes and in (B) Diabetic 
synaptosomes. 
Figures 11A and 11B indicate that 1µM GVIA does perturb the Ca
2+
 entry in both 
control and diabetic nerve terminals. The result demonstrates that this toxin 
blocks N-type VGCCs at least to a certain extent. 
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Previously, researchers have implicated the role of N-type channels in the Glu 
release in control terminals (Ladera et al., 2009) and this was demonstrated using 
sub-maximal Ca
2+
 level i.e. HK1.25C (Figure 12) . 
 
Figure 12: 1µM GVIA perturbs HK1.25C evoked Glu release in Control 
synaptosomes. 
When FM2-10 dye release was studied with control terminals using HK5C no 
change in dye release is observed, a result similar to that for Aga TK but different 
from Nif. These results lead to the conclusion that the N-type VGCCs do not play 
a role in switching the mode of exocytosis in control nerve terminals.   
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Figure 13: No change in the FM2-10 dye release in control terminals evoked 
with HK5C following treatment with 1µM GVIA 
Clearly, 1µM GVIA does not affect either the Glu release or the FM2-10 dye 
release in control terminals, but it appears to inhibit significant amount of Glu 
release in diabetic terminals (Figure 10B). Therefore, this concentration of GVIA 
cannot be used to study the FM2-10 dye release in diabetic terminals.  
However, as the data suggests that N-type channels do play a role in SV 
exocytosis in diabetic terminals, further studies were undertaken. Investigations 
were carried out to ascertain whether the use of sub-maximal dose of GVIA 
might produce a sub-maximal blockade of N-type VGCCs  in diabetic terminals, 
such that Glu release is not perturbed, but that such a reduction in Ca
2+
 entry may 
be sufficient to switch the mode of exocytosis. Thus, the concentration of GVIA 
was varied and its effects were observed. Figures 14-18 demonstrate the effect 
that increasing sub-maximal concentrations of GVIA have upon HK5C evoked 
Glu release and FM2-10 dye release from diabetic terminals.  
As demonstrated in Figure 14, 100 nM GVIA has no effect on the HK5C evoked 
Glu release in diabetic terminals (Fig 14A) and negligible effect on FM2-10 dye 
release (Fig 14B). 
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Figure 14: 100 nM GVIA has no effect on HK5C evoked (A) Glu release or (B) 
FM2-10 dye release on diabetic nerve terminals.  
When the concentration of GVIA was increased to 150 nM, there was no effect 
on Glu release (Figure 15A) although there was a small effect on FM2-10 release 
but this was not statistically significant (Figure 15B).  
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Figure 15: 150 nM GVIA has no effect on (A) HK5C evoked Glu release but has 
a small but non-significant effect on (B) HK5C evoked FM2-10 dye release in 
diabetic nerve terminals. 
Then the concentration was increased to 200 nM. GVIA failed to have an effect 
on HK5C evoked Glu release (Figure 16A), but the FM2-10 dye release appears 
to be increased (Figure 16B) as compared to the effect produced by 150 nM 
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GVIA. However, the increase in the FM2-10 dye release is still not significant as 
compared to control nerve terminals.  
 
Figure 16: 200 nM GVIA has no effect on (A) HK5C evoked Glu release but has 
a small but non-significant effect on (B) HK5C evoked FM2-10 dye release in 
diabetic nerve terminals. 
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With an increase to 300 nM of GVIA, no effect on Glu release is demonstrated 
(Figure 17A), but now a significant increase in FM2-10 dye release-for the first 
30s out of the 120s measurement cycle-is observed when compared to the control 
nerve terminals. This is an important result, as a condition has been established 
such that, this sub-maximal dose of GVIA can be involved in switching of the 
mode of exocytosis. However, this experiment needs to be carried out more times 
in order to show the significant difference for the entire time course. 
 
Figure 17: 300 nM GVIA has no effect on (A) HK5C evoked Glu release but has 
a significant effect on (B) HK5C evoked FM2-10 dye release in diabetic nerve 
terminals. 
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The use of a higher concentration of N-type Ca
2+
 channel blocker (400 nM 
GVIA) actually induced a small blockade in HK5C evoked Glu release (Figure 
18A), but this is less than as seen with 1µM GVIA. Clearly, as this condition 
causes less SV to exocytose one would expect a reduction in the amount of FM2-
10 dye that would be released and this is actually what is found when the effect of 
400 nM GVIA on FM2-10 dye release from diabetic terminals is measured 
(Figure 18B).  
 
Figure 18: 400 nM GVIA reduces both (A) HK5C evoked Glu release and (B) 
HK5C evoked FM2-10 dye release in Diabetic nerve terminals. 
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From the above results obtained with GVIA, there remains a possibility that the 
best sub-maximal concentration of GVIA to study the role of N-type Ca
2+
 
channels in regulating the mode of exocytosis has not yet been established, as this 
could be between 200 and 300 nM (250 nM) or even between 300 and 400 nM 
(350 nM). Such concentrations of GVIA need to be tested in the future.  
After monitoring the role of individual VGCCs, we conclude that in control 
terminals L-type channels play an important role in the switching of the mode of 
exocytosis, whilst in the diabetic terminals N-type channels seem to play distinct 
role in controlling the fusion of the vesicles and also the mode of exocytosis.  The 
present results support this argument that P- and N-type channels in the control 
synaptosomes, and L- and P- type channels in diabetic synaptosomes do not play 
a role in regulating the mode of exocytosis.  
II.2.4 Role of P-, Q- and N-type VGCCs  
A toxin that blocks several channels together was tested in the following 
experiments. N-, P- and Q-type Ca
2+
 channels are inhibited by ω-conotoxin 
MVIIC (MVIIC) (Wright and Angus, 1996). 
Figure 19A establishes that 1µM MVIIC treatment leads to a reduction in HK5C 
evoked Glu release from control synaptosomes. However, in diabetic terminals, 
MVIIC induced a smaller amount of inhibition of HK5C evoked Glu release 
(Figure 19B) than that seen in the control terminals.   
This result obtained is not surprising; as more N-type channels are active in the 
diabetic synaptosomes in comparison to the control. Also it has been established 
that MVIIC binds to N-type Ca
2+
 channels with an affinity of 10-100 fold lower 
than GVIA (Randall and Tsien, 1995) and blocks P-type Ca
2+
 channels at 
concentrations 100-1000 fold higher than Aga TK with very slow on/off kinetics. 
It is believed that, MVIIC is potent at inhibiting Q-type channels (Wright and 
Angus, 1996). Thus, this toxin probably only partially blocks the three distinct 
channels but as only the N-type channels seems to be important for diabetic 
terminals, one would expect less blockade in these terminals. 
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Figure 19: Significant decrease in HK5C evoked Glu release pon application of 
1µM MVIIC on (A) Control Synaptosomes and (B) Diabetic Synaptosomes.  
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II.2.5 CaMKII define mode of exocytosis for RRPs  
Research was carried out to determine whether CaMKII might play a role in 
regulating the mode of exocytosis. An increase in the level of [Ca
2+
]i during 
stimulation activates CaMKII and this can regulate SV release by several distinct 
mechanisms (Pang et al., 2010). This can be tested by using a specific CaMKII 
inhibitor 10µM KN93. This methoxybenzenesulfonamide compound exerts its 
effect by competing for the CaM binding site of CaMKII, thereby inhibiting 
CaMKII‟s effect (Rezazadeh et al., 2006). Importantly, the specificity of KN93 
can be assessed by using its inactive homolog, KN92, which is known not to 
affect CaMKII. To study effect of CaMKII, three stimuli; HK5C, ION5C and 
4AP5C were employed.  
Remarkably, when the Glu release was studied using the above three stimuli, it 
was discovered that, 10µM KN93 significantly reduced the number of SVs fusing 
when HK5C (Figure 20A) and ION5C (Figure 20B) were applied whereas 
interestingly, the Glu release was unaffected with 4AP5C (Figure 20C) 
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Figure 20: 10µM KN93 produced a significant decrease in Glu release  in 
Control Synaptosomes stimulated with (A) HK5C, (B) ION5C and but failed to 
exhert an effect with (C) 4AP5C stimulation. 
 
 
112 
These effects observed are not due to changes in the evoked increase in the 
[Ca
2+
]i, as 10µM KN93 does not change the [Ca
2+
]i when stimulated by HK5C 
(Figure 21A), ION5C (Figure 21B) and 4AP5C (Figure 21C). 
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Figure 21: 10 µM KN93 produced no change in the level of [Ca2+]i obtained  in 
Control Synaptosomes upon stimulation with (A) HK5C, (B) ION5C or (C) 
4AP5C. 
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The specificity of KN93 was tested using its inactive homolog, KN92 (Wheeler et 
al., 2008). 2 µM KN92 failed to affect the evoked Glu release induced by these 
three distinct stimuli (Figures 22 A, B and C). Note that whilst the experiments 
with HK5C and ION5C were done thrice, the result with KN92 and 4AP5C was 
determined only once. However, as KN93 itself failed to affect 4AP5C evoked 
release (Figure 20C), it was believed that KN92 has no action upon 4AP5C 
evoked Glu release.  
 
Figure 22: 2 µM KN92 produced no significant decrease in Glu release in control 
synaptosomes stimulated by (A) HK5C, (B) ION5C or (C) 4AP5C. 
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The results following CaMKII inhibition demonstrated in Figure 20 can be 
explained in terms of the pools of SVs that are being stimulated by the various 
stimuli. Both HK5C and ION5C cause sufficient [Ca
2+
]i increase at the AZ and 
areas distant from this to induce the release of both the RRPs and RPs. Whereas, 
4AP5C causes an increase in the [Ca
2+
]i that is sufficient to evoke the release of 
the RRPs, but it does not induce the RP of SVs to fuse. This information indicates 
that, 10µM KN93 inhibits the release of the RPs but not RRPs. This is obvious 
when the Glu release evoked by the three stimuli in presence of KN93 is 
compared (Figure 23): all three stimuli release similar amounts of Glu and this 
represents the release of the RRPs. 
 
Figure 23: Comparable amounts of Glu release observed in the presence of 10 
µM KN93 when evoked with HK5C (orange line), ION5C (green line) and 
4AP5C (pink line). 
The data with KN-93 can be explained by the interaction of CaMKII and 
synapsin I (Refer discussion for details). From these results the role of CaMKII in 
regulating the mode of exocytosis can only be assessed by studying 4AP5C 
evoked release of the RRP (Figure 24) as the number of SVs exocytosing is not 
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changed. One cannot use HK5C or ION5C as there is a difference in the number 
of SVs exocytosing with or without 10µM KN93. Excitingly, Figure 24 
demonstrates that CaMKII inhibition with 10µM KN93 leads to a larger increase 
in 4AP5C evoked FM2-10 dye release indicating that active CaMKII induces 
K&R mode of exocytosis for some RRP of vesicles. 
 
Figure 24: 10 µM KN93 causes an increase in FM2-10 dye release in control 
terminals stimulated by 4AP5C. 
Having established the role of VGCCs for both control and diabetic terminals, 
and a role of CaMKII on control terminals (similar studies with KN93 need to be 
undertaken on diabetic terminals in the future), the role of specific 
phosphoproteins in defining the mode of exocytosis was investigated.  
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II.2.6 Myosin II is unaltered in diabetic synaptosomes  
Unpublished study by Dr. A. Ashton and colleagues reveal that myosin II may 
play a role in switching of the mode of exocytosis with a particular stimulus. This 
question was addressed by comparing control and diabetic terminals.  
Figure 25A and 25B is a repeat of previous experiments. It shows that inhibition 
of myosin II with its potent inhibitor Bleb (Shu et al., 2005) has no effect on the 
HK5C evoked Glu release whereas, it increases the amount of FM2-10 dye 
release in control nerve terminals (Figure 25B). This indicates that, myosin II 
induces K&R mode of exocytosis on RRP with HK5C evoked release. 
 
Figure 25: 50 µM Bleb has no effect on HK5C evoked (A) Glu release but this 
significantly increases (B) FM2-10 dye release in control terminals. When 
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equivalent experiments were performed on the diabetic terminals in the presence 
and absence of 50µM Bleb, it was established that the Glu release was not 
perturbed (Figure 26A). Likewise, it also causes similar increase in the FM2-10 
dye release (Figure 26B). Therefore, it can be concluded that no difference in the 
activity of myosin II is observed in diabetic and control terminals. 
 
Figure 26: 50 µM Bleb has no effect on HK5C evoked (A) Glu release but this 
significantly increases (B) FM2-10 dye release in diabetic terminals. 
 
 
119 
II.2.7 Inhibition of Protein Phosphatase 2B/Calcineurin increases 
the kiss-and-run mode of exocytosis in control synaptosomes  
The results seen above in which HK5C evoked FM2-10 dye exocytosis was 
increased in the presence of Bleb suggested that, HK5C induced increase in 
[Ca
2+
]i at the AZ is sufficient to activate myosin II (Tokuoka and Goda, 2006; 
Bhat and Thorn, 2009), which would normally close the pore quickly (i.e. 
produce apparent K&R exocytosis). This action of myosin II may override the 
action of other proteins that might regulate the mode of exocytosis, e.g. role of 
dynamin (see later). Thus, research was undertaken to investigate the interaction 
of myosin II with other components of the regulatory machinery including protein 
PP2B/ CaN in control nerve terminals. The inhibition of CaN with cyclosporine 
A (Cys A), results in a larger increase in stimulus evoked changes in [Ca
2+
]i, and 
so it was speculated as to whether Cys A treatment would lead to a further 
activation of myosin II, which would then lead to a even larger increase in FM2-
10 dye release when myosin II was inhibited by Bleb. Indeed, perhaps myosin II 
could be a protein whose phosphorylation state was regulated by CaN. In order to 
compare Bleb action vs Bleb plus Cys A action, it was necessary to repeat earlier 
experiments (already carried out in Dr. Ashton‟s laboratory), to monitor the effect 
of Cys A on control terminals. Figure 27A demonstrates that 1µM Cys A does not 
perturb the Glu release when evoked with HK5C. However, inhibition of CaN 
decreases the amount of HK5C evoked FM2-10 dye release from control 
synaptosomes. This is because activated CaN allows the RPs to undergo FF and 
inhibition by Cys A results in some of the RPs being converted to a K&R mode 
of exocytosis.  
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Figure 27: 1 µM Cys A has no effect on HK5C evoked (A) Glu release but this 
significantly decreases (B) FM2-10 dye release in control terminals  
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II.2.8 Dual effect of Mysoin II and PP2B inhibitor  
Figure 28A demonstrates that, the dual treatment of Cys A plus Bleb does not 
have any effect on the HK5C evoked Glu release. However, the initial hypothesis 
was disproven when the effect of Cys A plus Bleb on HK5C evoked FM2-10 dye 
release was investigated. Rather than observing an increase in FM2-10 dye 
release, Cys A appear to prevent Bleb from inducing any increase in FM2-10 dye 
release, such that there is much less dye release in the presence of both drugs than 
when there was only Bleb present (Figure 28B).  
Figure 28: 1 µM Cys A + 50 µM Bleb has no effect on HK5C evoked (A) Glu 
release compared to non-treated cont but this treatment reduces (B) less HK5C 
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evoked FM2-10 dye release compared to control synaptosomes treated with 50 
µM Bleb alone. 
The result obtained in Figure 28B is very significant (explained in details in 
discussion) as this could help future researches to understand precisely the 
molecular mechanism that occurs in the switching of the mode of different SVs.  
II.2.9 Effect of the inhibition of dynamin on Control Terminals  
Figure 29A demonstrates that inhibition of dynamins I and II with 160µM 
dynasore (Dyn) has no effect on the HK5C evoked Glu release on the control 
synaptosomes. Furthermore, no effect on FM2-10 dye release was also observed 
in Figure 29B. 
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Figure 29: 160 µM DYN has no effect on HK5C evoked (A) Glu release or (B) 
FM2-10 dye release in control terminals. (Note this expt was done previously by 
A. Ashton and colleagues and is included so that one can compare this with 
subsequent novel experiments) 
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II.2.10 Dual effect of Dynamin and Myosin II inhibitor  
A novel experiment investigating the dual effect of 50µM Bleb and 160µM Dyn 
on the SV exocytosis from synaptosomes was carried out. As these drugs do not 
individually affect the Glu release, it was fully expected that the dual treatment 
would not affect HK5C evoked Glu release and, therefore, the number of SVs 
exocytosing. Figure 30A demonstrates that this is the case. From all the current 
(e.g. Figure 30A) and previous results (e.g. Figure 29) it was anticipated that 
myosin II was capable of bypassing the role of dynamins, so Bleb should cause 
an increase in HK5C evoked FM2-10 dye release even when dynamins are 
inhibited by Dyn. However, again the hypothesis was disproved, as when HK5C 
evoked FM2-10 dye release was compared following treatment with 50µM Bleb 
alone and the combination of 50µM Bleb and 160µM Dyn (Figure 30B), it was 
observed that the action of Bleb was blocked i.e. less dye was released. This 
result suggests that, all the RRPs were switched back to K&R mode under this 
dual treatment mode. This result is crucial, as it helps to determine the pathway in 
mode switching, although currently this result remains difficult to interpret. 
Clearly, more experiments need to be repeated on this facet to understand this 
fully.  
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Figure 30: 50 µM Bleb + 160 µM Dyn has no effect on HK5C evoked (A) Glu 
release compared to non-treated cont but this treatment reduces (B) HK5C 
evoked FM2-10 dye release compared to control synaptosomes treated with 50 
µM Bleb alone. 
 II.2.11 Dynamin inhibition switches the RPs to full fusion in 
Diabetic terminals  
As differences in the mechanism of VGCCs were obtained in control and diabetic 
synaptosomes, it was decided to examine if there were differences in the 
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contribution that dynamins play in HK5C evoked SV exocytosis from diabetic 
synaptosomes. HK5C evoked Glu release was not affected by the treatment with 
160µM Dyn (Figure 31A). However, in comparison to control synaptosomes, it 
was detected that Dyn significantly increased the amount of HK5C evoked FM2-
10 dye release from the diabetic synaptosomes, suggesting that dynamins can 
play a role in defining the mode of exocytosis in diabetic nerve terminals.  
 
Figure 31: 160 µM Dyn has no effect on HK5C evoked (A) Glu release but this 
significantly increases (B) FM2-10 dye release in diabetic terminals. 
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Clearly, there appears to be a difference in response to HK5C stimulation 
between control and diabetic terminals following inhibition of dynamins. It was 
therefore, investigated whether there was a difference in the effect of Dyn 
between control and diabetic terminals when the SV exocytosis were stimulated 
using 4AP5C.  
Figure 32A demonstrates that Dyn did not affect the 4AP5C evoked Glu release. 
However, inhibition of dynamins led to a larger amount of FM2-10 dye release 
evoked by 4AP5C in control terminals. This suggests that dynamins can induce 
SVs to exocytose by a K&R mode when evoked by 4AP5C but that this is 
switched to FF when dynamins are inhibited by Dyn (Figure 32B).  
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Figure 32: 160 µM Dyn has no effect on 4AP5C evoked (A) Glu release but this 
significantly increases (B) FM2-10 dye release in control terminals.  
In contrast, when 4AP5C evoked Glu (Figure 33A) and FM2-10 dye release 
(Figure 33B) was measured in diabetic synaptosomes in the presence of Dyn, 
neither the Glu or FM2-10 dye was altered compared to the non-treated control. 
Note that there is a need to do more experiments for release of Glu. These results 
highlight differences between the control and diabetic synaptosomes, which may 
help us to elucidate the precise mechanisms occurring. In particular, this could 
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reveal that the drugs and their target proteins may actually be acting on only one 
pool of the two pools of SVs. This is considered in more detail in the discussion 
at the end of this chapter.  
 
Figure 33: 160 µM Dyn has no effect on 4AP5C evoked (A) Glu release or (B) 
FM2-10 dye release in diabetic terminals.  
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II.2.12 Role of Protein Phosphatase 2A 
From the previous experiments, it has been established that the diabetic terminals 
undergo more K&R mode of exocytosis in comparison to control nerve terminals 
(Figure iB). In control synaptosomes, RRP of vesicles undergo K&R mode of 
exocytosis. However, in diabetic terminals as less FM2-10 is released, it is 
believed that some of the RP of vesicles also undergo K&R mode along with the 
RRPs. In Dr. Ashton‟s laboratory it is already established that, PP2A inhibitor 
okadaic acid (OA) plays a role in switching the RRP  of vesicles from K&R mode 
to FF mode of exocytosis in control terminals (demonstrated by Figure 34) when 
FM2-10 dye release is evoked with HK5C. 
 
Figure 34: Significant increase in FM2-10 dye release from control terminals 
upon stimulation with HK5C in the presence of 0.8 µM OA  
The current study was undertaken to establish conditions whereby all those 
vesicles that are undergoing K&R in diabetic terminals can be switched to FF. 
Hence, the role of PP2A in the diabetic terminals was studied. Figure 35 
demonstrates the effect of 0.8µM OA on HK5C evoked release. As Glu release 
was not perturbed by OA (Figure 35A), FM2-10 dye assay was subsequently 
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measured. The study revealed that OA increases the amount of dye released from 
the diabetic terminals significantly. However, careful analysis of all experiments 
previously carried out with control terminals indicates that, there is less FM2-10 
dye being released from the diabetic terminals and so not all the SVs are being 
switched by OA treatment to FF in the diabetic terminals. This could be explained 
by the suggestion that, OA just works on the RRP vesicles and fails to switch 
those RPs that are undergoing K&R in diabetic terminals. In control terminals, 
only the RRP SVs are undergoing K&R. 
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Figure 35: 0.8 µM OA has no effect on HK5C evoked (A) Glu release but this 
significantly increases (B) FM2-10 dye release in diabetic terminals (but not as 
much when compared to Figure 34 for Control Synaptosomes). 
When the action of OA in diabetic terminals was measured following 4AP5C 
evoked release, significant amounts of FM2-10 dye was released indicating that, 
the OA did cause a switch of some RRPs of SVs to a FF mode (Figure 36).  
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Figure 36: Increase in 4AP5C evoked FM2-10 dye release in diabetic terminals 
in the presence of 0.8 µM OA . 
II.2.13 Protein Kinase C switches some SVs to full fusion mode of 
exocytosis in diabetic terminals  
The role of PKC was studied by treating the synaptosomes with active phorbol 
esters (PMA) which activate this kinase (Lou et al., 2008a). 1µM of PMA is 
known to cause switching of the RRPs to FF, that were normally undergoing 
K&R, when release is evoked with HK5C (e.g. Figure 37) without affecting the 
total number of SVs exocytosing, as shown by the lack of effect of PMA on 
HK5C evoked Glu release. 
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Figure 37: Significant increase in HK5C evoked FM2-10 dye release upon 
application of 1 µM PMA in control terminals. 
Glu release evoked with HK5C in diabetic nerve terminals was not affected by 
PMA (Figure 38A). However, the HK5C evoked FM2-10 dye release was 
significantly increased following PMA treatment on diabetic synaptosomes 
(Figure 38B), but the amount of release was not as great as that seen in the 
control terminals (Figure 37). When PMA was added to diabetic terminals and 
4AP5C evoked FM2-10 dye release was measured, PKC activation led to an 
increase in dye release indicating that, some RRP SVs have been switched to a FF 
mode (Figure 39).  
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Figure 38: 1 µM PMA has no effect on HK5C evoked (A) Glu release but this 
significantly increases (B) FM2-10 dye release in Diabetic terminals (but not as 
much when compared to Figure 37 for Control Synaptosomes).  
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Figure 39: Increase in 4AP5C evoked FM2-10 dye release upon application of 1 
µM PMA in diabetic terminals. 
II.2.14 Dual treatment by inhibiting PP2A and activating PKC 
switches all the pool of SVs to full fusion in diabetic terminals   
It would appear from the results with OA or PMA in diabetic terminals that some 
SVs which were undergoing K&R exocytosis were not switched to FF. Thus, the 
dual effect of 0.8 µM OA+ 1 µM PMA was investigated to observe whether this 
treatment might produce maximal FM2-10 dye release and therefore complete 
switching of SVs to FF.  
The double treatment had no effect on the amount of HK5C evoked Glu release in 
diabetic terminals (Figure 40A). However, such dual treatment induced a 
significantly larger amount of dye to be released from the nerve terminals upon 
the application of HK5C (Figure 40B) on diabetic terminals. This FM2-10 dye 
release is larger in comparison to treatment with PMA (Figure 41) or OA alone 
(Figure 42). 
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Figure 40: 0.8 µM OA +1 µM PMA has no effect on HK5C evoked (A) Glu 
release but this significantly increases (B) FM2-10 dye release in Diabetic 
terminals.  
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Figure 41: Significant difference observed between HK5C evoked FM2-10 dye 
release in diabetic terminals treated with 1 µM PMA compared to joint treatment 
with 0.8 µM OA +1 µM PMA  
 
Figure 42: Significant difference observed between HK5C evoked FM2-10 dye 
release in diabetic terminals treated with 0.8 µM OA compared to joint treatment 
with 0.8 µM OA +1 µM PMA. 
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The 0.8µM OA +1µM PMA dual treatment also increased the amount of 4AP5C 
evoked FM2-10 dye release from diabetic terminals, (Figure 43) but this did not 
produce a bigger difference than treatment with the individual drugs alone i.e 
PMA alone (Figure 44) or OA alone (Figure 45).  
 
Figure 43: 0.8 µM OA + 1 µM increases 4AP5C evoked FM2-10 dye release ± 
in diabetic terminals 
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Figure 44: No significant difference observed between 4AP5C evoked FM2-10 
dye release in diabetic terminals treated with 1 µM PMA alone and with 0.8 µM 
OA +1µM PMA. 
 
Figure 45: No significant difference observed between 4AP5C evoked FM2-10 
dye release in diabetic terminals treated with 0.8 µM OA alone and with 0.8 µM 
OA +1 µM PMA 
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II.3 Discussion 
It was already established in Dr. Ashton‟s laboratory that the diabetic terminals 
exhibited a larger stimulus induced increase in [Ca
2+
]i levels and a higher 
proportion of K&R mode of exocytosis as compared to the control terminals 
(Figure iB and iC). However, the Glu release remained unchanged (Figure iA). 
The main aim of this study was to establish any biochemical changes that occur in 
the diabetic terminals that could account for the changes outlined above. The 
approach employed was to establish role for various VGCCs, Ca
2+ 
dependent 
kinases and protein phosphatases in regulating the mode of exocytosis and to 
decipher differences between control and diabetic terminals, which could shed 
light on this process.  
II.3.1 Role of VGCCs 
The main cause for the difference in the behaviour of diabetic terminals and 
control terminals was speculated to be due to the level of [Ca
2+
]i obtained during 
stimulation and, therefore role of various VGCCs was examined. The blockade of 
P-type VGCC with 50 nm Aga TK (Wright and Angus, 1996; Serulle et al., 2007) 
did not block the Glu release from HK5C evoked diabetic and control 
synaptosomes (Figure 1A and B). Additionally, no change in the mode of 
exocytosis was observed in both the terminals (Figure 4). However, it perturbed 
change in the [Ca
2+
]i from HK5C evoked control and diabetic terminals (Figures 
2A and B) and also reduced the HK1.25C evoked Glu release in the control 
synaptosomes (Figure 3A), suggesting that the P-type channels can play a role in 
the evoked release of Glu in control terminals under certain conditions. However, 
even under these conditions (e.g. see Figure 3B) 50 nm Aga TK failed to perturb 
Glu release from diabetic terminals, and so P-type channels probably do not play 
a role in mode switching in diabetic terminals.    
The role of L-type channels was investigated using the blocker 1 µM Nif (Yang 
et al., 2009). This VGCC blocker does not affect the HK5C evoked Glu release in 
control and diabetic terminals (Figures 5A and 5B). When evoked with HK1.25C, 
1 µM Nif treatment blocked Glu release in the control terminals but exhibited no 
effect on the diabetic terminals. This result may suggest that L-type channels do 
not play a role in mode switching in diabetic terminals. Furthermore, when FM2-
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10 dye study was observed in the control terminals, blockade of L-type VGCCs 
induced a switch in the mode of exocytosis to FF, (Figure 7A) whilst Nif had no 
effect upon diabetic terminals. Therefore, L-type channels appear to play a role in 
defining the mode of exocytosis in the control terminals. Under the appropriate 
conditions, Ca
2+
 going through the L-type channels would enable the RRP of SVs 
to undergo K&R mode of exocytosis, but Ca
2+
 fails to flow through this channel 
due to its blockade by Nif, the mode is switched to FF. This is further confirmed 
when the FM2-10 curve is compared with OA treated control synaptosomes 
(Figure 8). However, no such switch was observed in the diabetic terminals 
(Figure 7B).  
It can thus be concluded that, L-type channels can play a role in defining the 
mode of exocytosis in control terminals. This result is similar to the results 
obtained by Xia et al., (2009) when studying the exocytosis of DCVs. However, 
no previous studies have discovered a role for such channels in defining the mode 
of exocytosis in nerve terminals. Previously, some models of synaptic 
transmission have revealed a role for L-type VGCCs in NT release under certain 
conditions (Nachman-Clewner et al., 1999), and such channels have been shown 
to  be important for LTM formation (Fourcaudot et al., 2009). In contrast, it was 
found that in diabetic terminals, L-type channels do not perform the same roles as 
in control terminals. This may be due to fact that, in diabetic terminals either the 
L-type channel are less active, or that other channels are more active such that the 
role of L-type channels is replaced.  
The treatment of the terminals with the N-type VGCC blocker, 1 µM GVIA 
(Verma et al., 2009) revealed some interesting results. Although, the HK5C 
evoked Glu release from the control terminals were unaffected (Figure 10A), the 
release was perturbed in the diabetic terminals (Figure 10B). This result indicates 
that, N-type VGCC play a major role in Glu release in diabetic synaptosomes 
relative to their contribution to release in control terminals. Further investigation 
in control terminals indicated that blockade of N-type channels played no role in 
regulating the mode of exocytosis (Figure 13). 
There are several explanations for the fact that the N-type blocker reduced the 
Glu release in diabetic terminals. In such tissues, the N-type channels are either 
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overactive, or the number of these channels are increased through the insertion of 
additional N-type channels in the presynaptic membrane or such channels remain 
open for a longer period of time. Any of these explanations would mean that, the 
roles of other channels are reduced such that most of the Ca
2+
 entry into these 
terminals will be through N-type channels. There are various phosphorylation 
cascades that could contribute to this effect, and activation of PKC is an attractive 
candidate mechanism; as PKC can enhance N-type channel activity directly and 
antagonize signalling cascades that inhibit N-type channel opening (Ahmed and 
Siegelbaum, 2009). An additional explanation is that, one might be able to 
enhance coupling between Ca
2+
 influx through the N-type channels and the 
release machinery. In many CNS terminals, Ca
2+
 influx through N-type channels 
is less efficiently coupled to release compared to Ca
2+
 influx through P/Q-type 
channels (Ahmed and Siegelbaum, 2009). Perhaps it could be possible that, as N-
type channels are important in the diabetic terminals, these channels increase the 
total [Ca
2+
]i load. Interestingly, it has been found in other conditions that one can 
get upregulation of Ca
2+
 channels e.g. upregulation of N-type channel in the 
spinal cord is related to inflammation in the hind paw induced after chronic 
constrictive nerve injury. This condition leads to symptoms of allodynia and 
hyperalgesia (Verma et al., 2009) and intriguingly, these have often been 
observed in uncontrolled diabetic rats.  
Conditions were established in the diabetic terminals such that Glu release was 
not perturbed, even though some but not all N-type channels were blocked. This 
concentration could then be used to study the FM2-10 dye release. 300 nm GVIA 
did not affect HK5C evoked Glu release but this toxin did induce an increase in 
FM2-10 dye release. This release was greater at all time points relative to the 
control but statistically the difference was only significant in the early stages of 
the time course (Figure 17). This experiment needs to be repeated several more 
times to establish that there is a significant difference for the whole time course of 
release. Further study need to measure the 300 nM GVIA induced reduction in 
HK5C evoked changes in [Ca
2+
]i. Likewise, it needs to be established whether 
250 or 350 nM GVIA may be a better concentration of toxin to use than 300 nM.  
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1µM MVIIC (which blocks multiple VGCCs) significantly reduced HK5C 
evoked Glu release in both control and diabetic terminals (Figure 19) but the 
extent of blockade in diabetic terminals was significantly less than in control 
terminals. This result is not surprising as, MVIIC is known to block N-, P-, and 
Q-type VGCCs (Wright and Angus, 1996) and control terminals seem to rely on 
several channel subtypes for release, whilst N-type channels seem to play the 
major role in diabetic terminals. As  MVIIC has 10-100 times lower affinity for 
N-type channels than GVIA (Randall and Tsien, 1995) not all the N-type 
channels in the diabetic terminals will be blocked, no other channels play that 
much of a role and so more Glu release will be observed than seen in the control 
terminals.  
Overall, all these experiments indicate that L-type channels play a role in 
establishing the mode of exocytosis in the control terminals, whilst N-type 
channels play a crucial role in the diabetic terminals. However, the precise 
concentration of GVIA to be used to study this phenomenon still needs to be 
established.  
II.3.2 Role of Calcium/Calmodulin dependent Kinase II  
Previous data indicated that both Ca
2+ 
and protein phosphorylation regulate the 
switch between the two modes of exocytosis. Treatment with 10 µM KN93 (that 
specifically blocks the action of CaMKII) (Wheeler et al., 2008) was undertaken 
to elucidate the role of CaMKII. When three different stimuli were used to study 
evoked Glu release, it was established that HK5C and ION5C evoked release 
were perturbed in the presence of KN93, whilst 4AP5C evoked release was not 
affected in the control terminals. This result can be explained from knowing that 
4AP5C induces smaller changes in the amount of Ca
2+
 influx, which is sufficient 
enough to release the RRP but not the RP. From this data, it can be inferred that; 
inhibition of CaMKII blocks the release of the RP of SVs but not the RRP (Figure 
23). The data with 10µM KN-93 can be explained by the fact that, the RP of SVs 
is associated with the cytoskeleton, and in order for these vesicles to exocytose 
they need to be dissociated from the cytoskeleton. The SVs are linked to each 
other by the phospho-protein synapsin 1, that binds the fibrous proteins actin and 
spectrin and is linked to the cytosolic surface of all SV membranes. Additionally, 
 
 
145 
synapsin filaments radiate from the PM and attach to vesicle-associated synapsin. 
These interactions may allow the SVs to face in the right direction, i.e. towards 
the PM. Synapsins are preferentially located near the RPs at the ultrastructural 
level i.e near the vicinity of the AZ (Fdez and Hilfiker, 2006). After the arrival of 
AP, the Ca
2+
 entry results in the activation of CaMKII, which then phosphorylates 
synapsin 1 (Shupliakov, 2009). Upon phosphorylation, synapsin 1 loses affinity 
for both the SV membrane and the actin microfilaments (Cingolani and Goda, 
2008). This mechanism enables the SVs to detach from the cytoskeleton and such 
vesicles are then available to contribute to NT release (Fdez and Hilfiker, 2006). 
The results obtained suggest that, the RPs are attached to the cytoskeleton and 
that the inhibition of CaMKII by KN93 results in the synapsin 1 remaining in its 
dephosphorylated form, such that the RPs cannot detach from the cytoskeleton; 
and are therefore unavailable for exocytosis as is demonstrated by the decrease in 
the Glu release (Figure 20A and B). This result also emphasizes the fact that, 
HK5C and ION5C evoke release of not only the RRP but also the RP of vesicles. 
Likewise, this also provides further evidence of the claim that 4AP5C only acts 
on the RRP and does not act on the RP of vesicles. 
Importantly, the role of CaMKII in regulating the mode of exocytosis could be 
studied by evoking FM2-10 dye release with 4AP5C. In control terminals, it was 
found that blockade of CaMKII resulted in the switching of the mode of 
exocytosis, from K&R to FF (Figure 24). Thus, phosphorylation of certain 
proteins by CaMKII results in the RRP undergoing exocytosis by a K&R mode, 
whilst failure to phosphorylate such proteins leads to the vesicles exocytosing by 
the FF mode. Similar studies needs to be carried out in the future on diabetic 
nerve terminals. 
II.3.3 Role of Myosin II  
The inhibition of myosin II by Bleb was responsible for the switch in mode of 
exocytosis when evoked by HK5C from K&R to FF in control terminals and in 
the diabetic terminals, indicating that the function of myosin II was unaltered in 
such synaptosomes. Previous results in chromaffin cells in which catecholamine 
vesicle fusion was studied demonstrated a similar role of myosin II in regulating 
the mode of fusion (Aoki et al., 2001). However, it is difficult to directly compare 
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control synaptosomes (Figure 25B) and diabetic synaptosomes (Figure 26B) as 
these were done several months apart. To directly compare the exact amounts of 
FM2-10 dye being released between control and diabetic one actually needs to do 
these at the same time (i.e. in the same experiment). Whilst one can observe that a 
drug has an effect upon FM2-10 dye release from either type of synaptosome, the 
actual absolute amounts sometimes vary and this makes it difficult to assign the 
change in release to a particular pool of SVs. This argument is put forward 
because it was speculated that the effect of Bleb on diabetic synaptosomes is 
probably due to the switch of RRP of SVs to FF, but that there is no switch of 
those RP of SVs that are undergoing K&R. This is because it has been 
hypothesized that myosin II acts when activated by the high amount of Ca
2+
 at the 
AZ following application of HK5C. However, such levels of Ca
2+
 will not be 
seen by the RP of vesicles as they are exposed to the bulk [Ca
2+
]i which is 
probably not sufficient enough to activate myosin II. Thus, it is believed that the 
Bleb treatment in the diabetic terminals induces the RRP to switch to FF, but as 
myosin II is not activated by the level of Ca
2+
 that activates the RP, those RP of 
SVs that are K&R will not be switched to FF. This is not so obvious if one 
compares Figs 25B and 26B.  
II.3.4 Role of Calcineurin  
1µM Cys A inhibits CaN, Ca
2+
-dependent protein phosphatase (Batiuk et al., 
1995; Igarashi and Watanabe, 2007). When control terminals were treated with 
Cys A, there was no effect on HK5C evoked Glu release but, intriguingly, there 
was a decrease in HK5C evoked FM2-10 dye release. Furthermore, inhibition of 
CaN with Cys A results in a larger increase in [Ca
2+
]i following application of a 
stimulus, a result seen previously (Person and Raman, 2010). This treatment was 
repeated herein, just to compare with the dual treatment involving the inhibition 
of myosin II and CaN. Such treatment failed to perturb HK5C evoked Glu release 
but unexpectedly, decreased the HK5C evoked FM2-10 dye release compared 
with Bleb treatment alone. This disproved the initial hypothesis that, the 
combination of these two drugs may result in a larger increase in FM2-10 dye 
release, due to a CaN mediated increase in [Ca
2+
]i upon stimulation. This could 
possibly activate myosin II further (thus, get greater K&R) but this would be 
switched to a greater amount of FF due to the fact that Bleb inhibited myosin II. 
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One possible explanation could be that, all the RP of vesicles are switched to 
K&R mode of exocytosis with the dual treatment (usually the Cys A only causes 
a switch of some of the RP of SVs to this mode), whilst Bleb induces the RRP of 
vesicles to undergo FF. Thus, the two drugs give opposing effects and so 
compared to Bleb alone there will not be as much FM2-10 dye released following 
the dual treatment. This might appear to suggest that, Cys A has counteracted 
Bleb‟s action but the hypothesis above suggests that the two drugs are acting on 
different pools of SVs. However, the fact that Bleb treatment may increase the 
effect of Cys A on the RP of vesicles will need to be further investigated in 
future. These results and explanation actually add to the knowledge gained in Dr. 
Ashton‟s laboratory about the pools of SVs and modes of exocytosis. It now 
seems apparent that, Cys A may only work on the RP of SVs (remember with 
HK5C all the RRP of SVs are already releasing via a K&R mode). Indeed, in 
preliminary experiments Dr. Ashton has found that Cys A fails to have an effect 
on the mode of exocytosis evoked by 4AP5C and this fits in with the fact that, 
4AP5C only evokes exocytosis of the RRP and Cys A does not affect the RRP. 
Thus, it would appear that dephosphorylation of protein substrates for CaN is 
required for the RP to undergo the FF mode of exocytosis, and prevention of 
dephosphorylation by blockade of CaN will lead to the RP of SVs undergoing 
K&R exocytosis. This argument is supported by the study carried out in 
Drosophila which demonstrated that, CaN was required for endocytosis to the RP 
but not for the RRP (Kumashiro et al., 2005). Clearly, this effect may involve 
inhibiting the role of dynamin in clathrin-dependent endocytosis, which is 
associated with FF as dephosphorylation of dynamin is required for this latter 
process to occur. 
An obvious future study is to carry out an equivalent experiment to Figure 28B 
where dual treatment of Bleb and CaN are applied on diabetic terminals.  
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II.3.5 Role of Dynamins 
In order to directly study the role of dynamin an inhibitor of its GTPase activity - 
160µM Dyn was employed (Chung et al., 2010). In the control terminals, Dyn did 
not affect the amount of Glu or FM2-10 dye release when evoked with HK5C 
(Figures 29A and B). This result with Glu release also confirms another result 
that has been established in the Dr. Ashton‟s laboratory. It has been shown that all 
three stimuli (HK5C, ION5C and 4AP5C) actually only evoke one round of SV 
fusions (of either the RRP and the RP or just the RRP) (Ashton, unpublished 
observation). This is confirmed herein because if there were several rounds of 
release, those SVs which exocytosed by FF and recycled by the dynamin 
requiring clathrin-dependent endocytotic pathway would be inhibited by Dyn, and 
so one should observe a reduction in the amount of Glu released compared to the 
control; and this is not seen. Likewise, recycling by a dynamin-dependent 
clathrin-independent mode (possibly K&R, see below) should be perturbed and 
so less release should occur if there was recycling and re-releasing of SVs during 
the time of application of these stimuli.  
In the diabetic terminals, HK5C evoked release of Glu was not perturbed by Dyn 
treatment, but it was found that these synaptosomes discharged significantly 
greater amount of FM2-10 dye than control terminals (Figures 31A and B). This 
interesting result suggests that, dynamins do play a role in defining the mode of 
exocytosis of some of the SVs in the diabetic terminals. Active dynamin causes a 
greater amount of the K&R mode of fusion. However, both the 4AP5C evoked 
release of Glu and FM2-10 dye were not changed following Dyn treatment on the 
diabetic synaptosomes. As 4AP5C only releases the RRP, this result suggests that 
Dyn allows the RPs to undergo FF mode of exocytosis and not the RRPs (as no 
extra release observed with 4AP5C). It can thus be concluded that, dynamins 
work on the RPs in defining the mode of exocytosis in diabetic terminals and 
there is no effect on the RRP of vesicles. It should be noted that just as with 
experiments with Bleb the absolute amount of FM2-10 dye released from Dyn 
treated terminals cannot be directly compared between the control (Figure 29B) 
and diabetic synaptosomes (Figure 31B), as both these experiments were not 
performed at the same time.  
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The result obtained also suggests that even though dynamins are required for 
replenishment of RRPs in the control synaptosomes (Lu et al., 2009); it works on 
defining the mode of exocytosis on the RPs in the diabetic terminals.   
The last couple of arguments might suggest that Dyn would act on the RPs and 
switch them to FF, whilst Bleb acts on the RRPs to switch them to FF. However, 
the result for control synaptosomes for 4AP5C evoked Glu and FM2-10 dye 
release following Dyn treatment also needs to be considered. Whilst inhibition of 
dynamins has no effect on 4AP5C evoked Glu release, there is more FM2-10 dye 
release. Thus, with 4AP5C evoked release it would appear that Dyn is inducing 
the RRP of SVs to switch to a FF mode of exocytosis. This result differs from the 
findings in control synaptosomes with HK5C evoked release treated. A possible 
explanation for the difference obtained could be that, HK5C induces a larger 
change in the Ca
2+
 level at the AZ than 4AP5C, and the former condition can 
activate myosin II whereas 4AP5C does not (Tokuoka and Goda, 2006; Bhat and 
Thorn, 2009). Thus, the activated myosin II can close the pore independently of 
any action of dynamin and so dynamin action can be blocked by Dyn but myosin 
II if active can still close the pore. However, as myosin II is not activated upon 
the application of the 4AP5C stimulus but dynamins are, these latter proteins will 
play a role in closing the pore and when blocked by Dyn, a switch to FF is 
observed; as demonstrated by the increase in FM2-10 dye release. Such an 
explanation is borne out by the results with the diabetic terminals. Upon 
application of the HK5C stimulus, some RP of SVs are undergoing K&R release 
(as explained previously this may be due to the larger changes in [Ca
2+
]i obtained 
following HK5C application). However, as these RP of SVs is not exposed to 
levels of Ca
2+
 that could activate myosin II; the mode of these vesicles can be 
regulated by dynamins (unlike the RRP of SVs). However, with 4AP5C 
stimulation the increase in [Ca
2+
]i level at the AZ in diabetic terminals may now 
be sufficient to activate myosin II and so Bleb can regulate the mode of 
exocytosis and this will bypass any role of dynamins.  
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II.3.6 Dual effect of Dynamin and Myosin II inhibitor 
HK5C evoked Glu release in control synaptosomes, was not changed following 
the dual treatment with 50µM Bleb and 160µM Dyn. From all the experiments 
and discussion above, it was expected that such a joint treatment would cause all 
SVs to switch to FF. However, completly disproving the hypothesis, this dual 
treatment significantly reduced the amount of FM2-10 dye release. This finding 
remains unexplained, as it was believed that myosin II bypasses the role of 
dynamins and therefore, by inhibiting both of these proteins could result in more 
of the FF mode of exocytosis. Perhaps, the inhibition of both of these proteins 
causes activation of another protein or these two proteins actually regulate each 
other in some way, possibly, at some particular stage in the vesicle pathway. 
Future experiments utilizing this dual treatment on diabetic terminals may help 
reveal the complex interactions that might be occurring. 
II.3.7 Role of Protein Phosphatase 2A and Protein Kinase C 
Phosphatases play a crucial role in a number of signal transduction pathways in 
neurons (Rusnak and Mertz, 2000). Dr Ashton had already established that, 
inhibition of PP2A with 0.8µM OA results in switching of the mode of exocytosis 
from K&R to FF mode of exocytosis in the control terminals (Figure 34). As 
there is more K&R exocytosis observed in the diabetic terminals this must be 
because some RPs along with all the RRPs release via this mode. 0.8µM OA did 
switch the mode of exocytosis to FF in such diabetic terminals (Figure 35), but 
this switch did not produce maximal FF as in control terminals. As a complete 
switch to FF of the RRP of SVs was apparent with 4AP5C in OA-treated diabetic 
terminals (Figure 36), such results suggest that, the RP of SVs that were 
undergoing K&R in the diabetic terminals could not be switched by inhibiting 
PP2A. These results suggest that, PP2A exclusively acts on the RRPs of SVs, and 
the RPs in the diabetic terminals that undergo K&R is unaffected. 
1µM of PMA causes a switch in the mode of exocytosis in the control terminals 
(Figure 37) and so this was studied in diabetic terminals. It is known that PMA 
activates the PKC and Munc 13 pathway, but it has been shown by Dr Ashton 
(unpublished observation) that PMA switches the mode of exocytosis in control 
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synaptosomes via the PKC pathway, as its action can be blocked by an inhibitor 
of PKC. Interestingly, similar results to those following OA treatment were 
observed in the daibetic terminals (Figure 38) This could also suggest that, PKC 
also acts exclusively on the RRPs (as shown with 4AP5C stimulation, Figure 39) 
and not on the RPs in the diabetic terminals.  
However, when diabetic nerve terminals were exposed to OA and PMA together, 
all the pools of SVs were switched to a FF mode of exocytosis   (Figure 40). This 
was further confirmed by comparing the combined treatment with the individual 
treatment. It was thus established that, PMA+OA induced more FM2-10 dye 
release than PMA alone (Figure 41) or OA alone (Figure 42). Thus, whilst each 
of these treatments seem to work exclusively on the RRP, the joint treatment also 
allows the switch of the RP. Clearly, there appears to be some extra activity that 
is acted upon under the dual treatment. This could involve a larger increase in the 
phosphorylated state of some PKC substrates due to the inhibiton of PP2A. 
Clearly, further studies need to be carried out in order to elucidate the mechanism 
by which such a joint treatment acts. However, this could be very useful in 
determining an important PKC substrate that regulates the modes of exocytosis.  
II.3.8 Summary of Results obtained 
The summary of the results obtained are depicted in the Figures and Tables 
below.The proposed difference in the Control and Diabetic nerve terminals are 
summarized in Table II.1 and Figure II.2 below: 
Table II.1:  Proposed difference in Control and Diabetic terminals using HK5C. 
 Control Terminals Diabetic terminals 
 RRP RP RRP RP 
K&R ✓ x ✓ ✓ (some) 
FF x ✓ x ✓ (some) 
Increase in [Ca
2+
]i    ✓✓ ✓ ✓✓✓ ✓✓ 
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Figure II.2: Proposed difference in Control and Diabetic terminals: (A) The Left 
panel depicts a typical Resting nerve terminal (when no stimulus is applied) with 
black vesicles representing the RRP and the green ones signifying the RPs. Note 
that just one RRP of SV and two RP vesicles have been illustrated as this reflects 
that usually the RP is larger than the RRP but this does not indicate the actual 
number of SVs in the RRP and the RP. The middle panel represents a typical 
increase in the [Ca
2+
]i upon application of stimuli (HK5C in this case). The 
orange colour represents the level of Ca
2+ 
and the level drops as you go further 
away from the AZ of the terminal (the intensity of the orange colour decreases). 
First the RRP are released by K&R mode of exocytosis as soon as the stimulus is 
employed. Thereafter, the RPs are released by FF seconds after the arrival of 
stimulus (represented by the Right panel). (B) In the diabetic terminal upon the 
arrival of stimulus (represented by the middle panel), the [Ca
2+
]i level is increased 
to a higher level than in the control terminal (Red colour). Herein, the RRPs are 
released similar to that of the control terminal. However, subsequently some RPs 
are released by K&R mode of exocytosis (due to the higher level of [Ca
2+
]i) and 
the rest of the RPs are released by FF mode of exocytosis. 
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Upon application of various drugs to such terminals to elucidate the role of the 
VGCCs, the protein kinases and phosphatases are summarized in Table II.3. 
Table II.3: Role of VGCCs, protein kinases and protein phosphotases in defining 
the mode of exocytosis in Control and Diabetic terminals. 
Role in 
defining of 
the mode of 
exocytosis  
 
Control Terminals 
 
Diabetic terminals 
         HK5C 4AP5C HK5C 4AP5C 
 RRP   RP RRP    RRP     RP RRP 
P-type 
VGCCs 
    x    x Not 
Tested 
x x Not 
Tested 
L-type 
VGCCs 
   ✓   x Not 
Tested 
x x Not 
Tested 
N-type 
VGCCs 
x x Not 
Tested 
✓ Not 
known 
Not 
Tested 
CaMKII Cannot 
be 
tested 
Cannot 
be 
tested 
✓ Not 
Tested 
Not 
Tested 
Not 
Tested 
Myosin II ✓ x x ✓ x ✓ 
Calcineurin x ✓ Not 
tested 
Not 
tested 
Not 
tested 
Not 
tested 
Dual effect of 
blocking 
x ✓ Not Not Not Not 
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Myosin II and 
Calcineurin 
tested tested tested tested 
Dynamins x x ✓ x ✓ x 
Protein 
Phosphatase 
2A 
✓ Possibly Not 
tested 
Possibly Possibly x 
Protein kinase 
C 
✓ x Not 
tested 
✓ x ✓ 
Dual effect of 
blocking 
Protein 
Kinase C and 
Protein 
Phosphastase 
2A 
Not 
tested 
Not 
tested 
Not 
tested 
✓ ✓ ✓ 
 
 
 
 
 
 
 
 
✓ Plays a Role in Defining the mode of exocytosis. 
x   Does not play a Role in Defining the mode of exocytosis 
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 An example of such drug action is illustrated in the change in the mode of 
exocytosis upon application of Dyn in Figure II.2 below: 
 
 
 
Figure II.4: Difference in the mode of release evoked by HK5C in Control and 
Diabetic terminals following application of Dyn: (A) There is no difference in the 
control terminal upon application of  Dyn. The panel is replica of the panel A in 
Figure II.1, and this indicates that dynamins do not play a role in the mode 
switching (with HK5C) in the Control terminals. (B) In the diabetic terminal, 
however, upon application of HK5C in presence of Dyn, the RRPs are still 
undergoing the K&R mode of exocytosis (represented by the middle panel) but 
those RPs undergoing K&R mode of exocytosis are switched to FF. This signifies 
that Dynamins play a role in defining the mode of exocytosis of RPs in Diabetic 
terminals. 
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II.4 Conclusions and Future Studies 
It can be concluded that, L-type channels play a role in the switching of the mode 
of exocytosis in control terminals. However, N-type channels play a significant 
role in the diabetic terminals and more experiments with the optimal sub-maximal 
concentration of ω-conotoxin GVIA need to be performed.  
Activated CaMKII can induce a K&R mode of exocytosis of RRPs in control 
synaptosomes, as the mode is switched to FF following KN93 induced inhibition 
of this enzyme. Additionally, these experiments confirmed that, 4AP5C 
exclusively releases the RRPs whilst HK5C and ION5C release both RRP and RP 
of SVs. A role for CaMKII in mode switching in diabetic terminals needs to be 
established.  
There was apparently not much difference in the role of myosin II in regulating 
the mode of exocytosis in control and diabetic synaptosomes when HK5C was 
employed, but 4AP5C activated myosin II, and thereby bypasses an effect of 
dynamin, in diabetic terminals. The dual blockade of myosin II and CaN led to 
the idea that, CaN only regulates the fusion mode of the RP of SVs in control 
terminals. Thus, by using diabetic terminals and comparing these to control 
terminals, it was established that, active PP2A regulates the mode of exocytosis 
of the RRP of SVs whilst active PP2B (CaN) regulate the mode of exocytosis of 
the RPs. The inhibition of both dynamins and myosin II resulted in many SVs 
undergoing a K&R mode of fusion via an unexplained mechanism. An 
explanation may be revealed in the future by repeating this study on diabetic 
synaptosomes.  
Finally, the dual treatment of OA and PMA led to a switch of all SVs to a FF 
mode by a mechanism that is not fully understood. More research needs to be 
carried out to understand the underlying mechanism of the changes observed.  
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III. Monitoring Behavioural Changes in Diabetic Rats 
using LABORAS 
As demonstrated in Chapter II, the diabetic rat terminals exhibit different 
biochemical changes when compared to control nerve terminals. Consequently, it 
was suspected that these changes affect the synaptic plasticity in the long-term 
and may result in some behavioural changes. Thus, some initial observations 
involving studying various aspects of behaviour was carried out. A newly 
developed behaviour registration system, Laboratory Animal Behaviour 
Observation, Registration and Analysis System (LABORAS) for the automatic 
registration of different behavioural elements of individually housed mice and 
rats was validated.  
III.1.1 Laboratory Animal Behaviour Observation, Registration 
and Analysis System  
LABORAS is a powerful system that fully automates the behavioural scoring of 
small laboratory rodents, like rats and mice. LABORAS not only provides 
tracking related data, but also provides you with data on a large number of real 
behaviours, unlike many other systems, such as photo-beam trackers and video 
tracking. It is a sophisticated and extensive technique rather than the conventional 
use of video systems or „infrared beam breaking‟ systems, as LABORAS 
measures vibrations. It thereby does not have the problems of reflections, poor 
resolution or large data files. LABORAS is independent of light conditions i.e.  
it can measure in dark and under all light conditions. It automates the behaviour 
scoring of up to eight solitary housed animals at the same time. This home-cage 
system can monitor behaviour of rats for over a 24hrs activity period for up to 7 
days. Van de Weerd et al., (2001) compared the conventional observation 
methods with LABORAS and showed that LABORAS is a reliable system for the 
automated registration of eating, drinking, grooming, climbing, resting and 
locomotor activity (LMA) of rodents during a prolonged period of time. Thus, 
this system can reduce observation labour and time considerably (Van de Weerd 
et al., 2001) and can be reliable and free of inter- and intra-observer bias or 
anticipated scoring, thereby providing a standard behavioural measurement 
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worldwide. LABORAS enables the researcher to carry out more and increasingly 
effective experiments in less time using fewer animals and less equipment. It is 
this unique functionality, which enables LABORAS to perform behavioural 
research faster, more consistently and more efficiently  than human observations 
or other automated systems can achieve. 
 
Figure V: The LABORAS behaviour registration system: Sensor platform 
1.Corian baseplate 2. Carbon Fibre measurement plate 3. Clear polycarbonate 
cage 4. Construction that holds upper part of the cage 5. LABORAS Control Unit 
(http://www.metris.nl/en/products/laboras/laboras_information/) 
LABORAS is based on vibration and force signal analysis to determine both the 
behaviour and the position of the animal. This system (Figure V) is made up of a 
triangular shaped sensor platform consisting of a heavy "Corian" baseplate where 
the force transducers are accumulated, a very lightweight and firm Carbon Fibre 
measurement plate (Carbon Fibre Plate 700 × 700 ×1000 × 30mm, Metris b.v.) 
which is positioned on the top of the transducers (Van de Weerd et al., 2001). 
These are positioned on two orthogonally placed sensors (SPS Load cell, 1 kg, 
AE-sensors BV, Dordrecht, The Netherlands) and a third ﬁxed point, attached on 
a bottom plate (690 × 690 × 976 × 13mm, Aeroweb Honeycomb material, CIBA-
Geigy, Switzerland). The whole structure is positioned on three poles, which have 
rubber feet to adjust height and to absorb external vibrations (Quinn et al., 2005). 
The rats are positioned in clear polycarbonate cages (floor area 840cm
2
, height 
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25cm/height to food hopper 15cm, cage: UNO Roestvaststaal, Zevenaar, The 
Netherlands, Hopper and Bottle: Lab Products Inc., Seaford, USA) with beddings 
(either wood shavings for control rats or sawdust for diabetic rats), which is 
placed on the sensor platform (Quinn et al., 2003). The upper part of the cage 
(including the top, food hopper and drinking bottle) is suspended in a high 
adjustable frame and is free from the sensing platform (As shown in Figure V). 
Four platforms are connected to the hardware and computer. The resultant 
mechanical vibration caused by the movements of the rats are picked up by the 
carbon fibre measuring plate and is transformed by each force transducer into 
electrical signals by each sensor (Quinn et al., 2005). These signals are ampliﬁed 
to a fixed signal and ﬁltered to eliminate noise by the pre-amplifier. According to 
the weight of the rats entered during the commencement of the experiment, the 
gain and offset of the pre-amplifier are adjusted. The software through a simple 
calibration practice regulates this. The output signals of the amplifiers are sent to 
the LABORAS Control Unit (LCU), which converts the analogue signals into a 
digital format. The LCU can handle the signals of up to eight measurement 
platforms. The LCU sends the data over a serial line and digitally stores on a 
computer for further processing. In this system, each movement pattern has a 
unique frequency and amplitude and can be differentiated by the computer into 
separate behavioural categories (Quinn et al., 2003). This is illustrated in the 
Figure W. The LABORAS software (Metris B.V., Hoofddorp, The Netherlands) 
consists of an administration module that registers information on the experiment 
and test conditions. The data acquisition and storage module controls the 
hardware and handles the storage of the sampled signals. The software then 
processes the stored data using several signal analysis techniques to classify the 
signals and registers the duration and frequency into multiple behavioural 
categories of eating, drinking, rearing, climbing, immobility, undefined, LMA, 
and grooming (Van de Weerd et al., 2001; Quinn et al., 2005).   
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Figure W: Vibration patterns corresponding to individual behaviours are 
represented pictorially (Van de Weerd et al., 2001) 
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Table III.A: Positional and vibrational parameters used in the behaviour 
classification algorithms 
Behaviour Description for LABORAS 
Drinking The animal stands upright to lick water from the water 
bottle 
Eating The animal eats food pellets while standing upright, 
gripping the bars of the food hopper with its front paws and 
gnaw the food between the bars. It also includes gnawing a 
particle of food clasped between the front paws 
Grooming Shaking, scratching, wiping or licking its fur, snout, ears, 
tail or genitals 
Motionless/Imm
-obility 
Movements are absent while the animal is in a sitting 
position 
Locomotor 
activity 
Activities such as walking, running, or jumping. 
Rearing Standing on the hind legs without touching the cage walls   
with the forepaws 
Undefined All behaviours that do not fit in one of the previous 
categories 
   
The time resolution for behavioural sampling was 0.25s and the measures based 
on changes of gravity of the rats. Changes in gravity that exceeded 1.45cm/ 0.25s 
were recorded as LMA. Immobility was registered when the animal moved less 
than 0.75mm/0.25s (Augustsson et al., 2003). The behaviour that dominates is 
scored. In addition, it also provides tracking parameters such as position, speed, 
maximum speed, average speed, travelled distance and position distribution.  
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III.2.1 Materials and methods 
For the validation study, 4 male Wistar rats either control or diabetic were used. 
At the time of the arrival, rats were about 160-200grams in weight. The animals 
were kept in same conditions as mentioned in section II.1.1 when not used for 
studies. 
During the 24hrs monitoring period, 4 rats were singly housed with ad libitum 
access to food and water in a temperature and humidity controlled enviornment. 
Prior to the study, the rats were weighed, along with the amount of food and 
water given during the study. The weight of the food and water after 24hrs of 
monitoring was also recorded. The instrument was calibrated and then the rats 
were transferred into the respective cages and monitored for 24hrs. Each batch of 
rats (i.e. either the control or the diabetic cohort) was monitored every alternate 
day (4 days in a week); 2 days for diabetic and 2 days for control.  
Most animals have circadian rhythm in their behaviour. Therefore, night-time 
tests would be more appropriate for rats since they are nocturnal animals, as they 
have high levels of activity after the beginning of darkness, thereafter periods of 
rest and activity alternate. Before dawn they have another (lower) activity peak. 
During the day, they mostly sleep (Borlongan et al., 1995). Consequently, the 
data presented has showed both the whole 24hrs period and the graphs for active 
period (Night time 19.00- 7.00). The active period is henceforth addressed as dark 
cycle. Additionally, 12hrs light cycle (7.00-19.00) was analyzed.  
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III.2.2 Statistical Analysis 
The results were obtained by averaging each 2.24hr time point data obtained 
during the two independent experiments carried out on the same week and with 
the age-matched data obtained during the next set of experiment performed. The 
data was plotted using Microsoft Excel and unpaired student t-test was used to 
obtain statistical significance. The results with p≤0.05 were considered to be 
statistically significant for all the experiments. 
The results presented compared the difference in each behavioural pattern found 
in each experiment and an average of the two independent experiments performed 
during different times of the year. The behavioural patterns were plotted as the 
total duration for which each were carried out and the frequency of the patterns. 
Additionally, the data is presented for the entire period of study (24hrs), for the 
dark cycle and light cycle. Each day the experiments were commenced at slightly 
different times (as following the 24 hours of measurements LABORAS takes 2 
hours to calculate the data), so the precise start time for each experiment were 
noted and then the time courses were adjusted accordingly e.g. so that the time 
points in the 24 hour period were the same.  
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III.3 Results  
As described earlier, LABORAS is capable of measuring various behavioural 
parameters at the same time.  
III.3.1 Comparison of weights  
The weights of the rats were monitored on daily basis along with the amount of 
food and water consumed. Figure 46 and 47 illustrates the comparison of weight 
gained by control (Cont) and diabetic (Diab) animals over the whole experiment, 
two independent experiments that were carried out. 
 
Figure 46: Diabetic rats gain significantly less weights than the Control rats over 
the period over 12 weeks after the STZ injection in (A) Expt 1 (B) Expt 2 
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It is clear from Figure 46 that the diabetic rats (DR) put on a little more than half 
the weight of the control rats (CR), for both the experiments (Figure 46A and 
Figure 46B). However, when the CR and the DR were compared against the two 
experiments, it was found that the amount of weight the DR gained in experiment 
2 (Expt 2) was significantly more than the DR from experiment 1 (Expt 1) 
(Figure 47B). However, no significant difference for the weight gained was 
observed in the CR (Figure 47A). Many factors could be responsible for the 
difference observed in the two experiments. It could be possible that the amount 
of STZ injected would be slightly different for the two experiments, and as a 
consequence the animals from expt 2 do not develop as severe diabetic condition 
as the rats in expt 1. Alternatively, the rats in expt 1 may have been more 
sensitive to the STZ treatment, or the rats from expt 2 might have become 
resistant to STZ treatment. These could possibly explain some of the 
descrepencies that were observed in the results from the two experiments. 
However, it should be noted that at the end of 12 weeks,the rats used in expt 2 
were still diabetic and this was checked by measuring their blood glucose levels, 
which was > 20mM for all the rats. 
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Figure 47: (A) No significant difference in the amount of weight gain observed 
in CRs from Expt 1 and 2 (B) Significant difference in the amount of weight 
gained observed in DRs from Expt 2 when compare to DRs from Expt 1 after 40 
days post-STZ injection. 
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III.3.2 Locomotor activity 
LMA is defined as the ability of animal to move from one place to another. 
LABORAS classes walking, running, climbing, jumping in its LMA category. 
For most of the weeks, DRs were significantly less locomotive than CRs in the 
24hrs (Figure 48A), or the dark period (Figure 48B). Please note that it is 
apparent from the figures that the rats only travelled for about 1 minute in each of 
the 2.24hrs sections during the whole 24hrs cycle. It should be remembered that, 
LABORAS measured several activities and so although the rats appear not to be 
expressing LMA they are carrying out many other activities. Further, it is clear 
that rats in cages (whether control or diabetic) are quite sedentary compared to 
when they are free in the wild. Clearly, this does suggests that this LMA may be 
measured in a slightly artificial situation but it can still show whether CRs and 
DRs behave different towards this activity. Likewise, the frequency of LMA was 
reduced in DRs relative to CRs in 24hrs (Figure 49A) or 12hrs dark cycle 
(Figures 49B and 49C) when the average of the two experiments is determined. 
However, no difference in LMA behaviour was observed in the 12hrs light cycle 
for both the duration and the frequency (Figures 48 and 49) indicating that the 
difference seen between the CRs and DRs occurs during the dark cycle.  
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Figure 48: DRs displaced significantly less duration of LMA than CRs for (A) 
12hrs dark cycle (B) 24hrs and (C) No significant difference observed in 12hrs 
light cycle for the Average of Expts 1 and 2 
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Figure 49: DRs frequency of LMA was significantly less than CRs for (A) 12hrs 
dark cycle (B) 24hrs and (C) No significant difference observed in 12hrs light 
cycle for the Average of Expts 1 and 2 
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In the average speed and distance (Figures 50) covered for expt 1, (Figures 50A) 
it was observed that the DRs covered a larger average distance with a greater 
average speed. This can explain why the DRs appear to be less locomotive, but 
actually cover more distance because they move quicker. However, expt 2 and the 
average of the two experiments displayed no difference for the 24hrs period 
(Figures 50B), 12hrs light (Figures 51A) and 12hrs dark period (Figures 51B). 
This could be because, as previously mentioned, the diabetes induced in the DRs 
was not similar in both the cases, or the CRs would be less active in one 
experiment and more in the other. Thus, this experiment needs to be repeated a 
few more times in order to eliminate and average the discrepancies observed in 
the two experiments.  
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Figure 50: When the average speed of DRs and CRs was compared for 24hrs it 
was found that in (A) Expt 1 DRs travelled with significantly more speed than 
CRs from Week 5-10, however for (B) Expt 2 and (C) Average of Expts 1 and 
Expt 2 no significant difference observed between DRs and CRs. 
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Similar difference was observed in the 12hrs dark cycle and 12hrs light cycle for 
both speed and distance covered by the DRs and CRs. However, only the average 
of the two experiments is presented for these time periods. 
 
 
 
Figure 51: No significant difference in the average speed of DRs and CRs was 
observed in the average of Expts 1 and Expt 2 in (A) 12hrs dark cycle and (B) 
12hrs light cycle. 
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Figure 52: No significant difference in the distance covered by DRs and CRs was 
observed in the average of Expts 1 and Expt 2 for (A) whole 24hrs (B) 12hrs dark 
cycle and (C) 12hrs light cycle. 
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III.3.3: Immobility:  
LABORAS describes immobility/resting behaviour as movements that are absent 
while the animal is in a sitting or lying position. In addition, short movements 
(e.g. turning over while sleeping) were also classed under immobility. Despite 
that for most of the weeks as stated in section III.3.2 DRs were less locomotive 
than the CRs, the duration of time DRs being immobile was significantly less 
than that for CRs for all the time periods for the average of the two expts (Figures 
53A, B and C). However, in expt 2 no difference was observed between the two 
sets of rats (not shown). Additionally, the frequency of immobility was similar for 
both the animals for all the time periods (Figures 54A, B and C). It should be 
noted that, the rats were immobile for most of the time during the study; 
therefore, not much of difference in the time spent in this behaviour is observed 
for the entire 24hrs or the dark or light cycle. One result which seems to be 
consistent between the 2 expts is that the DRs are less immobile (i.e. they are 
doing some measurable activity) during the light 12hrs period. This suggests that 
the DRs might respond differently to the light dark cycle. It should also be 
pointed out there is not a problem between the DRs showing less LMA but also 
less immobility as this simply means that the DRs must be doing more of some 
other measurable behaviour.  
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Figure 53: DRs display significantly less duration of immobility than CRs in 
Average of Expts 1 and 2 for (A) 24hrs, (B) 12hrs dark cycle and (C) 12hrs light 
cycle. 
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Figure 54: No significant difference in the frequency of immobility observed in 
CRs and DRs for the average of Expts 1 and 2 in (A) 24hrs, (B) 12hrs dark cycle 
and (C) 12hrs light cycle. 
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III.3.4 Rearing  
Rearing is defined as the rats standing upright on their hind legs (mostly against 
the wall of the cage). From the Figures 55A, 55B, 56A and 56B it can be inferred 
that, the DRs reared significantly less than the CRs, for both duration of 
monitoring and frequency (from week 3-8 in most of the cases) for the 24hrs and 
the 12hrs dark cycle. This suggests that the DRs were less keen to explore the 
surrounding environment. However, individual experiment carried out do not 
show a significant difference (not shown), but the average does support the 
conclusion that indeed DRs rear less when compared to CRs. Additionally, no 
significant difference was observed in rearing during the light cycle (figures 55C 
and 56C), suggesting that there was a change in nocturnal pattern of the diabetic 
rats.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
178 
 
Figure 55: DRs display significantly less duration of rearing in comparison to 
than CRs in Average of Expts 1 and 2 for (A) 24hrs, (B) 12hrs dark cycle and (C) 
No Significant difference observed between DRs and CRs for 12hrs light cycle. 
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Figure 56:  The frequency of rearing in DRs was significantly less than CRs in 
Average of Expts 1 and 2 for (A) 24hrs, (B) 12hrs dark cycle and (C) No 
Significant difference observed between DRs and CRs for 12hrs light cycle. 
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III.3.5 Grooming 
The animal shaking, scratching, wiping or licking its fur, snout, ears, tail or 
genitals is classified as grooming. Results obtained confirm that, no significant 
difference in the duration of grooming in the DRs and CRs for both 24hrs period 
(Figures 57A) and 12hrs dark cycle period (Figures 57B). However, the duration 
of grooming for DRs was significantly more during the light cycle (Figure 57C). 
This data is very important, as this strongly suggests that, the pattern of activity in 
the diabetic animals is changed such that, it is more active during the day and 
considerably less in the night. When the frequency of grooming was monitored in 
the two groups, it was concluded that DRs groomed more than CRs  for all 
periods (Figures 58). 
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Figure 57: No significant difference in the duration of grooming observed in DRs 
and CRs in Average of Expts 1 and 2 for (A) 24hrs, (B) 12hrs dark cycle and (C) 
DRs groomed significantly more than CRs for 12hrs light cycle. 
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Figure 58: DRs groom significantly more than CRs in Average of Expts 1 and 2 
for (A) 24hrs, (B) 12hrs dark cycle and (C) 12hrs light cycle. 
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III.3.6 Drinking  
LABORAS defines drinking behaviour when the rat stands upright gripping the 
water bottle and licking water. Not surprisingly, we discovered that the DRs 
drank copious amount of water more frequently as compared to the CRs (Figures 
59 and 60). However, it was observed that the difference in duration of time DRs 
drank more water than CRs was not that great (Figures 59), in contrast to the 
frequency of times (Figures 60). This data suggests that, the DRs spend less time 
drinking water, but have it more frequently as compared to the CRs. Additionally, 
in certain experiments, even though the physical measurements (weighing the 
water bottle before and after the 24hrs when rat was in cage) indicated that the 
DRs drank more than CRs (Figure 61), LABORAS did not record significant 
difference. This suggests either that LABORAS is not accurate in measuring 
drinking behaviour or just support the fact that the DRs drink more water in less 
duration of time. This is not surprising for diabetic animals, as it is already known 
that excess blood sugar, or glucose, in the body draws water from the tissues 
resulting in feeling dehydrated. This leads the animal to drink more water and 
thereby causing frequent urination.  
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Figure 59: DRs display significantly more duration of drinking in comparison to 
than CRs in Average of Expts 1 and 2 for (A) 24hrs, (B) 12hrs dark cycle and (C) 
12hrs light cycle. 
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Figure 60: DRs drink more frequently than CRs in Average of Expts 1 and 2 for 
(A) 24hrs, (B) 12hrs dark cycle and (C) 12hrs light cycle. 
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Figure 61: DRs consume significantly more amount of water than CRs in 24hrs 
for Average of Expts 1 and 2 
III.3.7 Eating: 
LABORAS classes eating behaviour as the period when rat eats food pellets 
while standing upright, gripping the bars of the food hopper. It is apparent in all 
diabetic cases that as the glucose does not get utilized properly by the brain and 
other parts of the body; the body craves continuously for glucose. This in turn 
leads to excessive hunger. The DRs thus consumed considerably more food as 
compared to the CR. In support of this theory, the duration (Figure 62) and 
frequency (Figure 63) of the eating behaviour for all the experiments and time 
periods recorded; show that DRs consumed significantly more food than CRs for 
longer period of time and more frequently. This was confirmed by simply 
weighing the amount of food added to the cage at time zero and weighing this 
again after 24hrs, where it was found that there was a significant difference in the 
amount of food consumed over a 24hrs period (Figure 64). This latter reflects the 
total consumption over the whole 24hrs period whilst our LABORAS data shows 
the consumption over an average 2.24hrs period in 24hrs or over an average 
2.24hrs period in the 12hrs dark or 12hrs light period. 
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Figure 62: DRs display significantly more duration of eating in comparison to 
than CRs in Average of Expts 1 and 2 for (A) 24hrs, (B) 12hrs dark cycle and (C) 
12hrs light cycle. 
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Figure 63: DRs eat frequently than CRs in Average of Expts 1 and 2 for (A) 
24hrs, (B) 12hrs dark cycle and (C) 12hrs light cycle. 
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Figure 64: Increase amount of food consumed in DR than CR for 24hrs the 
Average of Expts 1 and 2. 
III.3.8 Undefined: 
All behaviours not classified in one of the previous categories are classed as 
undefined behaviour. From the results obtained, it can be inferred that, DRs 
displayed significantly larger duration of undefined behaviour in comparison to 
the CRs when both the experiments were averaged (Figures 65). However, the 
frequency of undefined behaviour was similar in both sets of rats (Figures 66). It 
is difficult to interpret these results as we do not know what behaviours are 
occurring that LABORAS categories as undefined behaviour (i.e. not one of the 
behaviours that it can distinguish). However, if the relevant software is purchased 
other behaviours of rats can be analyzed by LABORAS and such software could 
be used in future experiments to try to determine what some of these undefined 
behaviours may actually represent.   
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Figure 65: DRs display significantly more duration of undefined behaviour in 
comparison to than CRs in Average of Expts 1 and 2 for (A) 24hrs, (B) 12hrs 
dark cycle and (C) 12hrs light cycle. 
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Figure 66: Similar frequency of undefined behaviour observed in DRs and CRs 
for Average of Expts 1 and 2 for (A) 24hrs, (B) 12hrs dark cycle and (C) 12hrs 
light cycle. 
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III.4 Discussion 
As characteristic biochemical changes were observed in the diabetic terminals, 
which may affect synaptic plasticity, the main aim of this study was to observe 
the behavioural changes that may occur due to the diabetic state. Standard 
LABORAS software was utilized in these experiments to assess the modification 
in the LMA, speed, distance, immobility, rearing, grooming, eating, drinking and 
undefined behaviours. LABORAS has been already a validated system that can 
perform behavioural recordings and classification in a standardized and non-
invasive way, with reduced experimental time required when prolonged periods 
of examination can be made (Van de Weerd et al., 2001; Quinn et al., 2003).  
The weight of the animal, and the amount of food and water consumed were 
constantly measured throughout the experiment. The results obtained from figures 
46, 59-61 and 62-64 illustrate the reduction in the weight gain of the DRs relative 
to the CRs, despite the higher consumption of water and food by the STZ-treated 
animals. These measurements confirm the diabetic condition. Weight loss, 
polyphagia, polydipsia and frequent urination (Kirpichnikov and Sowers, 2001; 
Latham et al., 2009) are very common symptoms observed in the diabetic state 
for any animal (including humans). It is well known that, symptoms of diabetes 
include elevated level of glucose in blood. This leads to the loss of glucose in the 
urine, thereby causing large urine output leading to dehydration, which 
consequently causes increased thirst and water consumption (Latham et al., 
2009). The lack of insulin in the diabetic animals (and humans) also affects the 
fat, protein and carbohydrate metabolism, leading to weight loss despite an 
increase in appetite (Kirpichnikov and Sowers, 2001). It is believed that, the 
increase in the hunger is because glucose cannot enter into various cells (despite 
the level of glucose being higher in the blood) due to the lack of insulin. This 
leads to the body continuously craving glucose and leading to increased hunger.  
The results obtained from figure 48A, 48B, 49A and 49B suggest that DRs are 
less locomotive compared to the CRs. This supports the initial hypothesis as it is 
well known that when the physical well-being of an individual decreases, it 
becomes less active. However, the average distance and speed for DRs are 
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significantly more than CRs (Figures 50, 51 and 52). Additionally no change in 
the LMA was observed during the light cycle.  
The data obtained suggests that DRs are less immobile than CRs (Figures 53 and 
54). As discussed already, one might believe that this contradicts with the LMA 
data obtained but as explained, this is not necessarily the case. Another possible 
explanation is that because LABORAS measures changes in gravity that exceed 
1.45cm/0.25s
 
 as LMA (Augustsson et al., 2003), it could be plausible that DRs 
travel with more speed and cover more distance in shorter periods of time (<1.45 
cm/0.25s), thereby not allowing LABORAS to classify this behaviour as LMA. 
Therefore, the LMA behaviour for DRs appears less than the CRs. However, the 
average distance and speed is recorded significantly more than the CRs (only in 
expt 1). This data indicates that, the DRs move more quickly than the CRs. This 
argument is confirmed by the result obtained by the immobility behaviour. 
Immobility is registered when the animal moved less than 0.75mm/0.25s 
(Augustsson et al., 2003). 
Thus, it can be concluded that the DRs are more active than CRs, and this may be 
just due to increase in the anxiety-like behaviour (Casarrubea et al., 2011). 
Additionally, it should be noted that differences in the two independent 
experiments (no significant difference in the average speed and distance in Expt 
2) is detected. Therefore, these experiments need to be repeated to obtain 
consistent results.  
Additionally, in this initial analysis of the data, all 4 rats were included for both 
experiments. Therefore, future research could involve going back and examining 
each of the individual rats for all these behaviours. It may be that in each 
experimental set there is one rat that is behaving oddly, and it thereby disturbing 
some of the results e.g. if one rat doesn‟t move at all or moves too much then this 
would have a large effect on the average for movement or immobility. 
Rearing is a vertical locomotion activity when the animal stands on its hind leg 
while raising up its forearm in the air or placed on the wall of the cage and this is 
seen as a survival strategy in assessing the environment for modification. 
Stimulating CNS increases rearing and inhibiting CNS causes decrease in rearing 
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behaviour (Aderibigbe et al., 2010). The results obtained from Figures 55A, 55B, 
56A and 56B reveals decrease in the rearing behaviour in DRs from an early 
stage after the induction of diabetes. It can thus be interpreted that, diabetes 
inhibits the CNS activity (Aderibigbe et al., 2010). Conversely, no difference in 
rearing is observed in light cycle (Figures 55C and 56C), suggesting that the day 
rearing activity of the diabetic animals is unchanged as compared to the dark 
cycle. 
A similar decrease in the rearing behaviour was observed by the study conducted 
by Shoji and Mizoguchi, (2011) in older rats. The present study may suggest that, 
the diabetic state leads to early ageing in the rodents (as discussed in the 
Introduction), displaying peculiar characteristics similar to the observed in older 
rats (Shoji and Mizoguchi, 2011). The decrease in rearing may be due to the 
decrease in the exploratory activity (Lumley et al., 2001). The 
rearing behaviour response is regulated by multiple NT systems; including 
GABA, cholinergic, adrenergic, opioid, serotonin, glutamate and dopamine and 
their receptors. A decrease in rearing behaviour may be due to potentiation of 
GABA or inhibition of serotonin, cholinergic and dopamine neurotransmission 
(Aderibigbe et al., 2010). 
Grooming in mammals is a self-directed (Wright et al., 2011), natural, stereotypic 
behaviour. Grooming is an important behavioural component in animals and is 
associated with de-arousal (absence of stimulation) in the CNS (Aderibigbe et al., 
2010; Casarrubea et al., 2011). First the head is groomed, then body regions, the 
genital regions and the tail. This cephalocaudal progression of grooming is 
defined as the „„syntactic groom chain.‟‟ Previous studies have demonstrated that 
multiple regions of the rodent brain, mainly brainstem, striatum, and cortex are 
used to implement the syntactic groom chain (Chen et al., 2010). Grooming 
stimulates the release of beta-endorphins. This is one physiological reason for 
why grooming appears to be relaxing (Keverne et al., 1989).  
The duration of grooming in DRs seems similar to that of CRs for 24hrs and dark 
cycle (Figures 57A and 57B). Intriguingly, the light cycle data indicate that DRs 
groom more than CR (Figure 57C). This further emphasizes that, the DRs display 
more activity during the day rather than night. In addition, the frequency of 
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grooming bouts is augmented (Figure 58). This behaviour is pathological and 
may lead to hair removal (this was not analyzed in this research although it was 
obvious that there was hair loss).  
There are several postulated roles of grooming, which may differ depending on 
environmental conditions. In addition to its hygiene function, grooming has been 
assumed to be involved in stress adaptation (Lumley et al., 2001). The stress 
response may be mediated via corticotropin-releasing hormone or neuropeptides 
such as neuromedin S, which can act on the amygdala to induce grooming by 
increasing mesolimbic dopamine secretion (McGowan et al., 2010). Additionally, 
novelty-induced grooming has been considered to be a displacement behaviour 
that may decrease stress-induced provocation. Stress hormones, such as 
glucocorticoids, increase hypothalamic arginine vasopressin and oxytocin in rats. 
It is thought that anxious rats groom more often (Casarrubea et al., 2011; Wright 
et al., 2011). Researchers have shown that activating the anxiogenic effect of 
various drugs, increases grooming behaviour, and is linked with the activation of 
serotonergic transmission. Grooming behaviour is due to the involvement of 
multiple neuromediators and brain regions (Howard et al., 2008). Electrical 
stimulation of the hypothalamus especially preoptic area also induces grooming 
in rodents (Lumley et al., 2001).  
Excessive grooming in rodents behaviour is very similar to that described for 
humans with the obsessive-compulsive disorder (OCD) spectrum disorder 
trichotillomania, where compulsive removal of hair is also a hallmark (Chen et 
al., 2010). 
In an experiment carried out on the Hoxb8 mutant mice, excessive pathological 
grooming behaviour was associated with a defect in microglia. Microglias are 
found in abundance in cortex, including the frontal orbital regions and basal 
ganglia. Microglia could affect neuronal activity and behaviour by a number of 
mechanisms. These include the secretion of cytokines that stimulate or inhibit 
neuronal activity. Such cytoskines can work in parallel with NTs. The duration of 
contact at synapses is dependent on neuronal activity. From the above, it can be 
concluded that, due to their mobility and dynamic contacts with synapses, 
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microglia could represent an additional system for stabilizing and managing 
neural networks (Chen et al., 2010).  
The results obtained from the current experiments suggest that, there is an 
increase in the anxiety in STZ-induced diabetic rats and this is in agreement with 
earlier experiments carried out by Ramanathan et al., (1998). This study also 
demonstrated that the augmented anxiety on various experimental paradigms 
including the social interaction test and the anxiolytic effect of diazepam in DRs 
(Ramanathan et al., 1998). It is believed that the augmented anxiety-related 
behaviour may be due to damaged corticosterone and hippocampal serotonergic 
systems (File and Seth, 2003). In addition, it is assumed that the hippocampus 
controls anxiety responses, especially the dorsal raphe nucleus. Previous reports 
suggest that the GABA neurons in the dorsomedial hypothalamus regulate a 
variety of physiologic and behavioural responses associated with anxiety and 
stress. It has also been proposed that, the reciprocal neural circuits linking the 
medial prefrontal cortex, the extended amygdala and the hypothalamus play a 
crucial role in mediating fear and responses to stress (File and Seth, 2003). 
 
As there are some discrepancies in the results observed in the two independent 
experiments, it is clear that further LABORAS monitoring needs to be performed. 
 
The data obtained demonstrates a marked increase in undefined behaviour in DRs 
compared to CRs (Figures 65 and 66). As no specific behaviours are classed 
under this category, it is difficult to interpret this result. Different software 
available for LABORAS to measure behaviours such as hind limb licking, 
scratching, wet dog shakes, head shakes, head twitches and purposeless chewing 
could be used in the future to  define what behaviours may be included in the 
general umbrella of undefined. 
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III.5 Conclusions and Future Studies 
The results obtained from the current experiments clearly demonstrate that, 
LABORAS is capable of detecting various behaviours over a long period of time 
in rats and this can detect differences between rats that have been treated with 
various pharmacological reagents e.g. STZ. These behavioural deficits can be 
seen in LABORAS under home cage conditions in the absence of lengthy 
behavioural pre-training and pharmacological intervention. LABORAS and the 
social interaction test therefore provide novel, highly sensitive, quantitative 
methods for establishing differences between CRs and DRs. The DRs were only 
measured up to 12 weeks following STZ injection. This is because the animal 
licence being operated under stipulates that the rats only up to 12 weeks 
following the induction of diabetes can be used. Currently, a new licence is being 
applied for in which one will be allowed to use rats up to 6-9 months following 
induction of diabetes. Such rats might show even more obvious behavioural 
differences compared to the control.   
It should be highlighted that LABORAS can only recognise behaviours that have 
established algorithms. Moreover, the LABORAS system can only be 
programmed to identify behaviours that produce vibrational signals of significant 
amplitude and consistency. More complex or refined behaviours such as yawning 
or disturbances of gait would therefore not be recognised (Quinn et al., 2005). It 
should be emphasized that, LABORAS continuously records data in real time and 
that one could chose to analyze what differences are occurring for every 60mins 
period of the day (or even shorter). Such analysis would enable us to see whether 
there are differences apparent between the CRs and DRs at particular times 
during the day and not just in the nocturnal 12hrs period. The current analysis has 
divided the day into ten 2.24hrs sections and the data presented actually 
represents the average of these 2.24hrs sections, for either the full 24hrs or 12hrs 
dark or 12hrs light cycle. Clearly, one could look at longer segments of time 
including summating all the activities over 24 or 12hrs. However, as this was the 
first use of LABORAS in this laboratory, it was choosen the times that we have 
shown. Further analysis may yield further interesting results. It was hoped that if 
2.24hrs sections gave a reliable measurement of differences in behaviour then 
perhaps rat behaviours could be measured just for this short period. 
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IV. General Conclusions 
From the results obtained in chapters II and III it can be concluded that diabetic 
rats display difference in both biochemical and behaviour when compared to the 
non-diseased rats.  
The biochemical changes suggest that, the L-type VGCCs play a crucial role in 
regulating the mode of exocytosis evoked by HK5C in control terminals, whilst in 
the diabetic terminals N-type VGCCs seem to be involved. For the same stimulus, 
dynamins did not play a role in switching of the modes of exocytosis in control 
terminals but did in the diabetic terminals. This can be reconciled by stating that 
only SVs, which are dependent on dynamins, are the RP. The inhibition of PP2A 
or the activation of PKC switched all SVs to a FF mode in control terminals 
whereas, in diabetic terminals not all SVs that were undergoing K&R fusion were 
switched to FF, although, the dual treatment with these drugs did switch all the 
vesicles to a FF mode by an unknown mechanism. More research needs to be 
preformed utilizing this dual treatment in order to understand the underlying 
mechanism for the changes observed.  
 Monitoring the eating and drinking habits and the weight of rats confirmed that 
STZ administration induces some classical symptoms of diabetes in such animals. 
The increase in average speed and distance, decrease in immobility, reduced 
rearing and increased frequency of grooming signify anxiety and stress induced 
behaviour in the diabetic rats that can be explained by various neuromediators 
acting in various brain regions. These initial studies (done over a 6 months 
period) need to be repeated a few more times to establish some consistent and 
repeatable behavioural patterns. The two sets of 4 animals (expts 1 and expt 2) 
varied in some cases and further analysis in the future will indicate whether these 
differences could be assigned to a rogue (in the sense that not behaving as they 
should) rat in each of the cohorts. Additionally, various other LABORAS 
softwares could be helpful to determine the undefined behavioural changes 
observed in the diabetic rats. Further, some behaviour indicated difference in the 
activity of DRs during day and the night monitoring. These data signify that DRs 
perhaps have altered active period in comparison to non-diseased rats. Again, one 
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could re-analyze the data in the future to choose to look at different periods of 
time within the 24 hours of data collection.  
 
The results obtained do support the hypothesis that distinct behavioural changes 
would be apparent in the diabetic rats. This hypothesis was based on the 
biochemical changes that were observed. The alteration in the behaviour may 
correlate with the biochemical changes observed and future work will need to be 
performed to prove this idea. Future experiments needs to be performed to 
determine the effects of the in vitro application of either insulin or high glucose 
levels on control and diabetic terminals, to observe if such conditions could make 
diabetic terminals behave like controls, or make control terminals behave like 
diabetic terminals (this would include the measurement of the amount of K&R 
and the level of [Ca
2+
]i induced by a stimulus). Additionally, in vivo 
administration of insulin injections (or slow insulin release with implanted 
peristaltic pumps) to rats that are made diabetic by STZ can be studied to 
ascertain whether such treatments now make terminals prepared from these 
animals identical to control terminals and whether behavioural differences are 
now corrected. A time course for reversal of diabetic induced effects could be 
performed in this type of experiment. Again, this could involve both behavioural 
and biochemical measurements.  
 
Long-term there remains the possibility of testing whether the regulation of 
neuronal N-type channels in the diabetic rat could reverse the changes seen in the 
rat. Such a proof of principle experiment could lead to the possibility that these 
treatments in humans could prevent any long-term synaptic plasticity changes 
seen in long-term diabetic patients. However, before this can ever be mooted a lot 
more research has to be carried out with this model of type 1 diabetes. Further, 
other models of type 1 diabetes and even models of type 2 diabetes could be 
studied to see whether similar biochemical difference are apparent between these 
diseased rats and control healthy rats. This would establish the generality and 
commonality of the changes that have been described in the biochemistry and 
behaviour of the STZ-type 1 diabetic rats. 
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VI. Appendices 
IV.1 Settings for plate reader 
Table VI.1.1: Tecan GENios ProTM microtitre plate reader’s settings for the 
measurement of glutamate release: 
Greiner 96 well, flat transparent bottom microtitre plate 
Fluorescence,  Kinetics 
Part of the plate: 1-9/7-12 
Excitation wavelength: 340 nm 
Emission wavelength: 465 nm 
Gain: 70 
Measurement mode: Bottom of the plate 
No. of cycles: 21/14  
Shake duration: 3s before the measurement and 1s in between the 
cycle 
Table VI.1.2: Tecan GENios ProTM microtitre plate reader’s settings for the 
measurement of FM2-10 dye release:  
Greiner 96 well, flat bottom black microtitre plate 
Fluorescence, Well Kinetics 
Part of the plate: 1-4/ 5-8 
Excitation wavelength: 485 nm 
Emission wavelength: 555 nm 
Gain: 40 
Measurement mode: Top of the plate 
No. of cycles: 461 
No. of flashes: 10: lag time 0 µs 
Mirror type: Dichroic 3 
Integration time: 40 µs 
Injector volume and speed: 40 µL  
Injection mode: Every injection refill. 
          Shake duration: 1s 
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Table VI.1.3: Tecan GENios ProTM microtitre plate reader’s settings for the 
measurement of the changes in intracellular [Ca
2+
]i: 
Greiner 96 well, flat bottom black microtitre plate 
Fluorescence, Well Kinetics 
Part of the plate: 1/2/3/4/5/6/7/8/9/10/11/12 
Excitation wavelength: 340 nm/ 390 nm 
Emission wavelength: 535 nm 
Gain: 30 
Measurement mode: Top of the plate 
No. of cycles: 40/160 
No. of flashes: 10: lag time 0 µs 
Mirror type: Dichroic 3 
Integration time: 40 µs 
Injector volume and speed:  None/ 40 µL  
Injection mode: Every injection refill. 
           Shake duration: 1s 
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Buffers used in the experiments 
Table VI.1.4: Homogenization Buffer (pH 7.4) 
Components Concentration Amount in 1 litre 
Sucrose 0.32M 109.54g 
Hepes 10mM 2.383g 
 
Table VI.1.5: L0 Buffer (pH 7.4) 
Components Concentration Amount in 1 litre 
NaCl 125mM 7.305g 
KCl 5mM 0.373g 
MgCl2 1mM 0.203g 
Hepes 20mM 4.766g 
Glucose 10mM 10mL* 
 
* Solution of 1.8 g glucose made in 10mL water before adding it to the buffer 
as glucose alone will not dissolve in the buffer 
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IV.2 Calculations 
All the data produced in the glutamate release, FM2-10 dye release and Fura-2 
assay were analyzed by methods outlined in appendix 6C (p121), appendix 6D 
(p129) and appendix 6E (p155) in the thesis of Pooja Mohanrao Barbar (Barbar, 
2010). As this information represents 46 pages of text, it was deemed reasonable 
just to cite these methods of analysis rather than repeating this text. 
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LABORAS Calculation: 
After 24 hours of monitoring, LABORAS provides data as shown below: 
Raw Data 
A B C D E F G H I J K L M N O 
WI
ND
O
W T-BEGIN T-END 
S
E
S
S
I
O
N 
C
A
G
E 
A
N
I
M
A
L 
C
O
D
E 
UNDE
F_D 
LOCO
M_D 
IMMOB_
D REAR_D 
GROOM
_D 
DRIN
K_D 
EAT_
D 
TOTA
L_D 
        [s] [s] [s] [s] [s] [s] [s] [s] 
               
1 000:00:00 002:24:00 2 1 0 0 900.24 20.3 6384.99 80.47 1018.12 86.76 149.15 8640 
2 002:24:00 004:48:00 2 1 0 0 1233.3 38.1 4324.49 517.25 2077.23 189.44 260.18 8640 
3 004:48:00 007:12:00 2 1 0 0 611.84 7.35 6832.52 193.79 774.94 20.79 198.77 8640 
4 007:12:00 009:36:00 2 1 0 0 423.95 0.51 7868.18 25.42 199.26 92.94 29.74 8640 
5 009:36:00 012:00:00 2 1 0 0 950.53 74.4 4086.04 741.8 1831.41 130.41 825.43 8640 
6 012:00:00 014:24:00 2 1 0 0 820.87 61.2 4742.44 498.73 1811.47 245.33 459.96 8640 
7 014:24:00 016:48:00 2 1 0 0 447.64 11.7 7669.21 36.93 458.47 0 16.06 8640 
8 016:48:00 019:12:00 2 1 0 0 743.57 63.7 4539.82 460.56 1812.83 106.34 913.17 8640 
9 019:12:00 021:36:00 2 1 0 0 733.53 63.8 4706.8 803.22 1553.05 86.47 693.12 8640 
10 021:36:00 024:00:00 2 1 0 0 1880.9 50.1 3390.33 694.29 1862.88 402.38 359.16 8640 
1 000:00:00 002:24:00 2 2 0 0 1746.6 104 3064.11 1087.48 1706.95 168.85 762.3 8640 
2 002:24:00 004:48:00 2 2 0 0 1168.4 10.1 5825.69 207.34 906.88 91.96 429.66 8640 
3 004:48:00 007:12:00 2 2 0 0 1211.8 21.6 5162.28 539.57 922.23 173.73 608.8 8640 
4 007:12:00 009:36:00 2 2 0 0 1378.1 23.7 5797.7 328.87 785.37 92.04 234.27 8640 
5 009:36:00 012:00:00 2 2 0 0 1213.5 79.1 4897.13 826.51 1080.35 83.18 460.24 8640 
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6 012:00:00 014:24:00 2 2 0 0 854.91 19.3 6906.26 194.48 558.24 53 53.77 8640 
7 014:24:00 016:48:00 2 2 0 0 1023.7 46.7 5596.29 568.65 854.75 112.57 437.37 8640 
8 016:48:00 019:12:00 2 2 0 0 919.46 32.6 5519.39 568.91 1101.37 27.38 470.88 8640 
9 019:12:00 021:36:00 2 2 0 0 1273.4 65.2 4214.23 814.27 1554.15 115.21 603.58 8640 
10 021:36:00 024:00:00 2 2 0 0 1724.4 67.5 4376.24 830.45 1055.67 119.04 466.72 8640 
1 000:00:00 002:24:00 2 3 0 0 1345.6 32.7 5470.09 351.83 1439.77 0 0 8640 
2 002:24:00 004:48:00 2 3 0 0 2024.5 28.6 4541.97 599.63 1439.2 0 6.12 8640 
3 004:48:00 007:12:00 2 3 0 0 2117.3 9.45 4734.75 590.71 1182.01 0 5.82 8640 
4 007:12:00 009:36:00 2 3 0 0 1143 5.92 6392.43 251.83 846.8 0 0 8640 
5 009:36:00 012:00:00 2 3 0 0 1459.5 105 3884.57 1211.63 1662.41 19.94 296.83 8640 
6 012:00:00 014:24:00 2 3 0 0 1118.2 24.2 5817.9 209.35 1194.63 71.32 204.4 8640 
7 014:24:00 016:48:00 2 3 0 0 1188.4 33.6 5215.64 570.7 1575.68 0 56 8640 
8 016:48:00 019:12:00 2 3 0 0 1383.9 32.5 5105.27 550.89 1546.18 0 21.29 8640 
9 019:12:00 021:36:00 2 3 0 0 1731 26 5595.42 368.57 834.36 0 84.66 8640 
10 021:36:00 024:00:00 2 3 0 0 1951.9 55.5 3265.38 1013.06 2224.41 0 129.76 8640 
1 000:00:00 002:24:00 2 4 0 0 1619.9 95.3 3594.84 892.97 1512.67 382.56 541.76 8640 
2 002:24:00 004:48:00 2 4 0 0 1419.2 73 3034.63 684.17 2441.07 445.6 542.38 8640 
3 004:48:00 007:12:00 2 4 0 0 1068 0 7391.89 53.9 45.63 27.94 52.64 8640 
4 007:12:00 009:36:00 2 4 0 0 936.15 21.2 5582.92 382.16 1164.94 182.12 370.55 8640 
5 009:36:00 012:00:00 2 4 0 0 1091.3 118 4234.73 997.63 1647.62 267.37 283.58 8640 
6 012:00:00 014:24:00 2 4 0 0 1071.7 43.3 6845.4 113.15 504.4 43.64 18.37 8640 
7 014:24:00 016:48:00 2 4 0 0 993.79 13.7 5893.27 296.51 1097.33 182.4 163.03 8640 
8 016:48:00 019:12:00 2 4 0 0 874.57 43.2 5026.94 638.5 1231.72 295.25 529.83 8640 
9 019:12:00 021:36:00 2 4 0 0 756.64 19.6 6384.5 289.03 874.04 204.5 111.69 8640 
10 021:36:00 024:00:00 2 4 0 0 1152.3 99.5 3953.41 1065.1 1655.56 180.76 533.31 8640 
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P Q R S T U V W X Y Z AA AB 
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F 
TOTAL
_F 
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AX 
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X 
SPD_
LAV
G SPD_AVG 
DISTAN
CE 
[count
s] 
[cou
nts] 
[counts
] 
[cou
nts] 
[cou
nts] 
[co
un
ts] 
[cou
nts] 
[counts
] [mm/s] [s] 
[mm
/s] [mm/s] [m] 
             
376 22 357 24 80 14 50 923 111 4723 64 0.129284 1.117 
284 48 167 128 183 25 59 894 235 1099 74 0.495 4.277 
186 5 166 35 47 3 22 464 168 6256 73 0.279418 2.414 
153 1 150 8 19 8 6 345 59 1452 51 0.013429 0.116 
244 78 105 174 157 13 59 830 234 5845 75 1.217602 10.52 
247 65 137 133 135 28 40 785 236 142 77 0.866094 7.483 
161 14 145 18 13 0 4 355 118 6179 65 0.05268 0.455 
238 76 135 149 143 18 82 841 275 4451 76 1.071967 9.262 
213 71 110 152 108 11 71 736 249 1768 73 0.973893 8.414 
466 67 290 137 209 43 50 1262 245 2974 78 0.759057 6.558 
547 101 351 253 192 29 102 1575 245 7722 74 1.3908 12.017 
477 10 418 54 87 15 44 1105 213 6469 67 0.254578 2.2 
528 30 431 126 111 31 95 1352 169 6799 69 0.551471 4.765 
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553 17 467 71 66 10 32 1216 209 4140 69 0.354261 3.061 
417 82 320 183 112 14 58 1186 282 5948 77 1.047931 9.054 
319 24 268 54 54 5 11 735 192 350 72 0.171335 1.48 
408 52 305 130 78 17 40 1030 208 8500 68 0.5769 4.984 
338 41 248 160 86 4 40 917 244 4156 71 0.62219 5.376 
384 79 236 209 162 17 70 1157 234 1228 72 0.761447 6.579 
531 68 439 166 129 17 91 1441 247 3426 76 0.930666 8.041 
414 27 357 66 108 0 0 972 234 1 81 0.401227 3.467 
454 29 277 131 140 0 1 1032 213 1398 71 0.574992 4.968 
657 10 522 107 101 0 1 1398 270 4682 67 0.470104 4.062 
311 7 257 51 67 0 0 693 169 5608 68 0.168353 1.455 
381 116 192 249 154 6 23 1121 243 7176 81 1.121285 9.688 
415 23 363 70 111 4 32 1018 312 65 98 0.195884 1.692 
384 36 278 114 109 0 11 932 320 3315 81 0.442153 3.82 
349 42 243 102 99 0 2 837 265 8202 76 0.337594 2.917 
510 25 425 92 105 0 10 1167 253 1420 76 0.276601 2.39 
598 47 420 201 210 0 9 1485 261 2866 75 0.739725 6.391 
480 96 301 195 197 53 85 1407 271 6134 76 1.197135 10.343 
377 85 212 168 254 50 130 1276 260 5577 71 0.974442 8.419 
389 0 385 13 9 4 21 821 53 5109 49 0.005656 0.049 
331 26 245 98 110 20 61 891 181 2700 75 0.512255 4.426 
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354 124 234 231 163 32 57 1195 302 7148 82 1.267996 10.955 
402 40 365 40 30 7 5 889 202 1918 78 0.298889 2.582 
354 17 306 66 82 20 27 872 179 5424 71 0.280503 2.424 
272 44 170 134 108 28 57 813 241 6401 77 0.823831 7.118 
299 25 253 75 76 19 26 773 242 5508 76 0.299285 2.586 
301 113 142 258 167 18 90 1089 304 3984 87 1.484556 12.827 
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After obtaining the raw data, behaviours from the four cages are grouped together 
into two sections for each behaviour; one for duration of behaviour and other for 
frequency as shown in the next section.  
Grouping the data for undefined behaviour: 
 Cage 1 Cage 2 Cage 3 Cage 4 
002:24:00 900.24 1746.55 1345.59 1619.89 
004:48:00 1233.28 1168.42 2024.49 1419.15 
007:12:00 611.84 1211.79 2117.26 1068 
009:36:00 423.95 1378.08 1143.02 936.15 
012:00:00 950.53 1213.52 1459.46 1091.33 
014:24:00 820.87 854.91 1118.17 1071.74 
016:48:00 447.64 1023.65 1188.42 993.79 
019:12:00 743.57 919.46 1383.85 874.57 
021:36:00 733.53 1273.37 1731.04 756.64 
024:00:00 1880.89 1724.4 1951.92 1152.33 
002:24:00 900.24 1746.55 1345.59 1619.89 
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As the first experiment for the week was started by 8.30-8.45 AM the 24 hour 
monitoring was divided accordingly as shown below and thereafter every 
consequent experiment was rounded to its nearest time point. 8.6 and 32.6 
signified same time point.  
8.6 900.24 1746.55 1345.59 1619.89 
11 1233.28 1168.42 2024.49 1419.15 
13.4 611.84 1211.79 2117.26 1068 
15.6 423.95 1378.08 1143.02 936.15 
18.2 950.53 1213.52 1459.46 1091.33 
20.6 820.87 854.91 1118.17 1071.74 
23 447.64 1023.65 1188.42 993.79 
25.4 743.57 919.46 1383.85 874.57 
27.8 733.53 1273.37 1731.04 756.64 
30.2 1880.89 1724.4 1951.92 1152.33 
32.6 900.24 1746.55 1345.59 1619.89 
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Such adjusted time points from the other set of data obtained were averaged such 
that three points were obtained. The average for all the time points for week 1 
was classed under 24hrs period, data from 11-18.2 and 32.6 were classed under 
12hrs light cycle and data from 18.2-30.2 was classed under 12hrs dark cycle. 
The reason for the overlap in the time point 18.6 was due to the fact that as this 
software could only divide the measurement duration into 10 time points (2.24hrs 
each) the measurement for 7PM was included between the 18.2 and 20.6. 
Average for duration of undefined behaviour for day 1 and 3 control rats 
undefined behaviour.  
 A B C D E F G H I 
1 8.6         
2 11 900.24 1746.55 1345.59 1619.89 1317.08 566.05 2409.52 677.82 
3 13.4 1233.28 1168.42 2024.49 1419.15 1261.39 1301.99 1796.33 740.35 
4 15.6 611.84 1211.79 2117.26 1068 1265.72 1164.11 2482.96 1934.47 
5 18.2 423.95 1378.08 1143.02 936.15 816.77 900.38 2038.85 1075.52 
6 20.6 950.53 1213.52 1459.46 1091.33 1208.23 1234.49 2457.63 1523.28 
7 23 820.87 854.91 1118.17 1071.74 1346.82 1817.92 1261.89 978.12 
8 25.4 447.64 1023.65 1188.42 993.79 1039.28 1063.48 1851.33 1129.19 
9 27.8 743.57 919.46 1383.85 874.57 687.18 607.41 1008.99 566.94 
10 30.2 733.53 1273.37 1731.04 756.64 977.1 640.83 1118.42 641.2 
11 32.6 1880.89 1724.4 1951.92 1152.33 1022.39 1413.27 1746.31 788.41 
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Average: 
 Average STD SEM=STD/SQT 
(N) 
24hrs: 11-32.6 1219.834 470.2855 166.271 
12hrs light 11-
18.2 and 32.6 1344.423 509.49 180.1319 
12hrs dark 18.2-
30.2 1094.219 404.0054 142.8375 
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Such average were obtained for duration and counts for diabetic and control rats 
and for individual and the average of the two independent experiment (N=16) for 
all the behaviours and such data obtained were plotted on the graph. 
UNDEF_D Average  SEM  
No. of weeks Cont  Diab  Cont  Diab  
1 1219.834 1174.333 166.271 152.3483 
2 1131.413 1285.041 70.2782 173.5174 
3 1061.835 1415.279 77.66578 204.774 
4 1028.014 1473.159 61.98718 274.1098 
5 980.5696 1166.966 62.89767 205.9138 
6 1239.763 1011.173 97.86969 149.5993 
7 814.5125 1186.246 53.17262 179.7136 
8 952.2577 1269.343 70.79017 136.2126 
9 777.9513 1057.475 59.85152 190.2915 
10 885.0213 1165.721 58.8881 175.0355 
11 989.7521 973.9916 208.5064 176.248 
12 989.7521 1074.571 208.5064 167.3297 
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A typical graph obtained 
 
Please note for presentational purposes it was not possible to plot for the whole 
time period. As the data obtained was enormous, this data can be represented in 
various different ways. The current analysis has divided the day into ten 2.24hrs 
sections and the data presented actually represents the average of these 2.24hrs 
sections either for the full 24hrs or the 12hrs dark and 12hrs light cycle. Clearly, 
we could look at longer segments of time including summating all the activities 
over 24 or 12 hours. However, as this was the first use of LABORAS in this 
laboratory, the times that have shown were choosen to be presented. Further 
future analysis by members of the laboratory may yield further interesting results. 
It was hoped that if 2.24hrs sections gave a reliable measurement of differences in 
behaviour then perhaps rat behaviours could be measured just for this short 
period. 
 
 
 
